Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 1PROTOCOL
TITLE: iNNOVATE Study: A Randomized, Double-Blind, Placebo-
Controlled, Phase 3 Study of Ibru tinib or Placebo in Combination 
with Rituximab in Subjects with Waldenström’s
Macroglobulinemia
PROTOCOL NUMBER: PCYC-1127-CA
STUDY DRUG: Ibrutinib (PCI-[ZIP_CODE])
IND NUMBER: 102,[ADDRESS_493191] NUMBER: 2013-005478-22SPONSOR MEDICAL 
MONITOR:
Pharmacyclics LLCPhone:Fax:
Email:
SPONSOR: Pharmacyclics LLC995 East Arques Avenue Sunnyvale, CA [ZIP_CODE]-4521[LOCATION_002] of America
DATE FINAL:
Amendment 1: Amendment 2:Amendment 2.1:Amendment 3:22 January 201407 March 201409 February 201502 June 2015 ([LOCATION_006] only)[ADDRESS_493192]/ethics 
committee.  This information cannot  be used for any other purpose  other than the evaluation or 
conduct of the clinical study without the pr ior written consent of Pharmacyclics LLC

Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493193] OF IN-TEXT TABLES .................................................................................................................... 7  
SYNOPSIS....................................................................................................................... ............................ 8  
ABBREVIATIONS................................................................................................................................... 14  
1. BACKGROUND..................................................................................................................... ............ 16  
1.1. Description of Waldenström’s Macroglobulinemia .................................................................. [ADDRESS_493194] Name  [CONTACT_13804] ......................................................................... 19  
1.3. Summary of Nonclinical Data ................................................................................................... 2 0 
1.3.1.  Pharmacology............................................................................................................... 20  
1.3.2.  Safety Pharmacology and Toxicology.......................................................................... 20  
[IP_ADDRESS].  Carcinogenesis, Mutagenesis, Impairment of Fertility.................................. [ADDRESS_493195] Metabolism ................................................................. 21  
1.5. Summary of Clinical Safety of Ibrutinib ................................................................................... 22  
1.5.1.  Monotherapy Studies.................................................................................................... 22  
1.5.2.  Combination Therapy Studies ...................................................................................... 22  
1.5.3.  Risks .......................................................................................................................... ... 23  
[IP_ADDRESS].  Bleeding-Related Events ............................................................................... 23  
[IP_ADDRESS].  Infections....................................................................................................... 23  
[IP_ADDRESS].  Cytopenias..................................................................................................... 23  
[IP_ADDRESS].  Atrial Fibrillation........................................................................................... 23  
[IP_ADDRESS].  Second Prim ary Malignancies....................................................................... 24  
[IP_ADDRESS].  Tumor Lysis Syndrome................................................................................. 24  
[IP_ADDRESS].  Diarrhea......................................................................................................... 24  
[IP_ADDRESS].  Rash............................................................................................................... 24  
1.6. Summary of Clinical Data with Ibrutinib in WM...................................................................... 24 
1.6.1.  Study PCYC-[ZIP_CODE]...................................................................................................... 24  
1.6.2.  Study [STUDY_ID_REMOVED].................................................................................................... 25  
1.7. Justification of Study Design and Dose Rationale .................................................................... 26  
2. STUDY OBJECTIVE ................................................................................................................ ........ 27  
2.1. Primary Objective.............................................................................................................. ........ 27  
2.2. Secondary Objective(s)......................................................................................................... ..... [ADDRESS_493196] SELECTION.............................................................................................................. ...... 33  
4.1. Eligibility Criteria for the Randomized Study (Arm A and Arm B) ......................................... 33  
4.1.1.  Inclusion Criteria.......................................................................................................... 33  
4.1.2.  Exclusion Criteria......................................................................................................... 36  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 44.2. Eligibility Criteria for Open-label Substudy Treatment Arm C ................................................ 37  
4.2.1.  Inclusion Criteria.......................................................................................................... 37  
4.2.2.  Exclusion Criteria......................................................................................................... 37  
5. TREATMENT OF SUBJECTS......................................................................................................... 3 8 
5.1. Randomization and Blinding..................................................................................................... 38 
5.2. Study Treatment ................................................................................................................ ........ 39  
5.2.1.  Treatment Arm A (Ibrutinib/Rituximab)...................................................................... 40  
5.2.2.  Treatment Arm B (Placebo/Rituximab) ....................................................................... 40  
5.2.3.  Treatment Arm C (Ibrutinib Open-label Substudy)...................................................... 40  
5.3. Study Medication............................................................................................................... ........ 40  
5.3.1.  Ibrutinib/Placebo .......................................................................................................... 40  
[IP_ADDRESS].  Formulation/Packaging/Storage .................................................................... 40  
[IP_ADDRESS].  Dose and Administration............................................................................... 41  
[IP_ADDRESS].  Overdose ....................................................................................................... 41  
[IP_ADDRESS].  Dose Hold, Reduction or Discontinuation of Study Drug 
(Ibrutinib/Placebo) ........................................................................................ 42  
[IP_ADDRESS].  Dose Modification of Study Drug (Ibrutinib/Placebo).................................. 42  
[IP_ADDRESS].  Dose Modification for Hepatic Impaired Subjects........................................ 43  
5.3.2.  Rituximab ..................................................................................................................... 4 3 
[IP_ADDRESS].  Formulation, Packaging, and Storage of Rituximab ..................................... 43  
[IP_ADDRESS].  Dosage, Preparation and Administration of Rituximab ................................ 44  
[IP_ADDRESS].  Dose Delay of Rituximab.............................................................................. 44  
[IP_ADDRESS].  Dose Interruption of Rituximab .................................................................... 45  
[IP_ADDRESS].  Dose Modification of Rituximab................................................................... 45  
[IP_ADDRESS].  Rituximab Associated “IgM flare”................................................................ 46  
5.4. Criteria for Perm
anent Discon tinuation of Study Drug............................................................. 46  
6. CONCOMITANT MEDICATIONS/PROCEDURES .................................................................... 46  
6.1. Concomitant Medications........................................................................................................ .. 46 
6.1.1.  Permitted Concomitant Medications ............................................................................ 46  
6.1.2.  Medications to be Used with Caution........................................................................... 47  
[IP_ADDRESS].  CYP3A Inhibitors/Inducers........................................................................... 47  
[IP_ADDRESS].  Drugs That May Have Their Plas ma Concentrations Altered By 
[CONTACT_183939]......................................................................................................... 47  
[IP_ADDRESS].  Concomitant Use of QT Prolonging Agents ................................................. 47  
[IP_ADDRESS].  Concomitant Use of Antiplatele t Agents and Anticoagulants....................... 47  
6.1.3.  Prohibited Concomitant Medications ........................................................................... 48  
6.2. Procedures ................................................................................................................................. 48  
6.2.1.  Minor Surgical Procedures ........................................................................................... 48  
6.2.2.  Major Surgical Procedures ........................................................................................... 48  
6.2.3.  Emergency Procedures ................................................................................................. 48  
6.3. Plasmapheresis ................................................................................................................. ......... 49  
7. STUDY EVALUATIONS .............................................................................................................. .... 49  
7.1. Screening/Administrative ....................................................................................................... ... 49  
7.1.1.  Informed Consent ......................................................................................................... 50  
7.1.2.  Confirm Eligibility ....................................................................................................... 50  
7.1.3.  Medical History and Demographics............................................................................. 50  
7.1.4.  Prior and Concomitant Medications............................................................................. 50  
7.1.5.  Adverse Events............................................................................................................. 50  
7.1.6.  Physical Examination ................................................................................................... 50  
7.1.7
. Eye-related Symptom Assessment ............................................................................... 51  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 57.1.8.  ECOG ........................................................................................................................... 51 
7.1.9.  Vital Signs .................................................................................................................... 51 
7.1.10.  Patient-Reported Outcomes.......................................................................................... 51  
[IP_ADDRESS].  EQ-5D-5L...................................................................................................... 51  
[IP_ADDRESS].  FACT-An ...................................................................................................... 51  
7.2. Clinical Laboratory Assessments .............................................................................................. 52  
7.2.1.  Hematology .................................................................................................................. 52  
7.2.2.  Chemistry (Serum) ....................................................................................................... [ADDRESS_493197] ............................................................................................................. 53  
7.3. Diagnostics/Procedures ......................................................................................................... .... 53  
7.3.1.  ECG ............................................................................................................................ .. 53 
7.3.2.  Bone Marrow Sampling and Pathological diagnosis.................................................... 53  
7.4. Pharmacokinetics/Biomarkers................................................................................................... 5 4 
7.4.1.  Pharmacokinetics.......................................................................................................... 54  
7.4.2.  Predictive Biomarkers and Mechanisms of Resistance................................................ 55  
7.4.3.  T/B/NK Cell Count....................................................................................................... 55  
7.4.4.  Genetic and Molecular Prognostic Markers ................................................................. 56  
7.5. Efficacy Evaluations........................................................................................................... ....... 56  
7.5.1.  Quantitative Seru m Immunoglobulin ........................................................................... 57  
7.5.2.  Serum Immunofixation................................................................................................. 57  
7.5.3.  Serum Protein Electrophoresis (SPEP)......................................................................... 57  
7.5.4.  Radiographic Imaging .................................................................................................. 57  
[IP_ADDRESS].  Radiographic Assessment ............................................................................. 58  
7.6. Sample Collection and Handling............................................................................................... 59  
7.7. Treatment with Ibrutinib for Subjects on Control Arm (Arm B) Following IRC-
Confirmed Disease Progression................................................................................................. 5 9 
7.7.1.  Criteria for Next-line Ibrutinib Therapy....................................................................... 59  
7.7.2.  Next-line Ibrutinib Therapy Treatment Phase .............................................................. 60  
8. STUDY PROCEDURES............................................................................................................... ..... 60  
8.1. Overview ....................................................................................................................... ............ 60  
8.2. Screening Phase................................................................................................................ ......... 61  
8.2.1.  Screening Visit ............................................................................................................. 61  
8.3. Treatment Phase ................................................................................................................ ........ 62  
8.3.1.  Week 1......................................................................................................................... .6 2 
8.3.2.  Weeks 2-4 (Arm A and Arm B ONLY) ....................................................................... 63  
8.3.3.  Weeks 5-16 (every 4 weeks) ........................................................................................ 63  
8.3.4.  Week 17........................................................................................................................ 64 
8.3.5.  Weeks 18-20 (For Arm A and Arm B ONLY)............................................................. 65  
8.3.6.  Week 21........................................................................................................................ 65 
8.3.7.  Week 25- until PD or Unacceptable Toxicity (Every 8 Weeks) .................................. 65  
8.3.8.  Suspected PD Visit ....................................................................................................... 66  
[IP_ADDRESS].  End-of-Treatment Visit ................................................................................. 67  
8.4. Follow-up P
hase ........................................................................................................................ 67  
8.4.1.  Response Follow-Up Visits (Until PD) ........................................................................ 67 
8.4.2.  Survival Follow-up....................................................................................................... 68  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493198] Information ............................................................................................................ ....... 71  
10.5.  Sample Size Determination (Treatment Arms A and B) ........................................................... 71  
10.6.  Efficacy Analysis.............................................................................................................. ......... 72  
10.6.1.  Primary Endpoint.......................................................................................................... 72  
10.6.2.  Secondary Endpoints.................................................................................................... 72  
[IP_ADDRESS].  Overall Response Rate .................................................................................. 73  
[IP_ADDRESS].  Hematologic Improvement............................................................................ 73  
[IP_ADDRESS].  Time to Next Treatment ................................................................................ 73  
[IP_ADDRESS].  Overall Survival (OS).................................................................................... 73  
10.6.3.  Exploratory Efficacy Endpoints ................................................................................... 73  
[IP_ADDRESS].  FACT-An ...................................................................................................... 73  
[IP_ADDRESS].  Euro QoL 5 Dimension Questionnaire (EQ-5D-5L)..................................... 74  
[IP_ADDRESS].  Duration of Response .................................................................................... 74  
[IP_ADDRESS].  Clinical Response Rate.................................................................................. 74  
[IP_ADDRESS].  Efficacy Assessments by [CONTACT_10670]........................................................... 74  
10.6.4.  Other Exploratory Endpoints........................................................................................ 74  
10.6.
4.1. Pharmacokinetic Analyses ............................................................................ 74  
[IP_ADDRESS].  Medical Resource Utilization and Health Economics Analyses ................... 75  
[IP_ADDRESS].  Biomarker Analyses ...................................................................................... 75  
10.7.  Safety Endpoints a nd Methods.................................................................................................. 7 5 
10.8.  Interim Analysis ............................................................................................................... ......... 76  
10.9.  Final Analysis................................................................................................................. ........... 77  
10.10.  Independent Review Committee (IRC) ..................................................................................... 77  
10.11.  Independent Data Monitoring Committee (DMC) .................................................................... 77  
11. ADVERSE EVENT REPORTING................................................................................................... 78  
11.1.  Adverse Event Definitions and Classifications ......................................................................... 78  
11.1.1.  Adverse Events............................................................................................................. 78  
11.1.2.  Severity Criteria (Grade 1-5)........................................................................................ 79  
11.1.3.  Causality (Attribution).................................................................................................. 80  
11.2.  Unexpected adverse events...................................................................................................... .. 80 
11.3.  Documenting and Reporting of Adverse Events ....................................................................... 81  
11.3.1.  Reporting of “IgM flare” (Tumor flare) ....................................................................... 81 
11.3.2.  Special Reporting Situations ........................................................................................ 81  
11.3.3.  Adverse Event Reporting Procedures........................................................................... 82  
[IP_ADDRESS].  All Adverse Events........................................................................................ 82  
[IP_ADDRESS].  Reporting Criteria for Serious Adverse Events............................................. [ADDRESS_493199] (AESI) .................................................................. 83  
[IP_ADDRESS].  Major Hemorrhage ........................................................................................ 83  
11.3.5.  Pregnancy ..................................................................................................................... 84  
11.3.6.  Other Malignancies ...................................................................................................... 84  
11.3.7.  Eye-related Adverse Events.......................................................................................... 84  
12. STUDY ADMINISTRATION AND INVESTIGATOR OBLIGATIONS .................................... 85  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493200] (IRB), Resear ch Ethics Board (REB) and Independent 
Ethics Committee (IEC) Approval ............................................................................................ [ADDRESS_493201] Maintenance ........................................................................... 87  
12.8.  Investigational Study Drug Accountability ............................................................................... 88  
12.9.  Study Monitoring/Audit Requirements ..................................................................................... [ADDRESS_493202] OF APPENDICES
Appendix 1.  Schedule of Assessments .................................................................................................. 97  
Appendix 2.  ECOG Status Scores ....................................................................................................... 100  
Appendix 3.  Inhibitors and Inducers of CYP3A ................................................................................. 101  
Appendix 4.  Modified 6th WM Response Criteria (NCCN  2014) for Investigator Assessment......... [ADDRESS_493203]-An (Version 4)..................................................................................................... [ADDRESS_493204] OF IN-TEXT TABLES 
Table 1:  WM International Prognostic Scoring System (IPSS)1..................................................... 17  
Table 2:  Study Drug (Ibrutinib/Placebo) Dose Modifications........................................................ 43  
Table 3:  Dose Modification for Rituximab Toxicity ...................................................................... 45  
Table 4:  Pharmacokinetic Sample Schedule................................................................................... 55  
Table 5:  Grading for Adverse Events of Ig M Associated Tumor Flare.......................................... 81  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 8SYNOPSIS
Study Title: iNNOVATE Study: A Randomized, Double-Blind, Placebo-Controlled, 
Phase [ADDRESS_493205] bo in Combination with Rituximab in 
Subjects with Waldenström’s Macroglobulinemia
Protocol Number: PCYC-1127-CA
Study Phase: Phase 3 
Study Duration: Estimated to be [ADDRESS_493206] 
and Reference Therapy:Ibrutinib will be supplied as [ADDRESS_493207] gelatin capsules for oral (PO) 
administration.
Matching placebo will be supplied as hard gelatin capsules and will look 
identical to ibrutinib capsules.Rituximab will be available as 100 mg/10 mL and 500 mg/50 mL solution 
in a single-use vial for intravenous (IV) administration.
Objectives: Primary Objective:
To evaluate the effect of the addition of ibrutinib to rituximab on 
progression-free survival (PFS) assessed by [CONTACT_393035] (IRC) in subjects with Waldenström’s macroglobulinemia
(WM).  Efficacy evaluation will be based on the modified Consensus Response Criteria from the VI
thInternational Workshop for WM
(IWWM) (NCCN 2014 ).
Secondary Objectives:
Efficacy
To compare the treatment arms in terms of the following:
•Overall Response Rate (ORR) assessed by [CONTACT_55543] (≥PR; according to 
the modified VIthIWWM [ NCCN 2014 ] criteria).
•Hematological improvement measured by [CONTACT_33308].
•Time to next treatment (TTnT)
•Overall survival (OS).
Safety
•To evaluate the safety and tolera bility of ibrutinib when combined 
with rituximab therapy compared to rituximab in combination with 
placebo.
Exploratory Objectives:
•Patient-reported outcomes (PRO) and disease-related symptoms 
according to FACT-An
•Patient-reported outcomes (PRO) and disease-related symptoms 
according to Euro QoL 5 dimens ion questionnaire (EQ-5D-5L).
•Duration of Response (DOR) according to IRC assessment.
•Clinical response rate (CRR) assessed by [CONTACT_55543] (≥MR; according to 
the modified VIthIWWM [ NCCN2014 ] criteria. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 9•Efficacy assessment by [CONTACT_10670] ( ≥PR and ≥MR; according to 
the modified VIthIWWM [ NCCN 2014 ] criteria).
•To determine the pharmacoki netics (PK) of ibrutinib in 
combination with rituximab in subjects with WM.
•Evaluation of medical resource utilization (MRU) (e.g. 
requirements of plasmapheresis, tr ansfusions and use of growth 
factors).
•Prognostic and predictive biomarke rs and genetics relative to 
treatment outcomes.
Open-label Substudy Treatment Arm C
•To evaluate the efficacy and safe ty of ibrutinib monotherapy in 
WM subjects who are considered refractory to their last prior 
rituximab-containing therapy. Efficacy and safety analysis will be conducted separately from the randomized study 
Study Design: This is a Phase 3, multicenter, ra ndomized, double-blind study of oral 
ibrutinib or placebo in combination with  intravenous rituximab therapy in 
subjects with WM. 
Approximately 150 subjects will be  randomized between Arm A 
(ibrutinib and rituximab) and Arm B (placebo and rituximab) and
stratified according to: 
•WM International Prognostic Scoring System (IPSS) assessed at
Screening (Low vs. Intermediate vs. High)
•Number of prior systemic treatment regimens (0, 1- 2 vs. ≥3)
•ECOG status (0-1 vs. 2)
Access to next-line ibrutinib (cross-ove r) for subjects treated with placebo 
in combination with rituximab (Arm B) may be provided after confirmed 
disease progression (by [CONTACT_55543]) and disease requiring treatment.
Open-label Substudy Treatment Arm C
Up to 30 eligible subjects will be enrolled in the open-label ibrutinib 
monotherapy substudy (Treatment  Arm C). For details regarding 
inclusion/exclusion criteria refer to Section 4.2 .
Subjects eligible for the randomized trial (Arm A or Arm B) are not 
eligible for participation in the substudy (Arm C). 
Population: Subjects must have a centrally conf irmed clinicopathological diagnosis of 
WM in accordance with the consensus panel of the Second International 
Workshop on WM ( Owen 2003 ). 
Subjects must be in need of treatm ent in accordance w ith the “Consensus 
Panel Two” recommendations from th e Second International Workshop 
on WM ( Kyle 2003 ).
Centers: Multicenter-International
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 10Inclusion Criteria:
Refer to Section [ADDRESS_493208] of 
inclusion/exclusion criteria.
Refer to Section 4.2 for 
eligibility criteria for open-
label substudy treatment Arm C.Disease Related
•Subjects with untreated or previously treated Waldenström’s
Macroglobulinemia
•Previously treated Waldenström’s Macroglobulinemia must have either documented disease progre ssion or had no response (stable 
disease) to the most recent treatment regimen
•Centrally confirmed clinicopathol ogical diagnosis of WM in 
accordance with the cons ensus panel of the Second International 
Workshop on WM ( Owen 2003 ).
•Measurable disease defined as s erum monoclonal IgM >0.5 g/dL.
•Symptomatic disease meeting at le ast 1 of the recommendations from 
the Second International Workshop on Waldenström's 
Macroglobulinemia for requiring treatment ( Kyle 2003 ).
Laboratory
•Adequate hematological function defined as: 
oAbsolute neutrophil count >750 cells/mm
3(0.75 x 109/L)
independent of growth factor support within [ADDRESS_493209] 
dose of study drug.  
oPlatelet count >50,000 cells/mm3(50 x 109/L) without 
transfusion support within [ADDRESS_493210] dose of study drug. 
oHemoglobin ≥8 g/dL without transfusion or growth factor 
support within [ADDRESS_493211] dose of study drug.
•Adequate hepatic and re nal function defined as:
oSerum aspartate transaminase (A ST) or alanine transaminase 
(ALT) <3.0 x upper limit of normal (ULN).
oEstimated Creatinine Clearance ≥30 mL/min.
oBilirubin ≤1.[ADDRESS_493212] (unless bilirubin rise is due to Gilbert’s 
syndrome or of non-hepatic origin).
•PT/INR ≤1.[ADDRESS_493213] and PTT (aPTT) ≤1.[ADDRESS_493214] unless 
abnormalities are unrelated to a coagulopathy or bleeding disorder 
(when treated with warfarin or othe r vitamin K antagonists, then INR 
≤3.0).
Demographic
•Men and women ≥18 years of age.
•Eastern Cooperative Oncology Group (ECOG) performance status 
0t o  2 .
Exclusion Criteria:
Refer to Section 4for the 
complete and detailed list of 
inclusion/exclusion criteria•Known involvement of the cent ral nervous system by [CONTACT_74594].
•Refractory to prior rituximab-c ontaining therapy defined as:
oRelapse after the last rituximab-containing therapy <[ADDRESS_493215] dose of rituximab,
OR
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493216] rituximab-containing therapy.
•Rituximab treatment within the last [ADDRESS_493217] dose of 
study drug  
•Prior exposure to ibrutinib or other BTK inhibitors.
•Received any WM-related therapy (e.g. chemotherapy, immuno therapy, investigational drug) ≤[ADDRESS_493218] 
administration of study treatment.
•Plasmapheresis <[ADDRESS_493219] one serum IgM central assessment was performed during the screening period and wa s >[ADDRESS_493220] recent 
plasmapheresis procedure.
oSubjects with high IgM values or viscosity symptoms during screening may receive plasmaphe resis prior to initiating study 
drug (Refer to Section 6.3 ) if the previous plasmapheresis was 
performed >35 days before the plasmapheresis performed during 
screening (in order to obtain a true baseline IgM value for efficacy evaluations).  
•History of other malignancies, except: 
oMalignancy treated with curativ e intent and with no known 
active disease present for ≥[ADDRESS_493221] dose of study 
drug and felt to be at low risk for recurrence by [CONTACT_35425].
oAdequately treated non-mela noma skin cancer or lentigo 
maligna without evidence of disease.
oAdequately treated carcinoma in  situ without evidence of 
disease. 
•History of stroke or intracranial hemorrhage within 12 months prior 
to enrollment.
•Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator’s opi[INVESTIGATOR_1649], could compromise the subject’s safety or put the study outcomes at undue risk.
•Currently active, clinically significa nt cardiovascular disease, such as 
uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as 
defined by [CONTACT_115233]; or a history of myo cardial infarction, unstable angina, 
or acute coronary syndrome within 6 months prior to randomization.
•Requires treatment with a strong cytochrome P450 (CYP) 3A 
inhibitor (see Appendix 3 ).
•Lactating or pregnant.
•Unable to understand the purpose and risks of the study and to provide a signed and dated info rmed consent form (ICF) and 
authorization to use protected hea lth information (in accordance with 
national and local subject privacy regulations).
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 12Study Treatment: 1:1 Randomiza tion between Arm A & Arm B
Arm A : Oral ibrutinib 420 mg daily (3 capsules) continuously until 
evidence of progressive disease or no longer tolerated by [CONTACT_393036] 375 mg/m2IV weekly for 4 consecutive
weeks, followed by a second 4-weekly rituximab course after a 3-month 
interval.
Arm B: Oral matching placebo capsules daily (3 capsules) continuously 
until evidence of progressive disease or no longer tolerated by [CONTACT_393037] 375 mg/m2IV weekly for 4 consecutive 
weeks, followed by a second 4-weekly rituximab course after a 3-month 
interval.
Access to next-line ibrutinib m onotherapy (cross-over) for subjects 
treated in Arm B may be provided after confirmed disease progression 
(by [CONTACT_55543]) and disease requiring treatment (Refer to Section 7.7 ).
Open-label Substudy Treatment Arm C 
Arm C: Oral ibrutinib 420 mg daily (3 capsules) continuously until 
evidence of progressive disease or no longer tolerated by [CONTACT_423]. 
Concomitant Therapy: Refer to Section 6for information on concomitant therapy.
Safety Plan: The safety of this study will be monitored by [CONTACT_120578] (DMC) in accordance with the Sponsor’s
procedures.
Statistical Methods and Data Analysis:Primary Efficacy Analysis:
The primary efficacy analysis of the randomized study will be performed using the intent-to-treat (ITT) population based on IRC assessed PFS. All subjects will be followed for PFS until a P FS event occurs (progression or 
death) or until the data cutoff.  PFS will be assessed based on the 
modified VI
thIWWM ( NCCN 2014) response criteria for WM and will be 
analyzed using the Kaplan-Meier me thod. The randomized treatment 
arms (Arm A and Arm B) will be compared using log-rank test.
Subgroup analyses will be performed for selected subgroups (eg, prior 
WM treatment history: untreated versu s previously treated) to assess the 
consistency of treatment effect across subgroups.
Secondary Efficacy Analysis:
Multiplicity adjustment for the ra ndomized treatment arm comparisons
will be made to control the overall type 1 error based on hierarchical 
testing procedure. The order of the secondary endpoints will be specified 
in the Statistical Analysis Plan (SAP).  Overall response rate (ORR) will 
be compared using the chi-square test .  The percentage of subjects with 
sustained hematological improvement  as measured by [CONTACT_393038] a nd compared using the chi-square 
test.  The distribution of the time  to improvement will be summarized 
using the Kaplan-Meier method as appropriate.  The distribution of OS and TTnT will be estimated using the Kaplan-Meier method similar to 
PFS.  Survival rate for OS at landmark points will be summarized based 
on the Kaplan-Meier method. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 13Exploratory Efficacy Analysis:
Other time-to-event analysis will be analyzed by [CONTACT_393039]-ra nk tests as appropriate.  Categorical 
endpoints will be compared between the two randomized treatment arms 
using chi-square test as appropriate. F or FACT-An, change in scores from 
baseline to each assessment will be summarized descriptively and 
compared between the two treatment arms.
Open-label Substudy Treatment Arm C 
PFS, ORR, hematological improvement  measured by [CONTACT_33308], TTnT, 
FACT-An, OS and other efficacy parameters will be summarized 
descriptively for the open-label ibrutinib monotherapy (Arm C). No 
comparator analysis will be done with Arms A or B. 
Safety Analysis:
Detailed tabulations of sa fety data (adverse events, clinical laboratory 
tests and other safety endpoints) w ill be summarized by [CONTACT_393040]. Summary statistics will include 
means, standard deviations, and medians for continuous variables and 
proportions for categorical variables.
The end of the study will occur appr oximately [ADDRESS_493222].
Safety analysis for Treatment Ar m C will be conducted separately.
Interim Analysis One interim analysis using the Lan De Mets alpha spending function based 
on O’Brien-Fleming boundary will be conducted at 70% information.
Sample Size Determination The sample size for the randomized portion of the study is calculated 
based on the assumption that the median PFS is [ADDRESS_493223] randomized.  Based on the assumed 2-fold improvement in median PFS 
of the rituximab in combination with ibrutinib arm (Arm A) over 
rituximab and placebo arm (Arm B) (hazard  ratio of 0.5), the study has at 
least 80% power to achieve a statistical  significance level of 5% (2-sided) 
under exponential distribution for PFS.
The sample size for the s ubstudy (Arm C) is not determined according to 
statistical calculation as the intent of  this substudy is to provide WM 
subjects who are considered refractory to the last prior rituximab-
containing therapy access to ibrutinib as well as evaluate safety and 
efficacy in the monotherapy setting. Up to 30 subjects will be enrolled in 
this substudy. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493224] aspartate aminotransferase
AUC area under the curveß
2M beta 2-microglobulin
BCR B-cell receptor
BR bendamustine and rituximab
BTK Bruton’s tyrosine kinase
CBC complete blood countCFR Code of Federal RegulationsCI confidence intervalCLL chronic lymphocytic leukemia
CR complete response
CRF case report form (paper or electronic as appropriate for this study)CRR clinical response rateCT computed tomographyCTCAE Common Terminology Criteria for Adverse Event 
CYP Cytochrome P
DLBCL diffuse large B-cell lymphomasDMC Data Monitoring CommitteeDOR duration of responseEDC electronic data captureeCRF electronic case report form
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology GroupEMA European Medicines AgencyEMSO European Society for Medical OncologyEOT End-of-Treatment visit
EQ-5D-5L Euro QoL [ADDRESS_493225]
IRC independent review committee 
ITT intent-to-treatIV Intravenous
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 15IWWM International Workshop on Waldenström’s Macroglobulinemia
IWRS interactive web response systemLPL lymphoplasmacytic lymphoma
MAPK mitogen-activated protein kinase
MCL mantle cell lymphomaMedDRA Medical Dictionary for Regulatory ActivitiesMGUS Monoclonal Gammopathy of  Undermined Significance
MR minor response MRI magnetic resonance imaging 
MRU medical resource utilization
NCCN National Comprehensive Cancer NetworkORR Overall Response RateOS Overall survival PD Progressive disease
PET positron emission tomography 
PFS progression-free survivalPK PharmacokineticPO oral PR Partial response
PRO patient-reported outcome(s)
PTT partial thromboplastin timeREB Research Ethics BoardR-CHOP rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone
SAE serious adverse event SI Standard International units
SPEP Serum protein electrophoresis
STAT3 signal transducer and activat or of transcription [ADDRESS_493226] Upper limit of normalVGPR very good partial response
USP [LOCATION_002] Pharmacopeia
WHO World Health OrganizationWM Waldenstr ӧm's Macroglobulinemia
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 161. BACKGROUND
1.1. Description of Waldenström’s Macroglobulinemia 
Waldenström’s macroglobulinemia (WM) is a di stinct lymphoprolifera tive B-cell disorder 
characterized by [CONTACT_393041] (Ig) M monoc lonal gammopathy in the serum. It is a 
subtype of lymphoplasmacytic lymphoma (LPL) as defined by [CONTACT_393042]-American 
Lymphoma and the World Health Organi zation (WHO) classification systems ( Harris 1994 ; 
Harris 1999 ). Although most cases of LPL are WM, ther e are exceptions in which the diagnosis 
of WM does not apply, for example, primary lymph node-based presen tations of LPL, or 
lymphoplasmacytic B-cell proliferations in th e bone marrow associated with IgA or IgG 
gammopathies (Buske 2013 ).
The disease begins with a malignant change to the B-cell during its maturation so that it 
continues to reproduce more malignant B-cells, resulting in an overproduction of monoclonal 
IgM antibody.  Clinical manifestations of WM include cytopenias resu lting from bone marrow 
infiltration by [CONTACT_393043] M paraprotein related symptoms such as 
cryoglobulinemia, the cold agglu tinin syndrome, demyelinating neuropathy, and symptomatic 
hyperviscosity.
Waldenström’s macroglobulinemia, which constitutes 1–2% of hematologic malignancies, is an 
orphan indication; the overall incidence of WM is [ADDRESS_493227] recognized risk factor 
for developi[INVESTIGATOR_393010] (MGUS), 
which confers a 46-fold higher relative risk compared to the general population.  Recently, a 
somatic mutation of the MYD88 gene (L265P) has been identified that appears to drive WM 
growth and proliferation.
WM remains an incurable disease with variabil ity in outcome.  Approximately 75% of patients 
are symptomatic and therefore require treatment to control symptoms related to tumor burden.  
The symptoms and signs of WM may vary but are usually related to signs of bone marrow 
infiltration such as anemia or cytopenias, or sy mptoms and signs due to hyperviscosity resulting 
from elevated IgM levels in the serum.  Asym ptomatic patients should be observed and serum 
IgM levels alone are not a basis for treatment.Anemia is the most frequent cytopenia requiring medical management, and with progression of 
their illness, WM patients become dependent on repeated blood transfusions for refractory 
anemia.  These supportive measures do not treat  the underlying biology of the disease and are 
often associated with iron overload.
Factors associated with a poor prognosis incl ude advanced age, high beta 2-microglobulin (ß
2M), 
low albumin, cytopenias, serum IgM monoclonal protein, and organomegaly.  An international 
prognostic scoring system for newly diagnos ed WM patients was recently developed 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 17(Morel 2009 ) based on 5 factors:  Age (>65 years) ß 2M (>3mg/L), anemia (Hb ≤11.5 g/dL), 
thrombocytopenia ( ≤100 x 109/L), IgM monoclonal gammopathy (>7.0 g/dL) with 5-year 
survival ranging from 36% to 87% in high and low-risk patients, respectively (Table 1).
Table 1: WM International Prognostic Scoring System (IPSS)1
Low-risk Intermediate-risk High-risk
Number of risk factors < 1 (except age) 2 or age > 65 years > 2 Risk factors
Percentage of patients 27% 38% 35%
5-year survival rate 87% 68% 36%
1Morel 2009
1.1.1. Existing Therapi[INVESTIGATOR_393011] (FDA) on 29 January 2015 for 
the treatment of Waldenström’s Macroglobulinemia and represents the first therapy approved for 
the treatment of this disease.  More recentl y, the European Medicines Agency (EMA) approved 
ibrutinib on 08 July 2015 for the treatmen t of adult patients with Waldenström’s 
Macroglobulinemia (WM) who have r eceived at least one prior therapy, or in first line treatment 
for patients unsuitable for chemoimmunotherapy.  Treatment options currently used for WM 
were originally developed from other lymphopro liferative diseases including multiple myeloma, 
non-Hodgkin’s lymphoma, and chronic lymphocytic  leukemia (CLL).  Th e primary treatment 
options for WM include alkylating agents (e g, cyclophosphamide or bendamustine), nucleoside 
analogs (cladribine or fludarabine), rituximab alon e, or rituximab in combination with alkylator-
based chemotherapy.  Bortezomib-based ther apy, nucleoside analogue-based therapy, 
thalidomide, or bendamustine are also other treatment options ( NCCN 2014).
Single agent use in relapsed/refractory WM has been assessed primarily in single arm Phase [ADDRESS_493228] numbers of subjects ( Rourke 2010 ).  However, a number of issues have made 
comparisons across studies difficult.  In severa l studies, heterogeneous populations have been 
enrolled, some including both previously untreated  and treated subjects.  In addition, response 
criteria varied depending on whether th e International Workshop on Waldenström’s
Macroglobulinemia (IWWM) consensus guidelines were used, and if so, which version was 
used.  In particular, the category of minor res ponse (MR) was first intr oduced and defined by [CONTACT_393044] ( Treon 2006) and subsequently is often included to report overall response rates in 
newer trials.  
Current treatment options do not target disease- specific abnormalities and are each associated 
with treatment-related side effects, particularly in older adults , that may be life-threatening.  In 
particular, a recent analysis of long-term safety  of fludarabine and chlorambucil in WM showed 
a marked increase in transformation into an aggressive form of lymphoma or into the 
development of acute myelogenous leukemia/my elodysplasia among patients that received a 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 18nucleoside analog versus othe r therapi[INVESTIGATOR_393012] (Buske 2013 ). Although the overall 
response rates (ORRs) are high with initial therapi[INVESTIGATOR_014], in  the salvage setting, the ORR is only in 
the range of 30% to 50%, with a median response duration of one year  or less.  Overall, there is a 
paucity of data describing the outcomes of patients with recurrent dise ase due to a lack of 
prospective and retrospective studi es.  As a result, there are li mited data available to support 
salvage therapi[INVESTIGATOR_393013] e available for relapsed or refractory WM. 
There is also an emerging concern in evaluating treatment outcomes with newer biologically 
targeted agents, such as rituximab, alemtu zumab, bortezomib, and everolimus.  Some 
investigators have reported that  there are circumstances where th e serum IgM level is discordant 
with effects on the bone marrow.  Bortezomi b and everolimus can suppress IgM levels 
independent of killing tumor cells in certain patients ( Strauss 2006; Treon 2007 ; Treon 2011) and 
another study showed that in patients treated w ith selective B-cell–depleting agents, such as 
rituximab and alemtuzumab, residual IgM-producing B cells are spared and continue to persist, 
thus potentially skewing the relative response and assessment to treatment ( Varghese 2009 ).
1.1.2. BTK Inhibition as a Treatment Option for WM
A widely expressed mutation, MYD88 L265P, was r ecently identified and provides insight into a 
potential oncogenic dr iving event in WM (Treon 2012).  The MYD88 L265P mutation was 
present in more than 90% of tumor samples fr om patients with WM.  Although highly associated 
with WM, the MYD88 L265P mutati on is not entirely specific; it has also been reported in a 
subset of diffuse large B-cell lymphomas (DLBCL s) and also occurs in a subset of other 
low-grade B-cell lymphoproliferative disorders ( Ngo 2011; Xu 2013). This mutation results in 
tonic MYD88-IRAK signaling that activates the NF-κ B and m itogen-activated protein kinase
(MAPK) pathways that are important for the growth and survival of WM cells (Treon 2012).
The role of Bruton’s tyrosine kinase (BTK) signaling, and the im pact of inhibition of BTK on 
WM cell signaling and survival has been studied in MYD88 L265P-expressing WM cells 
(Yang 2012).  
Ibrutinib, a potent and selective inhibitor of BT K, reduces the association of BTK to MYD88 
L265P, but not to MYD88 WT and si gnificantly reduced downstream NF-κ B, MAPK, and signal
transducer and activator of transcription 3 (STAT3) signali ng, and induced apoptosis in the 
MYD88 L265P-expressing cell lines BCWM.1 and MCWL-1 ( Yang 2013).  In addition, 
ibrutinib demonstrated robust killing in combin ation with a MYD88 inhibitor in primary WM 
patients' bone marrow tumor cells.  These preclin ical studies provided a strong rationale for 
further investigation of ibrutinib in WM.
In summary, ibrutinib is hypothe sized to have potentially impor tant clinical activity in WM by 
[CONTACT_393045] a critical si gnaling kinase in the MYD88 signaling pathway.  
Moreover, ibrutinib represents a therapeutic opt ion targeted to a specific signaling pathway 
involved in WM, in contrast to the currently utilized agents. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493229]-in-class, potent, orally admi nistered covalently-bindi ng inhibitor of Bruton’s 
tyrosine kinase (BTK).  Inhibition of BTK bl ocks downstream B-cell r eceptor (BCR) signaling 
pathways and thus prevents B- cell proliferation. In vitro, ibrutinib inhibits purified BTK and 
selected members of the kinase family with 10-fo ld specificity compared with non-BTK kinases. 
Ibrutinib (Imbruvica®) is approved by [CONTACT_393046] 1) mantle cell lymphoma 
(MCL) in patients who have received at least one  prior therapy, 2) chronic lymphocytic leukemia 
(CLL) in patients who have r eceived at least one prior therapy, 3) CLL in patients with 17p 
deletion, and 4) Waldenström’s Macroglobulinemia . Additionally, full marketing approval in the 
EU was granted by [CONTACT_393047]:  
(1) relapsed or refractory MCL, (2) CLL who have received at le ast 1 prior therapy, (3) CLL in 
the presence of del17p or the TP53 mutation in  subjects unsuitable for chemoimmunotherapy 
(first-line), and (4) WM w ho have received at least one prior ther apy, or in first line treatment for 
patients unsuitable for chemoimmunotherapy.  Ib rutinib is currently under investigation in 
various indications as a singl e agent and in combinations.
B cells are lymphocytes with multiple functions in the immune response, including antigen 
presentation, antibody production, and cytokine  release.  B-cells express cell surface 
immunoglobulins comprising the B- cell receptor (BCR), which is  activated by [CONTACT_375826].  Antigen binding induces receptor aggr egation and the clustering and activation of 
multiple tyrosine kinases, which in turn act ivate further downstream signaling pathways 
(Bishop 2003). 
The process of B-cell matura tion, including immunoglobulin chai n rearrangement and somatic 
mutation, is tightly regulated.  It is thought that B-cell ly mphomas and CLL result from 
mutations and translocations acquire d during normal B-cell development ( Shaffer 2002 ).  
Several lines of evidence sugge st that signaling th rough the BCR is necessary to sustain the 
viability of B-cell malignancies.  
The role of BTK in BCR signal transducti on is demonstrated by [CONTACT_147457] X-linked agammaglo bulinemia and the mouse genetic disease X-
linked immunodeficiency, both caused by a mutation in the BTK gene.  These genetic diseases 
are characterized by [CONTACT_393048] a failure to genera te mature B-cells.  The BTK 
protein is expressed in most he matopoietic cells with the excep tion of T-cells and natural killer
(NK) cells, but the selective effect of BTK mutati ons suggests that its primary functional role is 
in antigen receptor signaling in B-cells ( Satterthwaite 2000 ).  
Data from Study PCYC-[ZIP_CODE] demonstrate that a lthough ibrutinib is rapi[INVESTIGATOR_36062], once daily dosing with ibrutinib is  adequate to sustain 
maxim al pharmacodynamic activity for 24 hours postdose at dose levels ≥2.5 mg/kg .  In Study 
PCYC-[ZIP_CODE], the BTK occupancies for the 2.5 mg/ kg/day to 12.5 mg/kg/day cohorts and for the 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page [ZIP_CODE] mg continuous dosing cohort, were all above  90% at either [ADDRESS_493230] version of the ibrutinib Investigator's Brochure.
1.3. Summary of Nonclinical Data
Ibrutinib is a first-in-class, potent, orally admi nistered covalent inhib itor of Bruton’s tyrosine 
kinase (BTK) currently under investigation in various B-cell malignancies.  
For the most comprehensive nonclinical and clinical  information regarding ibrutinib, please refer 
to the current version of the Investigator's Brochure. 
1.3.1. Pharmacology 
Ibrutinib was designed as a selective and covalent inhibitor of the BTK protein ( Pan 2007 ).  In 
vitro, ibrutinib is a potent inhibitor of BTK activity (IC 50= 0.39 nM).  The irreversible binding 
of ibrutinib to cysteine-[ADDRESS_493231] ained inhibition of BTK 
catalytic activity and enhanced selectivity over ot her kinases that do not cont ain a cysteine at this 
position.  When added directly to human whole bl ood, ibrutinib inhibits si gnal transduction from 
the B-cell receptor and blocks  primary B-cell activation (IC 50= 80 nM) as assayed by [CONTACT_14181]-IgM 
stimulation followed by [CONTACT_398]69 expression (Herman 2011 ).
Ibrutinib arrested cell growth and induced apopt osis in human B-cell lymphoma cell lines in 
vitro and inhibited tumor growth in vivo in xe nograft models (Herman 2011). Ibrutinib also 
inhibited adhesion and migration of mantle ce ll lymphoma (MCL) cells in co-culture and 
reduced tumor burden in lymph node and bone marrow in a murine model of MCL dissemination 
and progression ( Chang 2013a ;Chang 2013b ).
For more detailed and comprehensive inform ation regarding nonclinical pharmacology and 
toxicology, please refer to the curre nt Investigator’s Brochure (IB).
1.3.2. Safety Pharmacology and Toxicology
In safety pharmacology assessments, no treatment -related effects were ob served in the central 
nervous system or respi[INVESTIGATOR_393014].  Furthe r, no treatment-related 
corrected QT interval (QTc) prolongation e ffect was observed at any tested dose in a 
cardiovascular study using te lemetry-monitored dogs.  
Based on data from rat and dog including general toxicity studies up to [ADDRESS_493232] potential for human t oxicity with ibrutinib is predic ted to be in lymphoid tissues 
(lymphoid depletion) and in the gastrointestinal tract (soft fe ces/diarrhea with  or without 
inflammation).  Additional toxicity findings se en in only one species with no observed human 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493233] udies to date include pancreatic acinar cell atrophy (rat), minimally 
decreased trabecular and cortical bon e (rat) and corneal dystrophy (dog).  
In vitro and in vivo genetic toxi city studies showed that ibruti nib is not genotoxic.  In a rat 
embryo-fetal toxicity study, ibrutinib admini stration was associated with fetal loss and 
malformations (teratogenicity) at ibrutin ib doses that result in approximately ≥8 times and 
20 times the exposure (AUC) in subjects administ ered the dose of [ADDRESS_493234] comprehensive nonclinical and clinical  information regarding ibrutinib, please refer 
to the current version of the Investigator’s Brochure.
[IP_ADDRESS]. Carcinogenesis, Mutagenesis,  Impairment of Fertility
Carcinogenicity studies have not  been conducted with ibrutinib.
Ibrutinib was not mutagenic in a bacterial mutage nicity (Ames) assay, was not clastogenic in a 
chromosome aberration assay in mammalian (CHO) cells, nor was it clastogenic in an in vivo 
bone marrow micronucleus assay in mice at doses up to 2000 mg/kg.
Fertility studies with ibrutinib have not been conducted in anim als. In the general toxicology 
studies conducted in rats and dogs , orally administered ibrutinib did not result in adverse effects 
on reproductive organs.1.4. Summary of Clinical Data
1.4.1. Pharmacokinetics and Product Metabolism
Following oral administration of ibrutinib at doses ranging from 1.25 to 12.5 mg/kg/day as well 
as fixed dose levels of 420, 560, and 840 mg /day (Studies PCYC-[ZIP_CODE]-CA, PCYC-1102-CA, 
PCYC-1104-CA), exposure to ibrutinib increas ed as doses increased with substantial 
intersubject variability.  The mean half-life (t
1/2) of ibrutinib across 3 c linical studies ranged 
from 4 to 9 hours, with a median time to maximum plasma concentration (T max) of [ADDRESS_493235] in subjects with chronic 
lymphocytic leukemia (CLL) approximately doubled  the mean systemic exposure compared to 
intake after overnight fasti ng with median time to T maxdelayed from [ADDRESS_493236] dose exposure.
The results of human mass balance study of [14C]-ibrutinib conducted in six healthy male 
subjects demonstrated that less than 10% of the total dose of [14C]-ibrutinib is renally excreted, 
whereas approximately 80% is recovered in fece s.  Subjects with mild and moderate renal 
insufficiency (creatinine cleara nce >30 mL/min) were eligible to enroll in Study PCYC-1102-CA 
in which pharmacokinetic (PK) assessments were included.  No dose adjustment is needed for 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 22mild or moderate renal impairment (greater than  30 mL/min creatinine clearance).  There is no 
data in patients with severe renal impairment or patients on dialysis.  The study of ibrutinib in 
hepatic impaired subjects is currently in progress.
1.5. Summary of Clinical Safety of Ibrutinib
A brief summary of safety data from monothera py and combination ther apy studies is provided 
in below. For more comprehensive safety inform ation please refer to the current version of the 
IB. Additional safety information may be available for approved indications in regional 
prescribing labels where the study is conducted (eg, USPI, SmPC). 
1.5.1. Monotherapy Studies
Pooled safety data for a total of [ADDRESS_493237] frequently reported treatment-emergent a dverse events (TEAEs) in subjects receiving 
ibrutinib as monotherapy (N=1071):
Most frequently reported 
TEAEs >10%  Most frequently reported Grade 3 or 4 TEAEs >2% Most frequently reported Serious TEAEs >1% 
Diarrhea Neutropenia Pneumonia
Fatigue Pneumonia Atrial fibrillation
Nausea Thrombocytopenia Febrile neutropenia
Cough Anemia Pyrexia
Anemia Hypertension  
Pyrexia Atrial fibrillation
Neutropenia 
1.5.2. Combination Therapy Studies
Pooled safety data for a total of 423 subjects treat ed with various therapi[INVESTIGATOR_14129] 4 studies conducted in B-cell mali gnancies, which included 1 randomized-control 
study, are summarized below. Therapi[INVESTIGATOR_393015], 
included BR (bendamustine and rituximab), FCR (fludarabine, cyclophosphamide, and 
rituximab), ofatumumab, and R-CHOP (rituxima b, cyclophosphamide, doxorubicin, vincristine, 
and prednisone).
Most frequently reported TEAEs in subjects receiving ibrutinib in combination therapy (N=423):
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493238] frequently reported 
TEAEs >10%  Most frequently reported Grade 3 or 4 TEAEs >2% Most frequently reported Serious TEAEs >1% 
Neutropenia Neutropenia Febrile neutropenia
Diarrhea Thrombocytopenia Pneumonia
Nausea Febrile neutrope nia Atrial fibrillation
Thrombocytopenia Pneumonia Pyrexia
Fatigue Hypertension 
1.5.3. Risks
[IP_ADDRESS]. Bleeding-Related Events
There have been reports of hemorrhagic events in  subjects treated with ibrutinib, both with and 
without thrombocytopenia. Thes e include minor hemorrhagic events such as contusion, 
epi[INVESTIGATOR_3940], and petechiae; and major hemorrhagic events, some fatal, including gastrointestinal 
bleeding, intracranial hemorrhage, and hematuria. Use of ibrutinib  in subjects requiring other 
anticoagulants or medications that inhibit platelet function may increase the risk of bleeding.
Subjects with congenital bleeding diat hesis have not been studied. See Section [IP_ADDRESS] for 
guidance on concomitant use of anticoagulants, antiplatelet therapy and/or supplements. See 
Section 6.2 for guidance on ibrutinib management  with surgeries or procedures.
[IP_ADDRESS]. Infections 
Fatal and non-fatal infections ha ve occurred with ibrutinib th erapy. At least 25% of subjects 
with MCL and 35% of subjects with CLL had Gr ade 3 or greater inf ections per NCI Common 
Terminology Criteria for Adverse Events (CTCAE). The most commonly reported infections 
include pneumonia, cellulitis, urinary tract infection and sepsis . Although causality has not been
established, cases of progressive multifocal leukoencephalopathy (PML) have occurred in 
patients treated with ibrutinib.
[IP_ADDRESS]. Cytopenias 
Treatment-emergent Grade 3 or 4 cytopenias (neu tropenia, thrombocytopenia, and anemia) were 
reported in subjects tr eated with ibrutinib. 
[IP_ADDRESS]. Atrial Fibrillation
Atrial fibrillation and at rial flutter have been reported in subjects treated with ibrutinib, 
particularly in subjects with cardiac risk factor s, acute infections, and a previous history of atrial
fibrillation. For atrial fibrillation which persists, consider the risks and benefits of ibrutinib 
treatment and follow the protocol dose modification guidelines (see Sections [IP_ADDRESS] and5.3.1.5).
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page [IP_ADDRESS]. Second Primary Malignancies
Second primary malignancies, most frequently skin  cancers, have occurred in subjects treated 
with ibrutinib. Second primary m alignancies including non-skin carcinomas have occurred in 
patients treated with ibrutinib. The most frequent second primary malignancy was non-
melanoma skin cancer.
[IP_ADDRESS]. Tumor Lysis Syndrome
There have been reports of tumor lysis syndrome (TLS) events in subjects treated with single 
agent ibrutinib or in combination with chemotherapy. Subjects at risk of TLS are those with 
comorbidities and/or risk factors such as high tumor burden prior to treatment, increased uric 
acid (hyperuricemia), elevated LDH, bulky disease at baseline, and pre -existing kidney 
abnormalities.
[IP_ADDRESS]. Diarrhea 
Diarrhea is the most frequen tly reported non-hematologic AE with ibrutinib monotherapy and 
combination therapy. Other frequently reported ga strointestinal events include nausea, vomiting, 
and constipation. These events are rarely se vere. Should symptoms be severe or prolonged 
follow the protocol dose m odification guidelines (see Sections [IP_ADDRESS] and [IP_ADDRESS]).
[IP_ADDRESS]. RashRash has been commonly reported in subjects trea ted with either single agent ibrutinib or in 
combination with chemotherapy.  In a ra ndomized Phase 3 study (PCYC-1112-CA), rash 
occurred at a higher rate in the ibrutinib arm than in the control arm. Most rashes were mild to 
moderate in severity.
1.6. Summary of Clinical Data with Ibrutinib in WM
1.6.1. Study PCYC-[ZIP_CODE]
Pharmacyclics LLC sponsored a Phase 1 dose escalation study (Study PCYC-[ZIP_CODE]) that 
enrolled subjects with a vari ety of B-cell malignancies ( Advani 2013 ).  Ibrutinib was well 
tolerated at doses that led to >90% occupancy of the BTK active site.  In this study, the ORR in 
54 evaluable subjects was 57%, including a comple te response rate of 16%.  The study enrolled 
4 male subjects with relapsed/refractory WM who received a median of 3 prior systemic 
regimens and were treated at 2 different dose levels (560 mg/day and 12.5 mg/kg/day). IgM values at baseline varied between 4.4–5.5 g/dL.  All [ADDRESS_493239] 1 adverse 
event (AE), and serious adverse events (SAEs) we re reported in 3 subjects.  The majority of AEs 
were Grade 1 and unrelated to ibrutinib, with the exception of 3 Grade 2 AEs (hypertension, atrial fibrillation [also an SAE], and pyrexia; a ll unrelated to ibrutinib) , and 1 Grade 4 AE of 
neutropenia (unrelated to ibrutinib).  The 5 reported SAEs were  all unrelated to ibrutinib 
([ADDRESS_493240] with Grad e 2 atrial fibrillation, 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 25Grade 1 pneumonia, and Grade 1 pneumonitis).  No subjects required a dose reduction or 
discontinue d due to an AE.  The majority of  AEs did not require treatment; the remainder was 
readily managed with concomitant medications.   
One out of the 4 subjects achieved disease stab ilization according to the treating physician but 
ultimately discontinued ibrutinib due to progressive disease after 8 months.  Three out of the 
4 subjects achieved a partia l response (PR) (IgM re duction of at least 50% from baseline).  The 
induced responses were durable, and all [ADDRESS_493241] been reported to date on the long term extension.
1.6.2. Study [STUDY_ID_REMOVED]
[STUDY_ID_REMOVED], an ongoing Investigator-sponsore d study conducted under IND 113,[ADDRESS_493242] 1 prior therapy fo r WM and met the criteria for further treatment 
according to the consensus panel criteria from the Second IWWM ( Kyle 2003 ).  In this Phase 2 
study, ibrutinib is administered orally 420 mg once daily and continued for 2 years or until 
progressive disease or intolerability.  
Enrollment of 63 subjects was completed in June 2013 ([ADDRESS_493243] University, and 10 subjects at Memorial Sloan-Kettering Cancer 
Center) and represents one of th e largest single-arm studies c onducted specifically in patients 
with WM.  A study progress update of [ADDRESS_493244] s, including 17 with refractory disease was 
presented at the American Societ y of Hematology in December 2013 (Treon 2013). Median 
baseline characteristics included an age of 63 year s, 2 prior therapi[INVESTIGATOR_014] (ran ge 1-6), hematocrit of 
30.8%, hemoglobin of 10.5 g/dL, serum IgM of 3,610 mg/dL, serum M-protein of 2.14 g/dL.  At
the time of best response, medi an serum IgM levels and M-protein declined to 1,340 mg/dL and 
0.84 g/dL, respectively, and median hematocrit a nd hemoglobin rose to 38.1% and 12.6 g/dL, 
respectively.  Thirty-four s ubjects had a 6-month bone marrow assessment showing tumor 
reduction from a median of 70% to 45%.  With a median follow-up of 6 cycles (range 2-15), the 
best overall response rate, with minor response (MR) or better based on the consensus criteria 
adapted from the 3rd Interna tional Workshop on WM, is 81% (4  very good partial response 
[VGPR]; 32 PR, 15 MR), with a major response rate (P R or better) of 57.1% and a median time 
to response of [ADDRESS_493245] did not respond to 
ibrutinib treatment. Grade > 2 treatment-related tox icities include thrombocytopenia (14.3%); 
neutropenia (19.1%); stomatitis (1.6 %); atrial fibrillation (1.6%); diarrhea (1.6%); herpes zoster 
(1.6%); hematoma (1.6%); hyperten sion (1.6%) and epi[INVESTIGATOR_3940] (1.6%) . Fifty-nine subjects remain 
on study with 7 subjects receivi ng reduced doses of ibrutinib. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493246] recent approval of 
IMBRUVICA in WM (IMBRUVICA®USPI, January 2015, IMBRUVICA®Prescribing 
Information, 2015).
1.7. Justification of Study Design and Dose Rationale 
Rituximab is a chimeric human/mouse an tibody that targets the CD20 surface antigen
(Cheson 2002) which is almost always present on WM cells ( San Miguel 2003 ;Konoplev 2005;
Dimopoulos 2009) .  As a single agent at standard dose (ie, 4 weekly infusions at 375 mg/m2), 
rituximab induced a partial response in 35% of untreated and in 20% of previously treated 
patients and the median duration of respons e was 27 months in a study conducted by [CONTACT_1345] 
(Gertz 2004 ). An extended rituximab regimen (rituximab for 4 weeks and for those without 
progression at week 12, 4 additi onal weekly infusions of ritu ximab) reported higher response 
rates (44% and 48%) ( Dimopoulos 2002a; Treon 2005) and a median PFS in patients with 
relapsed WM of around 15 months and 18 months in patients with no prior therapi[INVESTIGATOR_014]
(Treon 2005 ;Ghobrial 2004 ;Dimopoulos 2002b ). As a single agent rituximab is neither 
myelosuppressive nor stem cell toxic. Thus, based on this positive toxicity profile, rituximab 
single agent therapy  is an a ppropriate therapy for WM patient s who present with cytopenias, 
impaired performance, neuropathy or cold-agglutinin anemia ( Kilidireas 2006 )a n di s  a  
recommended therapy for previously treated WM by [CONTACT_393049] (NCCN) and European Society fo r Medical Oncology (ESMO) guidelines.
The rationale for use of ibrutinib in the proposed study is based on the results from Studies 
PCYC-[ZIP_CODE] and an ongoing Investigator-ini tiated study conducted under IND 113,935 that 
demonstrate promising single-agent activity in subjects with prev iously treated WM 
(Section 1.6.1 and Section 1.6.2, respectively).
A Phase 2 investigator-initiated  study of continuously admini stered ibrutinib (420 mg) in 
combination with rituximab (375 mg/m2) administered weekly for the first four weeks (cycle 1), 
then monthly until cycle 6 indicated that ibrutini b in combination with rituximab was safe and 
well tolerated regimen for subjec ts with high-risk CLL. At 18  months the approximate PFS was 
78%; with an approximate OS of 84%. This combination induced high rates of durable responses 
with an overall response rate of 95% (8% CR) ( Burger 2014). For further details, see 
Section 3.2.
Additional Phase 1 combination studies (P CYC-1108-CA and PCYC-1109-CA) demonstrated 
that ibrutinib could be safely combined with chemoimmunotherapy regimens such as 
bendamustine/rituximab (BR) and monoclonal CD ̻20 antibody, ofatumumab, and even more, 
the combinations may enhance its clinical activity in subjects with relapsed and refractory CLL. 
In study PCYC-1108-CA, ibrutinib in combination w ith the BR regimen resulted in an overall 
response rate of 93% (13% CR). The  toxicity profile of the combin ation is similar to that of BR 
alone ( Brown 2013). In study PCYC-1109-CA, ibrutinib in  combination with ofatumumab 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 27resulted in an overall response rate of up to 100% when combining these 2 agents, without 
additional toxicity ( Jaglowski 2012).  
A Phase 1b/2 study (PCYC-1102-CA) demonstrated that continuous ibrutinib monotherapy once daily (either at 420 mg or 840 mg) in treatment na ïve CLL/SLL patients (n=31) was safe and 
well tolerated with a trend toward improved tolera bility with continued ti me on treatment.  With 
a median follow-up of 22.1 months, 26 out of 31 patients remained on study treatment with only 
two discontinuations due to adverse events ( O’Brien 2013 ).  This single agent therapy induced 
high rates of durable responses with an overall response rate of  87%, with 13% achieving a CR.  
The 30 month PFS rate was 96.3% and corresponding OS was 96.6% with the median PFS and OS not yet reached ( O’Brien 2014).
In addition, a Phase 1b study (DBL1002) in subject s with treatment naïve NHL demonstrated 
that ibrutinib in combination with R-CHOP ha d an acceptable safety profile with encouraging 
efficacy leading to a Phase 3 randomized trial design in de novo DLBCL.  Of the 33 patients 
enrolled, 30 completed 6 cycles of therapy, w ith only one discontinuing for an adverse event.
The overall response rate in DLBCL was 100%, with a CR rate ≥ 60%.  There were no 
unexpected adverse events noted during the course of the study ( Younes 2014 ).
The proposed dose for ibrutinib is 420 mg per day (3 x 140-mg capsules) administered once 
daily without interruption. In the ongoing Phase 2 study ([STUDY_ID_REMOVED]), the 420 mg dose 
administered once daily appeared  safe and favorable responses were seen in subjects with 
previously treated WM as outlined in Section 1.5.2 . In addition, ibrutinib at a dose of 420 mg 
per day was safely combined in the above-men tioned combination studi es with rituximab, BR 
(PCYC-1108-CA) or ofatumumab (PCYC-1109-CA).
As the PCYC-[ADDRESS_493247] shown promising single-agent 
activity, an open-label ibrutinib su bstudy (Arm C) is included to further investigate the safety 
and efficacy of ibrutinib monotherapy in subj ects with WM who would otherwise be excluded 
from the randomized study because they are cons idered refractory to th e last prior rituximab-
containing therapy.
2. STUDY OBJECTIVE 
2.1. Primary Objective
To evaluate the effect of the addition of ibrutinib to rituxima b on progression-free survival (PFS) 
assessed by [CONTACT_79029] (I RC) in subjects with WM. Efficacy evaluations
will be based on the modified Consensus Response Criteria from the VIthInternational 
Workshop for WM (NCCN 2014 ).
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 282.2. Secondary Objective(s)
Efficacy
To compare the treatment arms in terms of the following:
• Overall Response Rate (ORR) assessed by [CONTACT_55543] (≥PR; according to the modified VIth
IWWM [ NCCN 2014] criteria).
• Hematological improvement measured by [CONTACT_33308].
• Time to next treatment (TTnT).
• Overall survival (OS).
Safety
• To evaluate the safety and to lerability of ibrutinib when co mbined with rituximab therapy 
compared to rituximab in combination with placebo.
2.3. Exploratory Objectives
• Patient-reported outcomes (PRO) and diseas e-related symptoms according to FACT-An. 
• Patient-reported outcomes (PROs) and diseas e-related symptoms according to Euro QoL 
5 dimension questionnaire (EQ-5D-5L).
• Duration of response (DOR) according to IRC assessment.
• Clinical response rate (CRR) assessed by [CONTACT_55543] (≥MR; according to the modified VIth
IWWM [ NCCN 2014] criteria).
• Efficacy assessment by [CONTACT_10670] (≥PR and ≥MR; according to the modified VIth
IWWM [ NCCN 2014] criteria).
• To determine the pharmacokinetic s (PK) of ibrutinib in comb ination with rituximab in 
subjects with WM.
• Evaluation of medical resource utilization (MRU) (eg, requirements of plasmapheresis, 
transfusions and use of growth factors).
• Prognostic and predictive biomarkers and ge netics relative to treatment outcomes.
Open-label Substudy Treatment Arm C 
The objectives are to evaluate the efficacy and safety of open-label ibrutinib monotherapy in 
WM subjects who are considered refractory to th e last prior rituximab-containing therapy (refer 
to Section 4.2 ). PFS, ORR, hematological improvement  measured by [CONTACT_33308], TTnT, FACT-
An, OS and other efficacy parameters as well as safety analyses will be summarized 
descriptively for Arm C. No comparator analysis will be done with Arms A or B. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493248] prior rituximab-
containing therapy (refer to Section 4.2 ).
The study duration is estimated to be [ADDRESS_493249]. 
Approximately 150 subjects will be randomized in a 1:1 ratio to receive ibrutinib and rituximab 
(Treatment Arm A) or placebo a nd rituximab (Treatment Arm B).
Up to 30 subjects will be enrolled in the open-la bel ibrutinib monotherapy substudy (Treatment 
Arm C).The study will include a Screening Phase, Treatment Phase and a Follow-Up Phase. 
The Screening Phase assessments will be performe d within [ADDRESS_493250] signs informed consent. During the Screening Phase, the 
subjects’ eligibility will be determined. Eligib le subjects must ha ve clinicopathological
diagnosis of Waldenström’s macroglobulinemia (WM) confirmed by [CONTACT_393050] 
(Owen 2003). Subjects with previously treated WM mu st have documented relapsed/refractory 
disease from their most recent prior therapy accor ding to the modified WM consensus criteria.
Further, subjects must have symptomatic disease meeting at least 1 of the recommendations from 
the Second International Workshop on Walden ström's Macroglobulinemia for requiring 
treatment. Subjects who meet all the  inclusion/exclusion criteria are eligible to  enter the study.
The Treatment Phase will extend from randomization (Arm A and Arm B) or  first dose of study 
drug (Arm C) until the End-of-Treatment Visit (w hich should occur [ADDRESS_493251] dose of 
study drug or prior to the start of a new anti cancer treatment). Initiation of study treatment 
should occur within 72 hours of randomization.  All subjects in Arms A and B will receive intravenous rituximab weekly for 4 consecutive weeks, followed by a second course of rituximab 
administered weekly for 4 consecutive weeks afte r a 3-month interval. In addition, all subjects
in Arms A and B, according to randomization, will receive oral study drug (ibrutinib or matching 
placebo), administered daily and continuously un til criteria for permanent discontinuation of 
study drug are met ( Section 9.2 ), such as IRC confirmed disease progression, study drug is no 
longer tolerable by [CONTACT_1130], or study end. All subjects in Arm C w ill receive oral ibrutinib daily 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493252] discontinue all 
study treatment and may be assessed for potential cross over treatment.
After the End-of-Treatment Visit (30 days ± [ADDRESS_493253] dos e of study drug or prior to the 
start of a new anticancer treatment) has been performed, subjects will con tinue to be monitored 
through either response follow-up or survival foll ow-up and will continue until death, lost to 
follow-up, consent withdrawal, or study end, whichever occurs first.
•The Response Follow-up Phase will occur for su bjects who discontinue for reasons other 
than disease progression and will include efficacy assessments every 12 weeks until 
disease progression confirmed by [CONTACT_393051] (IRC), regardless of 
initiation of subsequent anticancer treatm ent. Subjects with IRC confirmed disease 
progression during the Response Follow-up Phas e will continue to be followed in the 
Survival Follow-Up Phase.
•The Survival Follow-up Phase will occur for subjects with IRC confirmed disease 
progression and will be followed for survival, subsequent anti-cancer therapy and other
malignancies every 12 weeks until study end.
Access to next-line ibrutinib (cross-over) for subjects with IRC confirmed disease progression 
and treated with placebo in combination with rituximab (Arm B) may be provided as outlined in 
Section 7.7.
An independent Data Monitoring Committee (DMC) will be formed and constituted according to 
regulatory agency guidelines. Detailed information regarding the composition of the DMC and 
detailed DMC procedures will be provided in a separate charter. The DMC will review the safety data periodically and the interim analys is results and provide recommendations according 
to the charter. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493254] a centrally conf irmed clinicopathological diagnosis of WM as 
defined by [CONTACT_393052] ( Owen 2003) ;and 
must be in need of treatment in accordance wi th the “Consensus Panel Two” recommendations 
from the Second International Works hop on Waldenström’s Macroglobulinemia ( Kyle 2003 ).
Those subjects who have been previously treat ed must have documented relapsed/refractory 
disease to their most recent prior therapy.
Subjects in Arms A and B who had previously received a rituximab-c ontaining regimen should 
have a documented response (at least MR) on the last prior rituximab-containing regimen and 
any previous rituximab therapy must have ended at  least 12 months prior to enrollment in this 
protocol. Subjects who do not meet these rituximab-re lated criteria may be eligible to enroll in 
the open-label ibrutinib monot herapy substudy (Arm C).
3.2. Study Rationale 
This is a randomized, double-blind, Phase 3 study designed to assess  the safety and efficacy of 
ibrutinib in combination with rituximab compared to placebo in combination with rituximab in 
subjects with WM. 
Rituximab, given either as a single agent or in  combination, is currently a recommended therapy 
for previously treated and untreated WM in NCCN 2012 and ESMO 2013 guidelines
(Anderson 2012; Buske 2013 ). All subjects will receive rituximab therapy ; the study will 
include two treatment arms with approximately  75 subjects in both treatment arms to observe 
71 PFS events. Assuming a 2-fold improvement (h azard ratio of 0.5) in  median PFS of the 
rituximab in combination with ibrutinib arm over rituximab and placebo arm (median PFS 
assumption for rituximab and placebo arm is 15 months), the study has at least 80% power to 
achieve a statistical si gnificance level of 5% (2-sided) under exponential distribution for PFS.
The proposed dose for rituximab is 375 mg/m2intravenous (IV) administered once weekly for 
[ADDRESS_493255] current treatment 
guidance for rituximab in relapsed/refractory WM ( Dimopoulos 2002a ;Treon 2005).
The proposed dose for ibrutinib is 420 mg per day (3 x 140-mg capsules) administered once daily 
without interruption. In the ongoing Phas e 2 study ([STUDY_ID_REMOVED]), the 420 mg dose 
administered once daily demonstrated a favorable be nefit/risk profile in s ubjects with previously 
treated WM as outlined in Section 1.6.2 .
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 33Ibrutinib at 420 mg in comb ination with rituximab 375 mg/m2intravenous (IV) has been shown
to be a safe, well tolerated and an active treatment regimen in high-risk CLL subjects
(Burger 2014 ). At a median follow up of 16.8 months, 31 of 40 subjects continued on therapy 
(14 out of 20 with del17p or TP53 mutation) without disease progres sion. 39 subjects were 
evaluable for response assessment per 2008 IWCLL guidelines; 34 (87%) achieved partial 
remission (PR), and three (8%) complete remi ssion (CR), accounting for an ORR of 95%. The 
ORR in the 20 patients with del17p or TP53 mutation was 90% (16 PR, 2 CR). Among the 9
subjects that came off study, four subjects came off study because of possibly treatment-related 
toxicity (two pneumonia, one pulmonary infection and one grade 3 mucositis), three subjects had 
progressive disease (including one  Richter’s transformation), a nd two subjects died while on 
therapy unrelated to study treatment (one due to infectious complications and one due to 
respi[INVESTIGATOR_393016]). Treatment generally was well 
tolerated, with infectious comp lications (8 cases of pneumonia and 9 cases of upper respi[INVESTIGATOR_58776]) being the most common complication.  There were nine Grade 3 or higher, possibly 
related AEs: lung infection (n=2), neutropeni a (n=2), upper respi[INVESTIGATOR_393017] (n=1), 
transaminase increase (n=1), mucositis (n=1), and peripheral neuropathy (n=1). Milder toxicities 
included Grade 1-2 bruising and rash (n=15), na usea or acid reflux (n=10), Grade 2 subdural 
hematoma (n=1), fatigue (n=7), bone pain, myalgias , and arthralgia (n=13), or diarrhea (n=17).  
Taken together, these data support the utility of the proposed combination of rituximab and 
ibrutinib in subjects with WM.
Ibrutinib monotherapy has indicated favorable responses in subjects who failed prior CD20 
therapy alone or in combinati on with other agents based on th e findings in an ongoing Phase 2 
study in WM ([STUDY_ID_REMOVED], refer to Section 1.6.2 ). Therefore, subjects who are considered 
refractory to the last prior ri tuximab-containing therapy may be e ligible to enroll in the open-
label monotherapy substudy (Treatment Arm C).
3.3. Statement of Compliance
This study will be conducted in compliance with this protocol, principles of International 
Conference on Harmonisation (ICH), Good Clinical Practice (GCP),  Declaration of Helsinki, 
and all applicable national and local regulations gove rning clinical studies.
4. SUBJECT SELECTION
4.1. Eligibility Criteria for the Ra ndomized Study (Arm A and Arm B)
4.1.1. Inclusion Criteria
To be enrolled in the study, each potential subjec t must satisfy all of the following inclusion 
criteria.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 34Disease Related
1. Subjects with untreated or previously  treated Waldenström’s Macroglobulinemia
a. Previously treated subjects must have e ither documented disease progression or had no 
response (stable disease) to the most recent treatment regimen.
2. Centrally confirmed clinicopathological diagnosis of WM in accordance with the consensus 
panel of the Second Intern ational Workshop on WM ( Owen 2003).
3. Measurable disease defined as s erum monoclonal IgM >0.5 g/dL.
4. Symptomatic disease meeting at least 1 of the recommendations from the Second 
International Workshop on Waldenström Macroglobulinemia for requiring treatment
(Kyle 2003 ):
a. Constitutional symptoms documented in th e subject’s chart w ith supportive objective 
measures, as appropriate, defined as one or more of the following disease-related 
symptoms or signs:
i. Unintentional weight loss ≥ 10% within the previous  6 months prior to 
Screening
ii. Fevers higher than 100.5°F or 38.0° C for [ADDRESS_493256] due to WM
c. Symptomatic hyperviscosity or serum visc osity levels greater than 4.0 centipoises
d. Lymph adenopathy which is either symptomatic or bulky ( ≥5cm in maximum 
diameter)
e. Symptomatic hepatomegaly and/or sple nomegaly and/or organ tissue infiltration
f. Peripheral neuropathy due to WM
g. Symptomatic cryoglobulinemia
h. Cold agglutinin anemia
i. IgM related immune hemolytic anemia and/or thrombocytopenia
j. Nephropathy related to WMk. Amyloidosis related to WMl.Hemoglobin ≤10g/dL
m. Platelet count <100x10
9/L
n. Serum monoclonal protein >5g/dL, with  or without overt clinical symptoms
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 35Laboratory
5. Adequate hematologic function defined as: 
a. Absolute neutrophil count >750 cells/mm3(0.75 x 109/L) independent of growth 
factor support within [ADDRESS_493257] dose with study drug.  
b. Platelet count >50,000 cells/mm3( 5 0x1 09/L) without transfusi on support within 
[ADDRESS_493258] dose of study drug.
c.Hemoglobin ≥ 8 g/dL without transfusion or growth factor suppor t within [ADDRESS_493259] dose of study drug.
6. Adequate hepatic and renal function defined as:
a. Serum aspartate transaminase (AST) or  alanine transaminase (ALT) <3.0 x upper 
limit of normal (ULN).
b.Estimated Creatinine Clearance ≥30 m L/min).
c.Bilirubin ≤1.[ADDRESS_493260] (unless bilirubin rise is due to Gilbert’s syndrome or of non -
hepatic origin).
7. PT/INR ≤ 1.[ADDRESS_493261] and PTT (aPTT) ≤1.[ADDRESS_493262] unless abnormality is unrelated to a 
coagulopathy or bleeding disorder (when treat ed with warfarin or other vitamin K 
antagonists, then INR ≤3.0).
Demographic8.Men and women ≥ 18 years of age.
9. Eastern Cooperative Oncology Grou p (ECOG) performance status of ≤2.
Ethical/Other10. Female subjects who are of non-reproductive po tential (ie, post-menopausal by [CONTACT_969] - no
menses for ≥2year; OR history of hysterectomy; OR hi story of bilateral tubal ligation; OR 
history of bilateral oophorectomy). Female subj ects of reproductive potential must have a 
negative pregnancy test upon study entry.
11. Male and female subjects of reproductive po tential who agree to use highly effective 
methods of birth control (eg, c ondoms, implants, injectables, co mbined oral contraceptives, 
some intrauterine devices [IUDs], complete abstinence
a, or sterilized partner) during the 
period of therapy and for [ADDRESS_493263]  dose of study drug and 90 days (males) after 
the last dose of study drug.
aComplete abstinence is a highly effective method only if defined as refraining from heterosexual intercourse 
during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the clinical tria l and the preferred and usual lifestyle of the subject. 
http://www hma.eu/fileadmin/dateien/Human_Medicines/01 
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493264] prior rituximab-containing therapy defined as either 
• Relapse after the last ritu ximab-containing therapy <[ADDRESS_493265] dose of 
rituximab, 
OR
• Failure to achieve at least a MR after the last rituximab-containing therapy.
If the subject meets this exclusion criteri on and therefore is excluded from the main 
randomized study, participation in  the non randomized substudy (Arm C) may be considered 
(Section 4.2 )
3. Rituximab treatment within the last [ADDRESS_493266] dose of study drug.
4. Known anaphylaxis or IgE-mediated hypersensitiv ity to murine proteins or to any component 
of rituximab.
5. Prior exposure to ibrutinib or other BTK inhibitors.
6. Received any WM-related therapy (eg, chem otherapy, immunotherapy, investigational drug)
≤[ADDRESS_493267] admi nistration of study treatment.
7. Plasmapheresis <[ADDRESS_493268] one serum 
IgM central assessment was performed during the screening period and was >[ADDRESS_493269] recent plasmapheresis procedure.
•Subjects with high IgM values or viscos ity symptoms during screening may receive 
plasmapheresis prior to initi ating study drug (refer to Section 6.3 ) if the previous 
plasmapheresis was performed >35 days befo re the plasmapheresis performed during 
screening (in order to obtain a true base line IgM value for efficacy evaluations).
8. History of other malignancies, except: 
•Malignancy treated with cura tive intent and with no known active disease present for
≥[ADDRESS_493270] dose of study drug and felt to be at low risk for recurrence by 
[CONTACT_35425].
•Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of 
disease.
•Adequately treated carcinoma in situ without evid ence of disease.
9. Vaccinated with live, attenuated vaccines wi thin [ADDRESS_493271] dose of study drug.
10.Recent infection requiring systemic treatment that was completed ≤[ADDRESS_493272] 
dose of study drug.
11. Known bleeding disorders (eg, von Willebrand’s disease) or hemophilia.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 3712. History of stroke or intracranial hemo rrhage within 12 months prior to enrollment.
13. Known history of infection with human immunodeficiency virus (HIV).
14. Active or chronic infection w ith hepatitis C virus (HCV) or hepatitis B virus (HBV) defined 
by [CONTACT_393053] (PCR).
15. Any uncontrolled active systemic infection.
16. Major surgery (as defined in Section 6.2.2 ) within [ADDRESS_493273] dose of study drug.
17. Any life-threatening il lness, medical condition, or organ system dysfunction that, in the 
investigator’s opi[INVESTIGATOR_1649], could compromise the s ubject’s safety or put the study outcomes at 
undue risk.
18. Currently active, clinically significant car diovascular disease, such as uncontrolled 
arrhythmia or Class 3 or 4 congestive hear t failure as defined by [CONTACT_393054]; or a history of myocardial  infarction, unstable angina, 
or acute coronary syndrome within  6 months prior to randomization.
19. Unable to swallow capsules or malabsorpti on syndrome, disease si gnificantly affecting 
gastrointestinal function, or resection of the stomach or small bowel, symptomatic 
inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction.
20. Requires treatment with a strong cyto chrome P450 (CYP) 3A inhibitor (see Appendix 3).
21. Lactating or pregnant.
22. Unwilling or unable to participate in a ll required study evaluations and procedures.
23. Unable to understand the pur pose and risks of the study and to provide a signed and dated 
informed consent form (ICF) and authorizati on to use protected health information (in 
accordance with national and local subject privacy regulations).
4.2. Eligibility Criteria for Open-l abel Substudy Treatment Arm C  
4.2.1. Inclusion Criteria 
To be enrolled in the substudy, each potential su bject must meet all of the inclusion criteria 
defined in Section 4.1.1. IN ADDITION, the following criterion must be met:
1. Disease that is refractory to the last prior rituximab-containing therapy defined as either 
• Relapse after the last rituximab-containi ng therapy <[ADDRESS_493274] dose of 
rituximab, 
OR
• Failure to achieve at least a MR after the last rituximab-containing therapy.
4.2.2. Exclusion Criteria
The exclusion criteria for the substudy are identical to those of the main randomized study as 
described in Section 4.1.2, EXCEPT for criteria 2, 3, and 4, wh ich are related to prior rituximab 
use and do not apply for the substudy Arm C.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493275] has completed all baseline (scr eening) procedures and met all requirements of 
the inclusion/exclusion criteria, study site personnel will submit the Eligibility Worksheet to the 
Medical Monitor or Sponsor designee for approv al. In order to begin treatment, study personnel 
will register the subject into th e Interactive Web Response System (IWRS) to have drug assigned 
to that subject. The first dose of study drug shoul d be administered after randomization, but no 
more than [ADDRESS_493276] has been randomized by [CONTACT_10966].
Approximately 150 subjects will be randomized in a 1:1 ratio to each of the 2 treatment arms:
• Treatment Arm A: Oral Ib rutinib in combination with intravenous Rituximab 
• Treatment Arm B: Oral Pl acebo in combination with intravenous Rituximab 
Central randomization will be implemented in th is study. Randomization will be stratified using 
the following stratification factors and subjects will be randomized in a 1:1 ratio to receive either 
ibrutinib/rituximab or placebo/rituximab)  within each randomization stratum: 
a) WM IPSS assessed at Screening (Low vs. Intermediate vs. High)b) Number of prior systemic treatment regimens (0, 1-2 vs. ≥3)
c) ECOG status (0-1 vs. 2)
The interactive web response system (IWRS) will assign a unique treatment code, which will 
dictate the treatment assignment and matching st udy drug kit for the subject. The requestor must 
use his or her own user identification and personal identification number  when contact[CONTACT_111127], and will then give the relevant subject details to uniquely identify the subject.
Subjects eligible for open-label substudy Arm C w ill be enrolled using the IWRS to obtain a 
unique treatment code.
Blinding
This is a double-blind study; therefore, subjec ts, investigators, and the Sponsor’s study team 
members will remain blinded to treatment assi gnment. The investigator may request to unblind 
subjects who meet the criteria for next-line therapy with ibrutinib per Section 7.[ADDRESS_493277] is reviewed, by [CONTACT_1034]’s  designee, the investigator will be informed if the request to 
unblind can be approved.
The investigator will not be provided with ra ndomization codes. The codes will be maintained 
within the IWRS, which has the functionality to allo w the investigator to break the blind for an 
individual subject.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 39Data that may potentially unblind the tr eatment assignment (ie, study drug plasma 
concentrations) will be handled with special care to ensure that the integrity of the blind is 
maintained and the potential for bias is minimi zed. This may include making special provisions, 
such as segregating the data in question from view  by [CONTACT_473], cl inical team, or others 
as appropriate until the time of database lock and/or unblinding.
Under normal circumstances, the blind should no t be broken. The blind should be broken only 
for subjects who meet the criteria for next- line therapy with ibrutinib and after approval is
received from the Sponsor’s designee per Section 7.7 , or if specific emergency treatment/course 
of action would be dictated by [CONTACT_393055]. In such cases, the 
investigator may in an emergency determine th e identity of the treatment by [CONTACT_117191]. It is recommended that the i nvestigator contact [CONTACT_393056], if possible, to 
discuss the particular situation before breaking the blind. Telephone  contact [CONTACT_376685] [ADDRESS_493278]'s source documents in a secure manner. A subject whose treatment 
assignment has been unblinded may continue the study treatment if receiving clinical benefit, 
and the subject should continue to return for scheduled study eval uations.  The single-blind (ie, 
subject remains blinded to treatment assignment)  should be maintained provided the subject’s 
safety is not compromised.
At the time of the interim analysis, the randomi zation codes and, if requi red, the translation of 
randomization codes into treatment and control gr oups will be disclosed to  those authorized and 
only for those subjects include d in the interim analysis.
5.2. Study Treatment
All eligible subjects for randomizat ion will be treated with rituxima b in combination with either 
ibrutinib (Arm A) or ma tching placebo (Arm B).
Oral study medications (ibrutinib/placebo) are r ecommended to be administered on an outpatient 
basis. Subjects will be randomized to ibrutini b or matching placebo in a 1:1 ratio. Blinded study 
medication will be administered for continuous daily dosing.
Open-label Substudy Treatment Arm C
Up to 30 subjects will be enrolled in an open-label substudy:
• Treatment Arm C: Oral ibrutinib 
All subjects eligible for the substudy will be treated with ibrutinib monotherapy with continuous 
daily dosing. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 40All subjects treated in this substudy will fo llow guidelines for ibrutinib/placebo dosing and 
toxicity management as described for the randomi zed treatment arms (Arm A and Arm B) in the 
protocol. 
5.2.1. Treatment Arm A (Ibrutinib/Rituximab)
Ibrutinib: 420 mg (3 capsules) orally administ ered daily beginning from Day 1 in Week 1
Rituximab: 375 mg/m2IV per package insert weekly for four consecutive weeks, followed by 
a second four-weekly rituximab cour se after a three-month interval.
Day 1 of Weeks 1-4 and Weeks 17-20 (tot al of 8 infusions of rituximab)
5.2.2. Treatment Arm B (Placebo/Rituximab)Placebo: [ADDRESS_493279] ered daily beginning from Day 1 in Week 1
Rituximab: 375 mg/m
2IV per package insert weekly for four consecutive weeks, followed by 
a second four-weekly rituximab cour se after a three-month interval.
Day 1 of Weeks 1-4 and Weeks 17-20 (tot al of 8 infusions of rituximab)
5.2.3. Treatment Arm C (Ibrutinib Open-label Substudy)Ibrutinib: 420 mg (3 capsules) orally administ ered daily beginning from Day 1 in Week 1
5.3. Study Medication
5.3.1. Ibrutinib/Placebo
For the purposes of this study, ibrutinib and placebo refers to the blinded label study drug used in 
this study in treatment arms A and B.  All subjects will follow the guidelines for ibrutinib dosing and toxicity management. Study drug refers to both ibrutinib and placebo. In the substudy(Arm C), subjects will receive ibrutinib and will also  follow the guidelines for ibrutinib dosing 
and toxicity management.
[IP_ADDRESS]. Formulation/Packaging/Storage
Ibrutinib capsules are provided as a hard gelatin  capsule containing 140 mg  of ibrutinib.  All 
formulation excipi[INVESTIGATOR_393018].  Refer to the 
ibrutinib Investigator's Broc hure for a list of excipi[INVESTIGATOR_840]. 
Matching placebo capsules are provided as a hard ge latin capsule and look identical to ibrutinib 
capsules.
The ibrutinib and placebo capsules will be packaged in opaque high-density polyethylene plastic 
bottles with labels bearing the appropriate label text as required by [CONTACT_40714].  All study drugs will be dispensed in child-resistant packaging.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 41Refer to the pharmacy manual/si te investigational product manual for additional guidance on 
study drug storage, prep aration and handling.
Study drug labels will contain information to me et the applicable regulatory requirements.
[IP_ADDRESS]. Dose and Administration
Study drug (3 capsules) is administered orally once daily with approximately 8 ounces (240 mL) 
of water. The capsules should be swallowed whole and should not be opened, broken, or 
chewed. The use of strong CYP3A inhibitors/ind ucers, and grapefruit and Seville oranges 
should be avoided for the duration of the study ( Appendix 3).
If a dose is not taken at the scheduled time, it can be taken as soon as possible on the same day 
with a return to the normal schedule the following day.  The subject should not take extra 
capsules to make up the missed dose. Missed doses of study drug will not be made up.
The first dose will be administered in the clin ic on Day [ADDRESS_493280]  be returned to the 
site and drug accountability records ( Section 12.8 ) updated at each visit.  Returned capsules must 
not be re-dispensed to anyone.
Study drug will be dosed 0-30 minutes before th e rituximab infusion at the Week 4 visit.
Study drug dosing is continuous (without interr uptions) throughout the Treatment Phase. If 
rituximab infusion is delayed due to scheduli ng conflicts, study drug dosing should continue. 
Refer to Section 7.4.1 for oral dose and administration in structions on PK sampling visits.
[IP_ADDRESS]. Overdose
Any dose of study drug administered in excess of that specified in this protocol is considered to 
be an overdose.  Signs and symptoms of an overdose that meet any Serious Adverse Event 
criterion must be reported as a Serious Adve rse Event in the appropriate time frame and 
documented as clinical sequelae to an overdose.
There is no specific experience in the manage ment of ibrutinib overdose in patients. No 
maximum tolerated dose was reached in the Ph ase 1 study in which subjects received up to 
12.5 mg/kg/day (1400 mg/day). Healthy subjects were exposed up to single dose of [ADDRESS_493281] experienced reversible Grad e 4 hepatic enzyme increases (AST and ALT) 
after a dose of 1680 mg. Subjects who ingested mo re than the recommended dosage should be 
closely monitored and given appropriate supportive treatment.
Refer to Section [IP_ADDRESS] for further information regarding AE reporting. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page [IP_ADDRESS]. Dose Hold, Reduction or Discontinuati on of Study Drug (Ibrutinib/Placebo)
Treatment with study drug shoul d be withheld for any unmanag eable, potentially study drug-
related non-hematological toxicity that is Grad e 3 or higher in severity and any hematologic 
toxicity meeting the criteria in Section [IP_ADDRESS] .  Subjects who require full-dose of anticoagulant 
treatment (eg, heparin) should have study drug held until stable on anticoagulant therapy 
(Section [IP_ADDRESS]).  Subjects that require an invasive procedure or surgery must have study drug 
withheld according to the guidance in Section 6.2.  Any other clinically important events where 
dose delays may be considered appropriate by [CONTACT_3433] e Investigator must be discussed with the 
Medical Monitor.
Study drug may be withheld for a maximum of 28  consecutive days for toxicity. Study drug 
should be discontinued in the even t of a toxicity lasting more than 28 days, unless reviewed and 
approved by [CONTACT_1689].
[IP_ADDRESS]. Dose Modification of Study Drug (Ibrutinib/Placebo)
The dose of study drug should be modified according to the dose modification guidance in 
Table 2 if any of the following toxicities occur:
• Grade 4 ANC (<500/ μL) for more than 7 days. The use of neutrophil growth factors is 
permitted per American Societ y of Clinical Oncology (ASC O) guidelines and must be 
recorded in the electronic case report form (eCRF).  Refer to Section 6 for instruction 
regarding the use of growth factor support.
• Grade 3 thrombocyt openia (platelets <50,000/μL) in the presence of Grade ≥2 bleeding 
events.
• Grade 4 thrombocytope nia (platelets<25,000/μ L).
• Grade 3 or 4 nausea, vomiting, or diarrhea if persistent, despi[INVESTIGATOR_9025]-emetic 
and/or anti-diarrheal therapy.
• Any other Grade 4 or unmanageable Grad e 3 toxicity attributed to study drug.
For Grade 3 or 4 atrial fibrillation or persistent atrial fibrillation of any grade, consider the risks 
and benefits of ibrutinib treatment . If clinically indicated, th e use of anticoagulants or 
antiplatelet agents may be considered for th e thromboprophylaxis of atrial fibrillation 
(Section [IP_ADDRESS]) .
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 43Table 2: Study Drug (Ibrutinib/Placebo) Dose Modifications
Occurrence Action to be Taken
First Withhold study drug until recovery to Grade ≤ 1 or baseline; may resta rt at original dose 
level
Second Withhold study drug until recovery to Grade ≤ 1 or baseline; may restart at 1 dose level 
lower (ie, 280 mg/day / 2 capsules)
Third Withhold study drug until recovery to Grade ≤ 1 or baseline; may restart at 1 dose level 
lower (ie, 140 mg/day / 1 capsule)
Fourth Discontinue study druga
aIf the oral study drug (ibrutinib/placebo) is discontinued for toxicity, subject will end the Treatment Phase of the 
study.
Please see Section [IP_ADDRESS] for guidelines for management of study drug in subjects who require 
treatment with a strong CYP3A inhibitor. 
Subjects enrolled in Arm C will receive ibru tinib monotherapy and will follow the same dose 
modifications as outlined for ibrutinib/placebo above.  All dos e modifications/reductions of the 
blinded oral study drug or open-label ibrutinib must be recorded in the eCRF.
[IP_ADDRESS]. Dose Modification for Hepatic Impaired Subjects
Ibrutinib is metabolized in the liver. For subjec ts with mild liver impairment (Child-Pugh class 
A), the recommended dose for ibrutinib/placebo is 280 mg daily (two capsules). For subjects 
with moderate liver impairment (Child-Pugh cl ass B), the recommended dose is 140 mg daily 
(one capsule). Subjects who develop severe he patic impairment (Child-Pugh class C) must hold 
study drug until resolved to moderate impairment (Child-Pugh class B) or better. Monitor 
subjects for signs of toxicity and follow dos e modification guidance as needed (Refer to 
Appendix 10).
5.3.2. Rituximab
All subjects in Arms A and B will receive r ituximab and will follow the package insert for 
rituximab dosing and toxicity management.
[IP_ADDRESS]. Formulation, Packaging, and Storage of Rituximab
Rituximab is a sterile, clear, colorless, preserva tive-free liquid concentrate for IV administration. 
Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg (10 mL) or 500 mg 
(50 mL) single-use vials. 
Rituximab vials should be stored refrigerated between 2° to 8°C (36° to 46°F). Vials should be 
protected from light. Do not freeze or shake. 
For more information regarding stability and storage refer to the Pharmacy Manual.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page [IP_ADDRESS]. Dosage, Preparation and Administration of Rituximab
The first dose of rituximab will be administered IV on Day 1 of Week 1 of the Treatment Phase, 
and will continue to be administered at the clin ical site weekly for four consecutive weeks, 
followed by a second four-weekly rituximab course  after a three-month interval (Week 1, 2, 3, 4
and 17, 18, 19, and 20).  Rituximab doses may be delayed for up to 3 days due to scheduling 
conflicts.
Rituximab will be administered IV by [CONTACT_393057].
Study drug will be administered 0–30 minutes prio r to rituximab infusion at the Week 4 visit.
Rituximab should not be mixed or diluted with other drugs.
Rituximab will be administered as an IV infusi on.  Premedication will be given prior to each 
administration.
Premedication: Prior to each infusion administer  acetaminophen (or equivalent) and an 
antihistamine.
• First Infusion: Initiate rituximab infusion at a rate of 50 mg/hr.  In the absence of infusion 
toxicity, increase infusion rate by 50 mg/hr increments every 30 minutes, to a maximum 
of 400 mg/hr.
• Subsequent Infusions: If no infusion reactions  occur during the firs t infusion, initiate 
rituximab infusion at a rate of 100 mg/hr.  In  the absence of infusi on toxicity, increase 
rate by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr.
In the event of an infusion reaction , institute medical management (eg, glucocorticoids, 
epi[INVESTIGATOR_238], bronchodilators, or oxygen) as appropriate.  If hypersensitivity (non-IgE-mediated) 
or an infusion reaction develops, the infusion should be temporarily slowed or interrupted.
The infusion can continue at one-half the prev ious rate upon improvement of subject symptoms.
Depending on the severity of the infusion reaction and the required interventions, treatment with 
rituximab may be temporarily or permanently  discontinued. See Section [IP_ADDRESS] for further 
instructions.
Unused rituximab must be disposed of accord ing to the sites drug disposal policy and drug 
accountability records updated.  
[IP_ADDRESS]. Dose Delay of Rituximab
In order to initiate a subsequent dose with  rituximab, the subject must not have any 
unmanageable, potentially rituxima b-related non-hematological toxici ty that is Grade [ADDRESS_493282] be discusse d with the Medical Monitor.  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493283] the 
Medical Monitor. 
Rituximab may be withheld for a maximum of 28  consecutive days for toxicity.  Rituximab 
should be discontinued in the event of a rituxi mab toxicity lasting more than 28 days, unless 
reviewed and approved by [CONTACT_1689].
[IP_ADDRESS]. Dose Interruption of Rituximab
Modify administration of rituximab for infu sion-related reactions of any severity.  
• For Grade 1 and 2 infusion-related reactions , slow the infusion rate by a minimum of 
50% and monitor subject closely.  Provide medical intervention as indicated.  If 
symptoms resolve, complete the infusion at  the decreased rate.  If symptoms do not 
improve, or worsen, discontinue the infusion.
• For Grade [ADDRESS_493284] closely and if symptoms resolve resume the 
infusion at 50% or less of the previous rate.  If there is no return of symptoms complete 
the infusion at the decreased rate. If sympto ms do not improve, or worsen, discontinue 
the infusion. 
• For Grade [ADDRESS_493285] the me dical monitor prior to re-challenge or if permanent 
discontinuation of rituximab is necessary.
[IP_ADDRESS]. Dose Modification of RituximabThe dose of rituximab should be modified according to the dose modification guidelines in 
Table 3 if any of the following toxicities occur:
• Any Grade 4 or unmanageable Grade 3 non-hemato logic toxicity attributed to rituximab.
Note: For guidance on management of rituximab in relation to infusion reactions see 
Section [IP_ADDRESS].
Table 3: Dose Modification for Rituximab Toxicity 
Occurrence Action to be Taken
1st-3rdWithhold rituximab until recovery to Grade ≤1 or baseline; may restart at 
original dose level
Fourth Discontinue rituximaba
aIf rituximab is discontinued for toxicity, subject may continue on study drug (ibrutinib/placebo).
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page [IP_ADDRESS]. Rituximab Associated “IgM flare” 
Plasmapheresis may be indicated before or durin g the initial rituximab therapy to avoid or to 
mange IgM-flare related complications such as hyperviscosity (Refer to Section 6.3 ).
Therapy with rituximab is commonly associated with a surge of IgM levels (IgM flare). This 
initial transient increase of IgM levels mostly does not indicate disease progression at treatment 
initiation and subjects may continue therapy with rituximab. The occurrence of rituximab 
associated IgM flare should be recorded as an adverse event (Refer to Section 11.3.1 ).  If 
necessary additional laboratory tests, physical  examinations, and in the case of previous 
lymphadenopathy or splenomegaly, computed to mography (CT) scans might be performed to 
discriminate IgM flare from diseas e progression and all relevant test s needed to be recorded in 
the eCRF.
5.4. Criteria for Permanent Discontinuation of Study Drug
Investigators are encouraged to keep a subject who is experienci ng clinical benefit in the study 
unless IRC confirmed disease progre ssion, significant toxicity puts the subject at risk, or routine 
noncompliance puts the study outcomes at risk.  For a complete list of criteria for permanent 
discontinuation of study treatment, refer to Section 9.2 .
An End-of-Treatment Visit ( Section [IP_ADDRESS]) is required for all subjects except for those subjects 
who have withdrawn full consent. 
6. CONCOMITANT MEDICATIONS/PROCEDURES
6.1. Concomitant Medications
6.1.1. Permitted Concomitant Medications
Supportive medications in accordance with standard practice (such as for emesis, diarrhea, etc.) 
are permitted.  Use of granulocyte colony-stimula ting factors or erythropoietin growth factors is 
permitted per institutional policy and in accordance with the ASCO guidelines ( Smith 2006 ).  
Transfusions may be given in accordance with institutional policy.
Short courses ( ≤14 days) of steroid treatment for non -WM related medical reasons (eg, joint 
inflammation, asthma exacerbation, rash, antiemetic  use and infusion reactions) at doses that do 
not exceed 100 mg per day of prednisone or equi valent are permitted. In addition, for subjects 
with chronic medical conditions, continuous admini stration of up to 20 mg per day of prednisone 
or equivalent is permitted for the treatment of this medical condition where no acceptable 
therapeutic alternat ive is available.
The use of these medications/transfusions must be recorded in the electronic case report form 
(eCRF).
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 476.1.2. Medications to be Used with Caution
[IP_ADDRESS]. CYP3A Inhibitors/Inducers
Ibrutinib is metabolized primarily by [CONTACT_097]3A. Avoid co-administration with strong CYP3A4
(eg, ketoconazole, indinavir, ne lfinavir, ritonavir, saquinavir, clarithromycin, telithromycin, 
itraconazole, and nefazadone) or mo derate CYP3A inhibitors and consider altern ative agents 
with less CYP3A inhibition. If a strong CYP3A inhi bitor must be used, reduce the ibrutinib to 
[ADDRESS_493286] be used, reduce 
ibrutinib to 140 mg for the duration of the inhibi tor use.  No dose adjustment is required in 
combination with mild inhibitors. Avoid grap efruit and Seville oranges during ibrutinib
treatment, as these contain mode rate inhibitors of CYP3A (see Section [IP_ADDRESS]).
Avoid concomitant use of strong CYP3A inducer s (eg, carbamazepi[INVESTIGATOR_050], rifampin, phenytoin, and 
St. John’s Wort). Consider alternativ e agents with less CYP3A induction.
A list of common CYP3A inhibitors  and inducers is provided in Appendix 3; a comprehensive 
list of inhibitors, inducers, a nd substrates may be found at 
http://medicine.iupui.edu/clinpharm/ddis/table.as px. This website is continually revised and 
should be checked frequently for updates.
For the most comprehensive effect of CYP3A inhi bitors or inducers on ibrutinib exposure, please 
refer to the current version of the IB .
[IP_ADDRESS]. Drugs That May Have Their Plasma Concentrations Altered By [CONTACT_393058] a substrate of P-gl ycoprotein (P-gp), but is a mild 
inhibitor (with an IC 50 of 2.15 μg/mL).  Ibrutinib is not expected to have systemic drug-drug 
interactions with P-gp substrat es. However, it cannot be excluded that ibrutinib could inhibit 
intestinal P-gp after a therapeutic dose. There is no clinical data available. Therefore, to avoid a 
potential interaction in the GI tract, narrow therapeutic range P-gp substrates such as digoxin, 
should be taken at least 6 hours before or after ibrutinib.
[IP_ADDRESS]. Concomitant Use of QT Prolonging Agents
Any medications known to cause QT prolongation s hould be used with caution; periodic ECG 
and electrolyte monitoring should be considered. 
[IP_ADDRESS]. Concomitant Use of Antiplatel et Agents and Anticoagulants
Warfarin or other vitamin K antagonists as well as supplements such as fish oil and vitamin E 
preparations should be avoided. Use ibrutinib with  caution in subjects re quiring anticoagulants 
or medications that inhibit plat elet function.  Subjects with conge nital bleeding diathesis have not 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493287]-surgery depending upon 
the type of surgery and the ri sk of bleeding (see Section 6.2).
Subjects requiring the initiation of therapeutic an ticoagulation therapy (e g, atrial fibrillation), 
consider the risks and benefits of  continuing ibrutinib treatment.  If therapeutic an ticoagulation is 
clinically indicated, trea tment with ibrutinib/placebo should be held and not be restarted until the 
subject is clinically stable and has no signs of bleeding. No dose reduc tion is required when 
study drug is restarted. Subjects should be observe d closely for signs and symptoms of bleeding.
6.1.3. Prohibited Concomitant Medications
Any other chemotherapy, anticancer immunotherapy, experimental therapy, or radiotherapy are 
prohibited while the subject is receiving study drug.
Corticosteroids for the treatme nt of the underlying disease are prohibited. Please refer to 
Section 6.1.[ADDRESS_493288] be notified in advance (or as soon as possible thereafter) of any instances in 
which use of prohibited therapi[INVESTIGATOR_393019].
6.2. Procedures
The following guidance should be applied duri ng the perioperative period for subjects who 
require surgical interventi on or an invasive procedur e while receiving study drug.
6.2.1. Minor Surgical ProceduresFor minor procedures (such as a central line pl acement, needle biopsy, lumbar puncture [other 
than shunt reservoir access] thor acentesis, or paracentesis) study drug should be held for at least 
[ADDRESS_493289] 7 days after 
the urgent surgical procedure.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 496.3. Plasmapheresis
Initial transient increases in serum IgM levels (IgM flare) are common (in up to 50% of patients) 
3 to 4 weeks after initiati on of rituximab therapy (Treon 2005; Ghobrial 2004 ;Dimopoulos 
2002a ). This flare may persist for up to 4 months and does not indicate treatment failure but may 
necessitate plasmapheresis to re duce hyperviscosity (Dimopoulos 2002a ; Ghobrial 2004 ; 
Dimopoulos 2002b ) or other clinical symptoms.
• Plasmapheresis at the discretion of the treating physician should be considered in subjects 
with IgM values above 5000 mg/dL before start of the treatment regime n to avoid clinical 
symptomatic ‘IgM flare’ on study treatment.
• Plasmapheresis should be considered in patients with signs of symptomatic 
hyperviscosity before start of the treatment regimen.
• Plasmapheresis should be considered in subj ects who developed a clinically symptomatic 
‘IgM flare’ (eg. hyperviscosity syndrome) on study treatment.
oThis initial transient increase of IgM leve ls will most likely not indicate disease 
progression and subjects may con tinue therapy with rituximab.
oIncrease of IgM levels after the firs t [ADDRESS_493290] requires plasmaphe resis prior to study treatment, the IgM level 
obtained prior to plasmapheresis should be consid ered as the baseline value and study treatment 
should be initiated shortly thereafter (not more than 7 days ) after last plasmapheresis. 
IgM level obtained within five half-lives (ie, ≤35 days) after the last plasmapheresis should not 
be considered for response evaluation.  An IgM level obtained more than 35 days after 
plasmapheresis can be used in response determination.
The IgM level prior to and after each plasmaphere sis during the screenin g phase and during the 
study should be collected centra lly and will be recorded in th e electronic case  report form 
(eCRF).
7. STUDY EVALUATIONS 
All subjects enrolled in the study, whether they are in the randomized treatment arms (Arm A 
and B) or in the ibrutinib monotherapy substudy (Arm C), will undergo the same study 
evaluations throughout the study.
7.1. Screening/Administrative
All screening clinical and laboratory assessments must be performed within [ADDRESS_493291] dose 
of study drug and prior to randomization.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493292]/Research Ethics 
Board/Independent Ethi cs Committee (IRB/REB/IEC) approve d informed consent form (ICF) 
confirming his or her willi ngness to participate in this study before any study-specific screening 
procedures are performed. In addition, subjects must sign all approved ICF amendments per the 
site IRB/REB/IEC guidelines du ring the course of the study. 
7.1.2. Confirm EligibilityAll necessary procedures and evaluations must be  performed to document that the subject meets 
all of the inclusion criteria and none of the exclusion criteria ( Section 4 ). Study site personnel 
will submit the Eligibility Worksh eet to the Medical Monitor or S ponsor designee for approval to 
proceed with randomization. 
7.1.3. Medical History and Demographics
The subject’s complete history through review  of medical records and by [CONTACT_147466]. Concurrent medical si gns and symptoms must be documented to 
establish baseline severities. A di sease history, including the date of  initial diagnosis and list of 
all prior anticancer treatments, dates administered, and responses and duration of response to 
these treatments, also will be recorded. 
7.1.4. Prior and Concomitant Medications
All medications from the time of signed consent through [ADDRESS_493293], height (screening only) and weight, and examination of the skin, eyes, ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, nervous system, and lymphatic system.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 51A limited symptom-directed physical examination w ill be required after W eek 1 at time points 
specified in the Schedule of Assessments ( Appendix 1).
7.1.7. Eye-related Symptom Assessment
The subjects will be asked about eye-related symp toms at Screening and after Week 1 at time 
points specified in the Schedule of Assessments ( Appendix 1).
If there are any eye- related symptoms of severity Grade ≥[ADDRESS_493294] 
develops any eye-related symptoms of severity Grade ≥2 while on study treatment, an 
ophthalmologic evaluation/consult must be perfor med and the outcome must be reported on the 
ophthalmologic eCRF. 
7.1.8. ECOG
The ECOG performance index is provided in Appendix 2 . The ECOG performance status will 
be assessed at time points specified  in the Schedule of Assessments ( Appendix 1). 
7.1.9. Vital Signs
Vital signs will include weight, blood pressure , heart rate, and body temperature and will be 
assessed at time points specified in the Schedule of Assessments ( Appendix 1).
7.1.10. Patient-Reported Outcomes
The PRO instruments, EQ-5D-5L ( Appendix 7), FACT-An ( Appendix 8), will be administered 
to all randomized subjects in this study.  These questionnaires are to be completed by [CONTACT_393059] s specified in the Sc hedule of Assessments.
[IP_ADDRESS]. EQ-5D-5L
The EQ-5D-5L is a standardized instrument  used to measure of health outcome ( EuroQol 
Group 1990). The EQ-5D-5L is a revised version of the traditional EQ-5D-3L and consists of a 
5-item questionnaire and a “thermometer” vi sual analogue scale ranging from 0 (worst 
imaginable health state) to 100 (best imaginable health state).  The scor es for the 5 dimensions 
are used to compute a single utility score rang ing from 0 to 1, representi ng the general health 
status of the individual. The 5 dimensions evaluated are mobilit y, self-care, usual activities, 
pain/discomfort, and anxiety/depression.
[IP_ADDRESS]. FACT-An
The Functional Assessment of Cancer Therapy– Anemia(FACT-An) for anemia and fatigue is a 
47-item cancer specific questionn aire consisting of a core 27- item general questionnaire (FACT-
G Total) measuring physical well-being, social/f amily well-being, emotional well-being, and 
functional well-being, as well as a 20-item an emia/fatigue questionnai re (FACT-An Anemia 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 52subscale) ( Cella 1997 ;Yellen 1997 ;Cella 2003 ).  Responses to all it ems are rated on a 5-point 
scale ranging from 0 “not at all” to 4 “very much”. The recall period is the past 7 days.
7.2. Clinical Laboratory Assessments 
7.2.1. Hematology
Hematology will be evaluated by a central laborato ry and will include a complete blood count 
(CBC) with white blood cell differential. In the event that the submitted central laboratory 
sample is unable to be resulted (ie, specimen cl otted, hemolysis, etc.), local laboratory results 
may be used to support eligibility.
7.2.2. Chemistry (Serum)
Serum chemistry will be evaluated by a cent ral laboratory and include sodium, potassium, 
chloride, blood urea nitrogen (BUN), creatinine, glucose, calcium, total protein, albumin, AST, 
ALT, alkaline phosphatase, total bilirubin, la ctate dehydrogenase (LDH), phosphate, uric acid, 
magnesium and bicarbonate.  In the event that the submitted central laboratory sample is unable 
to be resulted (ie, specimen clotted, hemolysis,  etc.), local laboratory results may be used to 
support eligibility.
7.2.3. Coagulation Studies
Measurement of prothrombin time (PT)/INR, and activated partial thromboplastin time (aPTT) 
will be performed at Screening, Week 17 and at the End-Of-Treatment visit using a central 
laboratory. In the event that the submitted central la boratory sample is unable to be resulted (ie, 
specimen clotted, hemolysis, etc.), local laborat ory results may be used to support eligibility.
7.2.4. Hepatitis SerologiesHepatitis serologies include hepatitis C anti body, hepatitis B surface antigen, and hepatitis B 
core antibody and will be evaluated by [CONTACT_343802].  PCR must be confirmed negative prior 
to randomization for subjects who are hepatiti s B core antibody positive, hepatitis B surface 
antigen positive or hepatitis C antibody positive.
7.2.5. Serum Viscosity
Measurement of resistance of blood to flow for evaluation of hyperviscosity syndrome will be 
performed at Screening by [CONTACT_12115].
7.2.6. Serum Free Light Chain Assay
Sample(s) will be sent to a central laboratory for measurement of i mmunoglobulin-free light 
chains in serum.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493295] may be 
performed more frequently if requ ired by [CONTACT_31665].
7.3. Diagnostics/Procedures
7.3.1. ECG
12-lead ECG will be taken in triplicate (≥1 minute apart) at Screening .
The ECGs should be performed prior to any bl ood samples being collected. Any clinically 
significant abnormalities noted at Screening should  be included in the medical history.  
In addition, ECGs can be performed at the investigator’s discretion, particularly in subjects with 
arrhythmic symptoms (eg, palpi[INVESTIGATOR_814], lightheadedness) or new onset dyspnea.
7.3.2. Bone Marrow Sampling and Pathological diagnosis Inclusion of the subject in the trial will be  based on central pathol ogical assessment and 
histopathological confirmation of lymphoplasmacytic lymphoma (L PL), which is the underlying 
histology of WM. Details regarding the central pathological review will be outlined in a separate 
pathology charter.
A central pathological review will be performed for all subjects. 
The following material will be sent to the central pathology laboratory:
• Bone marrow trephine (>=1 cm) in a contai ner of neutral buffered formalin (no other 
fixative allowed); Note that the trephine is obligatory for subject enrollment
• 4 bone marrow smears (air dried, unstained)
• 4 blood smears (air dried, unstained)
• Up to 10 mL of bone marrow aspi[INVESTIGATOR_337] (to be sent to central laboratory)
It is important to have marrow and blood smears se nt to central pathology , regardless of whether 
the smears are also reviewed elsewhere, to allo w the central hemato-pat hologist to generate a 
report based on all morphological feat ures including cytology on smears.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493296]/WM, the central 
pathology laboratory may request prior bone  marrow and lymph node/soft tissue biopsy 
specimens, to help confirm this diagnosis.  If requested, such material, particularly the paraffin 
blocks, should be sent to central pathology if at all possible.
The following clinical information should be  sent to central pa thology in all cases:
• Age, gender
• Splenomegaly (yes/no)
• Hepatomegaly (yes/no)
• Lymphadenopathy (yes/no, at which sites)
• Monoclonal IgM gammopathy (yes/no, and size of M-spi[INVESTIGATOR_393020], in g/dL)
• Leucocyte count, hemoglobin level, thrombocyte count
• Previous hematological diseases
• Immunophenotypic profile data if available
• Autoimmune disease, hemolysis
Additional Bone Marrow asse ssment should be obtained:
• to confirm CR at any time
• pre-dose at Weeks 49 and 97 to assess bone marrow/tissue response
• at time of progression or at suspected PD due  to progressive cytopenia without any other 
evidence of PD
Standard clinical Bone Marrow assessment will be performed at the study center’s local 
laboratory.
7.4. Pharmacokinetics/Biomarkers 
7.4.1. Pharmacokinetics
Plasma concentrations of ibrutinib and PCI-[ZIP_CODE] will be determined using a validated analytical 
method.  Other potential metabolites of ibrutinib may be explore d.  Refer to the Schedule of 
Assessments ( Appendix 1) and the Pharmacokinetic Sample Schedule ( Table 4 ).
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 55Table 4: Pharmacokinetic Sample Schedule
Study Arm Week Study Day PredoseTime Point Postdosea
1h ± 
15 min2 h ± 
30 min4 h ± 
30 min6 h ± 
1 h
A and B 4 22 X X X X X
C5 2 9X X X X X
aTime after ibrutinib/placebo dosing
Refer to the laboratory manual for instructions on collecting and processing these samples.  On 
the day of the sampling visit, the clinical staff w ill instruct the subject to not take a dose before 
arrival at the clinic.  Study drug intake will be observed by [CONTACT_96937].  The actual time (versus 
requested time) that each sample is drawn must be recorded using a 24 hour format.  The same 
clock should be used for recording the time of dosing. In the event that medical management
(use of steroids) is needed, use of st eroids for infusion should be recorded.
7.4.2. Predictive Biomarkers a nd Mechanisms of Resistance
Identification of signaling pathways or biomarkers that predict sensitivity or resistance to 
ibrutinib will be expl ored in this study. 
A predose blood sample will be collected at the following visits: Week 1, Week 17, Week 33, 
Week 49; Suspected CR and PD ; and End -of-Treatment (EOT).  If a subject progresses and 
returns to clinic within [ADDRESS_493297] dose of ibrutinib/p lacebo, then an additional 
post-progression blood sample will be collected.  If this post-progression blood sample is collected, then the biomarker blood sample co llection at the EOT Vi sit is not required.
Samples collected may be used for pharmacodynamic and biomarker assessments including BTK 
and other kinase activity and signaling, expressi on analysis, sequencing, flow cytometry and 
secreted protein analyses.  Fluids including blood collected during the course of the study may be 
used for, but not limited to, pharmacodynamics, biomarker and pharmacogenomic assessments.
A portion of pre-treatment bone marrow samples co llected may be used by [CONTACT_393060]. 
7.4.3. T/B/NK Cell Count
The blood sample(s) for T/B/NK cell count (CD3
+, CD4+, CD8+, CD19+, CD16/56+) must be 
taken predose.  Percentages and absolute counts of CD3+, CD4+, CD8+, CD19+, CD56+and 
CD16/56+cells will be collected.  Reference the La boratory Events Schedule for other sample 
timepoints for this assay.
Testing will be performed at a central laboratory.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 567.4.4. Genetic and Molecular Prognostic Markers
A blood sample will be collected at pre-dose Week 1 to study pretreatment prognostic factors.
The myeloid differentiation primary response gene 88 (MYD88), C-X-C chemokine receptor 
type 4 (CXCR-4) and other genetic and genomic a lterations thought to be prognostic of disease 
and/or treatment outcome may be tested.  
7.5. Efficacy Evaluations
Efficacy evaluations will be conducted as outli ned in the Schedule of Assessments Table 
(Appendix 1 ). Response assessments will be performed using the modified consensus criteria 
adapted from the VIthInternational Workshop on WM ( NCCN 2014) (Appendix 4).
Progression of nodal and extranodal disease should be evaluated based on the revised criteria for 
malignant lymphoma described in the re vised International Working Group for NHL
(Cheson 2007). The spleen is considered nodal disease.
Efficacy evaluation will include the following components:
• Hematologic parameters by [CONTACT_393061] (CBC)
• Quantitative IgM serum immunoglobulins 
• Quantitative serum-M protein (SPEP)
• Qualitative serum immunofixation, if applicable 
• Radiographic evaluation,  if applicable  
• Bone marrow aspi[INVESTIGATOR_12752], if applicable
In the event a subject required plasmapheresis pr ior study treatment, the IgM level obtained prior 
plasmapheresis will be considered as the base line value and study treatment should be initiated 
shortly thereafter (not more than 7 days) after last plasmapheresis.  IgM level obtained within 
five half-lives (ie, ≤35 days) after plasmapheresis should not be  considered as nadir on therapy or 
for response evaluation.  IgM levels obtained mo re than 35 days after plasmapheresis can be 
used in response determination.
Any suspected case of disease progression should be reported to the Spons or within 24 hours of 
awareness. If disease progression is suspected solely based on the results of a single examination 
or a single laboratory parameter (eg, IgM), th is finding should be confirmed by a subsequent 
evaluation at least within [ADDRESS_493298] fi nding and confirmation by [CONTACT_26732]. When disease 
progression has been confirmed by [CONTACT_26732], study treatment should be withheld. Once the IRC
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 57has confirmed disease progression, subjects should c ontinue to adhere to all other study-related 
procedures.  Whenever possible, subsequent anticancer therapy should be wit hheld until disease 
progression is confirmed by [CONTACT_26732].
If at any time CR is suspected (serum IgM va lues in normal range and disappearance of the 
SPEP), all assessments including serum immunofixation, bone marrow assessment and 
radiographic evaluation (if nodal/ext ranodal disease is present at baseline) must be performed 
according to the IWWM response assessment guidelines.
Determination of progression for the purpose of th e primary efficacy endpoint will be performed 
by [CONTACT_393062] i nvolved in the conduct of the 
study.Access to next-line ibrutinib (cross-over) for subj ects treated with placebo in combination with 
rituximab (Arm B) with IRC confirmed diseas e progression and symptomatic disease requiring 
treatment may be provided following S ponsor’s designee approval as outlined in Section 7.7 .
7.5.1. Quantitative Serum Immunoglobulin
Testing for IgA, IgG and IgM levels will be performed by [CONTACT_12115]. 
7.5.2. Serum Immunofixation 
Samples will be collected and sent to a centr al laboratory. Repetitive immunofixation on study is 
only required to confirm CR (conducted on the first observation that the subject has no 
detectable monoclonal protein) and then repeat ed every study visit un til disease progression. 
7.5.3. Serum Protein Electrophoresis (SPEP) Sample(s) will be sent to a central labor atory to quantify the serum-M protein.
7.5.4. Radiographic ImagingPretreatment tumor assessment will be perfor med up to [ADDRESS_493299] scan (with contrast unless contraindicated) of the neck, ches t, abdomen, and pelvis must be 
performed.  Information on extranodal involvement will al so be recorded.  
In the case where CT with contrast is contra indicated, an alternativ e would be MRI of the 
abdomen and pelvis and CT of  the chest without contrast.
NOTE: Positron emission tomography (PET)/CT hybr id scanners may be used to acquire the 
required CT images only if the CT produced by [CONTACT_3433] e scanner is of diagnostic quality, adheres to 
the specified slice thickness/scan  parameters, and includes the use of intravenous (IV) contrast.  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493300] be separated from the PET data prior to submitting the data, 
and cannot be transmitted as fused PET/CT images. 
If using a hybrid machine to acquire both PET a nd CT, the PET must be performed prior to the 
CT with IV contrast as to not compromise PET results. If independent CT and PET scanners are used, and the subject is rece iving both scans on the 
same day, the PET must be performed prior to the CT with IV contrast.
The same imaging method should be used for a given subject throughout the study.  The same 
equipment should be utilized for all scans whenev er possible.  The same radiologist should be 
assigned to read all the scan s for a given patient throughout the study as much as possible.
All subjects with presence of nodal and/or extranodal disease at  Screening per central radiology 
review will require follow up CT scans of the neck, chest, abdomen, and pelvis every [ADDRESS_493301] 2 years and thereafter every 24 week s, until disease progression is confirmed by [CONTACT_364129] (regardless of whether or not the patient remains on treatment). Follow up neck CT scans 
are only required for subjects with evidence of di sease involvement in the neck region identified 
during Screening. In the event di sease progression is suspected due to physical examination or 
laboratory test, a CT scan should be performed to evaluate nodal or extranodal progression 
regardless if the subject had nodal/ extranodal disease at Screening.
[IP_ADDRESS]. Radiographic Assessment
Progression of nodal and extranodal disease should be evaluated based on the revised criteria for 
malignant lymphoma described in the re vised International Working Group for NHL
(Cheson 2007). The spleen is considered nodal disease.
Up to 6 measurable lymph nodes (t arget lesions) should be consider ed if the long axis is more 
than 1.5 cm regardless of the short axis. If a lymph node has a long axis of 1.1 to 1.5 cm, it 
should only be considered abnormal if its short axis is more than 1.0 cm. Lymph nodes 
≤1.0cmx ≤1.0cm will not be considered as abnormal for relapse or progressive disease. In 
addition, target lesions should be clearly measurab le in at least [ADDRESS_493302] cranial-caudal measurem ent of the spleen will be assessed at Screening and all 
subsequent timepoint s (if applicable).
Nodal progression by [CONTACT_393063]:
• Appearance of any new lesion more than 1.5 cm in any axis during or at the end of 
therapy, even if other lesi ons are decreasing in size. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 59• At least a 50%increase from nadir in the sum of product (SPD) of any previously 
involved nodes, or in a singl e involved node. To be consider ed progressive disease, a 
lymph node with a diameter of the short axis of less than 1.0cm must increase by ≥50% 
and to a size of 1.5 x 1.5 cm or mo re than 1.5 cm in the long axis.
• At least a 50% increase in th e longest diameter of any si ngle previously identified node 
more than 1 cm in its short axis
Measurable extranodal disease s hould be assessed in a manner similar to that for nodal disease.
A central imaging service will be utilized to provide independent radiological assessments for 
independent response evaluation (Refer to Section 10.10 ). Central radiology review will be 
conducted throughout the study and the details of th e central radiology review activities will be 
specified in a separate charter and the SAP.
To ensure the required subsequent CT scans are performed per protoc ol, the presence of 
nodal/extranodal disease per central radiology re view will be communica ted to the site.  
However, no further details (eg, measurements or identified target/non-target lesions) will 
be reported back to the site.
7.6. Sample Collection and Handling
The actual dates and times of sample collection must be recorded in source documents for 
transcription to the eCRF or laboratory requisition form.  Refer to the Schedule of Assessments (Appendix 1 ) for the timing and frequency of all sample collections.
Instructions for the collecti on, handling, and shipment of samp les are found in the Laboratory 
Manual.
7.7. Treatment with Ibrutinib for Subjects on Control Arm (Arm B) Following IRC-
Confirmed Disease Progression
Subjects on the trial who have documented IRC c onfirmed disease progression and symptomatic 
disease meeting criteria for requiring treatment may be eligible to receive next-line therapy with 
ibrutinib. A request for next-line therapy with ibrutinib must be submitted to the Sponsor’s 
designee who will evaluate the request based on the criteria listed in Section 7.7.1. Local labs 
can be used to determine appropriate ness for start of next-line ibrutinib.
Next-line treatment with ibrutinib can be continued until disease progression as determined by 
[CONTACT_737], or until they meet th e following criteria for withdrawal in Section 9 .
7.7.1. Criteria for Next-line Ibrutinib Therapy
1. IRC confirmed disease progression and Sponsor approval.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493303] 1 of the recommendations from the Second 
International Workshop on Waldenström’s M acroglobulinemia for re quiring treatment 
(Section 4.1 . Inclusion criteria #4).
3. Compliant with the main study protocol procedures and no subsequent WM/anti-cancer 
therapy prior to IRC confirmed disease progr ession since discontinuing treatment on Arm B.
4.ECOG Performance Status of ≤ 2 (Appendix 2 ).
5.Platelet count > 50,000 cells/mm3and a bsolute neutrophil count >750 cells/mm3.
6. No uncontrolled active systemic fungal, bacteria l, viral, or other infection (defined as 
exhibiting ongoing signs/symptoms related to th e infection and without improvement, despi[INVESTIGATOR_393021]).
7. No currently active clinically  significant cardiovascular disease such as uncontrolled 
arrhythmia, congestive heart fail ure, any Class 3 or 4 cardiac disease as defined by [CONTACT_393064] F unctional Classification ( Appendix 5 ), or history of myocardial 
infarction within [ADDRESS_493304] dose with study drug.
8. Female subjects who are of non-reproductive po tential (ie, post-menopausal by [CONTACT_969] - no
menses for ≥2 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR 
history of bilateral oophorectomy). Female subject s of reproductive pote ntial must have a 
negative pregnancy test upon study entry.
9. Male and female subjects of reproductive po tential who agree to use highly effective 
methods of birth control (eg, c ondoms, implants, injectables, co mbined oral contraceptives, 
some intrauterine devices [IUDs], complete abstinenceb, or sterilized partner) during the 
period of therapy and for [ADDRESS_493305] dose of study drug and 90 days (males) after 
the last dose of study drug.
7.7.2. Next-line Ibrutinib Therapy Treatment Phase
Refer to the next-line ibrutinib therapy Schedule of Assessments ( Appendix 9) for a complete list 
of procedures to be performed at each scheduled study visit.
8. STUDY PROCEDURES
8.1. Overview
The study is divided into a Screening Phase, a Treatment Phase, and a Follow-up Phase.  The 
Schedule of Assessments ( Appendix 1) summarizes the frequency and timing of efficacy, PK, 
biomarker, and safety measurements applicable to this study.  All subjects enrolled will undergo 
the same study procedures throughout the study unless otherwise noted.
bComplete abstinence is a high ly effective method only if defined as refraining from heterosexual intercourse 
during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the clinical tria l and the preferred and usual lifestyle of the subject.  
http://www hma.eu/fileadmin/dateien/Human_Medicines/01-About_HMA/Working_Groups/CTFG/2014_09_HMA
_CTFG_Contraception.pdf
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493306] firs t read, understand, and sign the IRB/REB/IEC-
approved ICF before any study-specific screenin g procedures are perfor med. All study tests and 
procedures should be performed at the study center at which the subject was enrolled and will be 
receiving treatment. After signing the ICF, screening, and being deemed eligible for entry, 
subjects will be enrolled in the study.
8.2.1. Screening Visit
The following procedures will be performed at the Screening Visit within [ADDRESS_493307] 
dose of study drug and randomization unless otherwise noted:
• Medical history including demographic information
• Perform a complete physical examination, in cluding height and weight (may use prior 
height measurement if available in source documents)
• Eye-related symptom assessment
• Evaluation of ECOG performance status
• Obtain vital signs (including blood pre ssure, heart rate, and body temperature)
• Obtain triplicate 12- lead ECG ( ≥1 minute apart) 
• Record adverse events since signing the ICF
• Record concomitant medication history including over-the-counter dr ugs, vitamins and 
herbs since signing the ICF
• Imaging by [CONTACT_393065] 7.5.4 (if not performed within 
[ADDRESS_493308] dose of study drug)
• Obtain a bone marrow aspi[INVESTIGATOR_12752] (if not performed within [ADDRESS_493309] 
dose of study drug)
• Obtain blood specimens for the following laboratory tests:
oHematology
oSerum chemistry
oCoagulation studies (PT/INR, aPTT)
oHepatitis serologies 
oSerum viscosity
oSerum protein electrophoresis (SPEP)
oQuantitative serum immunoglobulins (IgA, IgG, and IgM)
oSerum free light chain assay
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 62oSerum immunofixation
oβ2-microglobulin
oBlood smear slides
oBone marrow smear slides
• Obtain serum pregnancy test for women of reproductive potential only
• Confirm eligibility (per inclusion/exclus ion criteria) and randomize/enroll via IWRS.
Dosing should occur within 72 hours of randomization/enrollment.
8.3. Treatment Phase
Following completion of the Screening Visit and once eligibility has been confirmed for 
treatment Arm A or Arm B, subjects will be random ized via an automatic IWRS or alternative 
system provided by [CONTACT_1034]. Randomization s hould occur as close to the time of the 
expected first dose as possible, i.e. not more than [ADDRESS_493310] prior rituximab-containing therapy 
(refer to Section 4.2 ) may be enrolled in Arm C via IWRS  and receive ibrutinib monotherapy if 
the eligibility criteria as sp ecified in Section 4.2 are met.
Study drug treatment with ibrutinib/placebo shou ld be continued until disease progression, 
unacceptable treatment-related toxicity, or other reasons outlined in Section 9.[ADDRESS_493311] may continue to receive study 
medication until disease progression is confirmed by [CONTACT_26732], at the discretion of the Investigator. 
Refer to the Schedule of Assessments ( Appendix 1) for a complete list of  procedures to be 
performed at each scheduled study visit.
8.3.1. Week 1
Pre-dose
• PRO assessments 
• Complete physical exam includi ng weight and height (may use prior height measurement 
if available in source documents)
• Eye-related symptom assessment
• ECOG performance status
• Vitals signs including blood pressu re, heart rate, and body temperature
• Collect blood samples for th e following laboratory tests:
oHematology
oSerum chemistry 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 63oSerum protein electrophoresis (SPEP)
oQuantitative serum immunoglobulins (IgA, IgG, and IgM)
oGenetic and molecular prognostic markers
oT/B/NK cell counts
oPredictive biomarkers and mechanisms of resistance
• Obtain urine pregnancy dipstick test fo r women of reproductive potential only
• Review of AEs and concomitant medications
• Review inclusion and exclusi on criteria to confirm subject eligibility prior to dosing
Dosing and Post-Dose
• Dispense study drug (ibrutinib /placebo for Arm A and B; open -label ibrutinib for Arm C)
• Administration of study drug
• Administration of rituximab (Arm A and Arm B ONLY)  
• Review of AEs and concomitant medications 
8.3.2. Weeks 2-4 (Arm A and Arm B ONLY)
Pre dose
• Collect blood samples for th e following laboratory tests:
oQuantitative serum immunoglobulins (IgA, IgG, and IgM)
•Review of AEs and concomitant medications
Dosing and Post-Dose
• Administration of rituximab (Arm  A and Arm B only) and study drug
• Review of AEs and concomitant medications
• Week 4 Only 
• PK (predose and post-dose)
8.3.3. Weeks 5-16 (every 4 weeks)
• PK (predose and post-dose) for Arm C ONLY (Week 5 Only)
• Continuous daily dosing of study drug (ibr utinib/placebo or open-label ibrutinib)
• PRO assessments (Weeks 5, 9 and 13 Only)
• Symptom-directed Physical Exam
• Eye-related symptom assessment
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 64• Collect blood samples for th e following laboratory tests:
oHematology
oSerum chemistry 
oSerum protein electrophoresis (SPEP)
oQuantitative serum immunoglobulins (IgA, IgG, and IgM)
• Overall Disease Assessment
• Review of AEs and concomitant medications
8.3.4. Week 17
Pre-Dose
• PRO Assessments
• Symptom-directed Physical exam
• Eye-related symptom assessment
• ECOG performance status
• Vitals signs including blood pressu re, heart rate, and body temperature
• Collect blood samples for th e following laboratory tests:
oHematology
oSerum chemistry 
oCoagulation studies (PT/INR, aPTT)
oSerum protein electrophoresis (SPEP)
oQuantitative serum immunoglobulins (IgA, IgG, and IgM)
oT/B/NK cell counts 
oPredictive biomarkers and mechanisms of resistance
oCT scan 
oOverall Disease Assessment
• Review of AEs and concomitant medications
Dosing and Post-Dose
• Dispense study drug (ibrutin ib/placebo for Arm A and Arm B and open-label ibrutinib 
for Arm C)
• Administration of study drug
• Administration of rituxima b (Arm A and Arm B ONLY) 
• Review of AEs and concomitant medications 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 658.3.5. Weeks 18-20 (For Arm A and Arm B ONLY) 
• Administration of study drug and rituximab 
• Review of AEs and concomitant medications
8.3.6. Week 21
• PRO assessments
• Continuous daily dosing of study drug (ibru tinib/placebo or open-label ibrutinib)
• ECOG performance status
• Vitals signs including blood pressu re, heart rate, and body temperature
• Symptom-directed Physical Exam
• Eye-related symptom assessment
• Collect blood samples for th e following laboratory tests:
oHematology
oSerum chemistry 
oSerum protein electrophoresis (SPEP)
oQuantitative serum immunoglobulins (IgA, IgG, and IgM)
• Overall Disease Assessment
• Review of AEs and concomitant medications
8.3.7. Week 25- until PD or Unacceptable Toxicity (Every 8 Weeks)
• PRO assessments (after Week 49, PRO assessments to occur every 16 weeks)
• Continuous daily dosing of study drug (ibru tinib/placebo or open-label ibrutinib)
• ECOG performance status
• Vitals signs including blood pressu re, heart rate, and body temperature
• Symptom-directed Physical Exam
• Eye-related symptom assessment
• Collect blood samples for th e following laboratory tests:
oHematology
oSerum chemistry 
oSerum protein electrophoresis (SPEP)
oQuantitative serum immunoglobulins (IgA, IgG, and IgM)
oT/B/NK cell counts (Weeks 33 and 49 only) 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 66oPredictive biomarkers and mechanisms  of resistance (Weeks 33 and 49 only)
oSerum free light chain assay (Weeks 49 and 97 only)
• CT scan (Weeks 33, 49, 65, 81, and 97 and every 24 weeks thereafter)
• Bone marrow aspi[INVESTIGATOR_337]/biopsy (Weeks 49 and 97) 
• Overall Disease Assessment
• Review of AEs and concomitant medications
8.3.8. Suspected PD Visit
The Suspected PD visit should be performed at  any time during the study, if based on clinical 
and/or laboratory evaluati on, the Investigator suspects progressive  disease (PD), or if the subject 
discontinues treatment for any other reason.  If po ssible, the visit should  be performed within 
[ADDRESS_493312]’s previous dose.  The following procedures will be performed:
• PRO assessments
• Complete physical exam including weight
• Eye-related symptom assessment
• ECOG performance status
• Vitals signs (including blood pressu re, heart rate, and body temperature)
• Collect blood samples for th e following laboratory tests:
oHematology
oSerum chemistry
oSerum protein electrophoresis (SPEP)
oQuantitative serum immunoglobulins (IgA, IgG, and IgM)
oSerum free light chain assay
oT/B/NK cell counts 
oPredictive biomarkers and mechanisms of resistance
• Imaging by [CONTACT_4654], if applicable 
• Bone marrow aspi[INVESTIGATOR_5179], if applicable
• Overall disease assessment
• Review of AEs and concomitant medications
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page [IP_ADDRESS]. End-of-Treatment Visit
An End-of-Treatment (EOT) visit should occur 30 days (± 7 days) from the last dose of study 
drug or prior to the start of a new anticancer trea tment.  If the subject starts a new anticancer 
treatment less than 7 days after the Suspected PD visit, only those procedures not conducted at 
the Suspected PD visit should be perform ed at the End-of-Treatment visit. 
The following procedures will be performed at the End-of-Treatment visit:
• PRO assessments
• Complete physical exam including weight
• Eye-related symptom assessment
• ECOG performance status
• Vitals signs (including blood pressu re, heart rate, and body temperature)
• Collect blood samples for th e following laboratory tests:
oHematology
oCoagulation studies (PT/INR, aPTT)
oSerum protein electrophoresis (SPEP)
oQuantitative serum immunoglobulins (IgA, IgG, and IgM)
oT/B/NK cell counts
oPredictive biomarkers and mechanisms of resistance
• Review of AEs and concomitant medications
• Bone marrow aspi[INVESTIGATOR_5179], if applicable
• Overall disease assessment
• Drug accountability
8.4. Follow-up PhaseOnce a subject has completed the End-of-Treatment  Visit they will enter the Follow-Up Phase.  
Subjects who withdraw from treatment for reasons other than PD and withdraw of consent will 
participate in ongoing follow-up visits. 
8.4.1. Response Follow-Up Visits (Until PD)
Subjects who discontinue the study for reasons ot her than PD will be followed every 12 weeks 
(±7 days) by [CONTACT_393066] (IRC), regardless of initiation of subsequent anticancer treatment. During this period, the following procedures will be performed:
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 68• Complete physical exam including weight
• Eye-related symptom Assessment
• ECOG performance status
• Vitals signs (including blood pressu re, heart rate, and body temperature)
• Collect blood samples for th e following laboratory tests:
oHematology
oSerum protein electrophoresis (SPEP)
oQuantitative serum immunoglobulins (IgA, IgG, and IgM)
• PRO assessments
• Overall Disease Assessment
• Survival status and new anticancer therapy use
8.4.2. Survival Follow-up
After IRC confirmed disease progression, subjects w ill be contact[CONTACT_393067] 12 weeks (±7 days) by [CONTACT_393068], the use of 
alternative antineoplastic therapy and occurrence of any other malignancy until death, withdrawal 
by [CONTACT_1130], lost to follow- up, or study terminated by S ponsor, whichever comes first. Every effort 
should be made to administer the questionnaire for subjects who are foll owed by [CONTACT_47322]. At 
the time of the interim analysis and at study clos ure, a survival sweep will be conducted. All subjects 
who are on study and not known to have died prior to the survival sweep will be contact[CONTACT_393069].
9. SUBJECT COMPLETI ON AND WITHDRAWAL
9.1. Completion
A subject will be considered to have completed th e study if he or she has died before the end of 
the study, has not been lost to follow-up, or has not withdrawn consent be fore the end of study. 
9.2. Withdrawal from Study TreatmentStudy treatment will be discontinued in the event of any of the following events:
• Confirmed progressive disease by [CONTACT_55543]
• Unacceptable toxicity: an intercur rent illness or adverse event that prevents further 
ibrutinib administration 
• Withdrawal of consent for treatment by [CONTACT_1130]
• Investigator decision (such as chronic noncomp liance, significant pr otocol deviation, or 
best interest of the subject)
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 69• Study termination by [CONTACT_2728]
• Subject becomes pregnant
All subjects, regardless of reason for disconti nuation of study treatment will undergo an End-of-
Treatment Visit and be followe d for progression and survival. 
The Investigator should notify the Sponsor within [ADDRESS_493313] discontinues ibrutinib 
treatment due to disease progression and shoul d provide documentation of disease progression 
for review by [CONTACT_1034]’s Medical Monitor.  If a subject shows signs of disease progression on 
physical examination or laboratory assessment, the subject may continue study treatment until 
disease progression is confirmed by [CONTACT_55543].  These s ubjects should stay in the study to be followed 
for survival. 
9.3. Withdrawal from Study
Withdrawal from study (including all follow-up) will occur under the following circumstances:
• Withdrawal of consent 
• Lost to follow-up
• Study termination by [CONTACT_2728]
• Death
If a subject is lost to foll ow-up, every reasonable effort should be made by [CONTACT_393070] t. The measures taken to follow-up should be documented.
When a subject withdraws before completing the study, the following information should be 
documented in the source documents:
• Reason for withdrawal
• Whether the subject withdraws full consent (i e, withdraws consent to treatment and all 
further contact) or partial c onsent (ie, withdraws consent to treatment but agrees to 
participate in follow-up visits)
10. STATISTICAL MET HODS AND ANALYSIS
Statistical analysis will be performed by [CONTACT_941] S ponsor or under the authority of the Sponsor.  A 
general description of th e statistical methods for the analysis of the efficacy and safety data is 
outlined below.  Specific details will be provided in the Statistical Analysis Plan (SAP).
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 7010.1. General Consideration
All analyses will be performed based on data up to the timepoint of clinical cutoff.  Long-term
follow-up data will be summarized separately when the entire study has completed. Statistical
inferences will be based on a 2-sided Type I rate of 0.05 unless otherwise specified.
For the open-label substudy (Arm C), the efficacy  and safety outcome of the substudy will be 
descriptively summarized and analyzed separately from the random ized treatment arms (Arm A 
and Arm B).
10.2. Randomization
For Treatment Arms A and B, central randomization will be implemented in this study.
Subjects who qualify for the substudy will not follow these procedures. Randomization will 
be stratified using the followi ng stratification factors and subj ects will be randomized in a 1:1 
ratio to receive either ibrutinib and rituxi mab or placebo and rituximab) within each 
randomization stratum: 
a) WM IPSS assessed at Screening (Low vs. Intermediate vs. High)
b) Number of prior systemic treatment regimens (0, 1-2 vs. ≥ 3)
c) ECOG (0-1 vs. 2)
10.3. Analysis Populations
The analysis populati ons are defined as:
• Intent-to-Treat (ITT) populati on: defined as all randomize d (Treatment Arms A and B) 
subjects. Subjects in this population will be an alyzed according to the treatment to which 
they are randomized.
• Safety population: All subjects who received at least 1 dose of study drug. Subjects in 
this population will be analyzed according to th e actual treatment received (ie, as treated).
Arm C safety analysis will be conducted separately.
• Pharmacokinetic-evaluable population: defined as all subjects who received at least [ADDRESS_493314]-treatment.
• Biomarker population: All subjects with suffici ent malignant cells collected from at least 
1 timepoint during the study. 
The ITT population will be used to summarize the study population and characteristics, efficacy, 
and PRO data; and the safety population will be used to summarize the safety data, unless 
otherwise specified.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 71For the open-label substudy (Arm C), the study population, characteristics, efficacy PRO and 
safety outcome of the substudy will be descri ptively summarized based on all subjects who 
received one dose of ibrutinib in Arm C. No comp arator analysis will be  done with Arms A or 
B.
Additional analysis populations may be included in the SAP to perform sensitivity and other 
exploratory analyses as appropriate.
10.4. Subject Information
Analyses of disposition, demographic, baseli ne disease characteristics, and prior and
concomitant therapy will be summarized by [CONTACT_393071]. Analyses 
on treatment compliance and extent of exposure will be similarly summarized based on the 
Safety population. No statistical testing is planned.
Unless otherwise specified, all continuous endpoi nts will be summarized using descriptive
statistics, which will include the number of subjects with a valid measurement (n), mean,
standard deviation, median, minimum, and maximum. All categorical endpoints will be 
summarized using frequencies and percentages.
10.5. Sample Size Determination (Treatment Arms A and B)
This study is designed to evalua te the effect of treatment on PFS and is powered for this 
endpoint. The desired operating characteristics for the PFS endpoint are used to determine the 
study’s total sample size and ove rall duration. The sample size a nd power calculations are based 
on a 2-sided log-rank test for PFS and the following considerations:
• 1:1 randomization ratio between 2 treatment arms
• Target hazard ratio of 0.5 with exponentia l distribution for PFS. Assuming the median 
PFS for the control arm (rituximab+placebo) is [ADDRESS_493315] ratio of 0.5 corresponds to 2-fold incr ease in median PFS for the treatment arm 
(rituximab+ibrutinib) relative to the control (ie, 30 months vs. 15 months, respectively).
• Minimum 80% power 
• 2-sided overall significance level of 0.05
• One interim analysis at 70% information (50 PFS events)
The interim analysis will be based on a group sequential design with Lan-DeMets spending 
function with O’Brien-Fleming boundary. Using the above assumptions, and based on an
accrual rate of approximately 12 subjects pe r month, the study will enroll approximately 
150 subjects (about 75 subjects to each arm) to observe [ADDRESS_493316] 6 (Cytel Software Corp, Cambridge, MA).
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 72Open-label Substudy Treatment Arm C
The sample size for the substudy (Arm C) is not de termined according to statistical calculation as 
the intent of this substudy is to provide WM subjects who are c onsidered refractory to the last 
prior rituximab-containing therapy access to ibrutinib as  well as to evaluate safety and efficacy in 
the monotherapy setting. Up to [ADDRESS_493317] deviations, median s, and ranges will be included.  For categorical
variables, frequency and percentage will be summarized. For time-to-event variables, Kaplan-
Meier estimates will be provided. 
All tests will be conducted at a 2-sided alpha level of 0.05, and 95% confidence intervals (CI) 
will be provided, unless stated otherwise. For the open-label substudy (Arm C), all rele vant efficacy outcomes will be descriptively 
summarized and analyzed separately from the randomized treatment arms (Arm A and Arm B).
10.6.1. Primary Endpoint
The primary endpoint is PFS, as a ssessed by [CONTACT_55543], which is defined as duration from the date of 
randomization to the date of dis ease progression or death, whicheve r is first reported, assessed 
according to the modified VI
thIWWM ( NCCN 2014) criteria.
The log-rank test will be used to compare surviv al curves between the two treatment arms for the 
primary endpoint, PFS. Additionally, the Kaplan-Meier method will be used to estimate the 
distribution of PFS for each treatment arm and the median PFS will be provided for each 
treatment arm.  The hazard ratio for ibrutinib re lative to placebo and its associated 95% CI will 
be calculated based on the Cox proportional hazards model. Sensitivity analyses will be described in the SAP as appropriate. Subgroup analyses will be performed for selected
subgroups (eg, prior WM treatment history: untreat ed versus previously tr eated) to assess the 
consistency of treatment effect across subgroups.
10.6.2. Secondary Endpoints
Multiplicity adjustment will be made in a sequential hierarchical manner based on a closed 
testing procedure as outlined in Section 10.8 to control the overall type 1 error. Details will be 
specified in the statis tical analysis plan.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 7310.6.2.1. Overall Response Rate
Overall response rate (ORR) is defined as the pr oportion of subjects who achieve PR or better 
according to the modified VIthIWWM ( NCCN 2014) criteria as assessed by [CONTACT_55543].  Overall 
response rate (ORR) will be compar ed using the chi-square test.
[IP_ADDRESS]. Hematologic ImprovementHematological improvement as measured by [CONTACT_393072]. The percentage of subjects with sustained hematological 
improvement as measured by [CONTACT_393073] a chi-square test. The distributi on of the time to improvement in hemoglobin 
will be summarized using Kaplan-Meier estima tes and time to improvement will be compared
using stratified or unstratified log-rank test as appropriate.
[IP_ADDRESS]. Time to Next Treatment
Time-to-next treatment (TTnT) is measured from the date of randomization to the start date of 
any subsequent WM treatment. Subj ects without subsequent treatme nt will be censored at the 
date of the last study visit. Detaile d censoring rules will be included in the SAP.  The analysis of 
TTnT will be analyzed using stratified or unstratified log-rank test as appropriate.
[IP_ADDRESS]. Overall Survival (OS) 
Overall survival (OS) is measured from the date  of randomization to the date of the subject’s 
death from any cause. Overall survival will be analyzed using the stratified log-rank test for 
treatment comparison. If the subject is alive or  the vital status is unknown, the subject will be 
censored at the date the subject was last known to be alive.  Th e overall survival distribution and 
median overall survival with its 95% CI will be  estimated using the Kaplan-Meier product-limit 
method. The same subgroup analysis of PFS may be performed for overall survival if the 
number of events within each subgroup is sufficien t.  The exploratory analysis on the effect of 
cross-over on overall survival may be described in the SAP (eg, detailed censoring rules) and 
performed as appropriate.
10.6.3. Exploratory Efficacy Endpoints
[IP_ADDRESS]. FACT-An 
PRO and disease-related symptoms according to  FACT-An for Anemia/Fatigue is measured by 
[CONTACT_393074] a 5-point scale ranging 
from 0 “not at all” to 4 “very much”. The recall period is the past 7 days .  Two summary scores 
will be calculated: the FACT-An total score (FACT-G plus An) and the FACT-An subscale 
score. Larger change from baselin e scores represents improvement of functional status and well-
being for all subscales and summary scale.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 74Detailed instrument description and scoring sy stem as well as additional analyses will be 
described in the SAP.
[IP_ADDRESS]. Euro QoL 5 Dimension Questionnaire (EQ-5D-5L)
For EQ-5D-5L, change in weighted utility scor e from baseline to each assessment will be 
summarized. The scores for the five categorical dimensions will be used to compute a single 
utility score ranging from zero (0.0) to one (1.0) representing the general health status of the 
patient.  The [LOCATION_008] weights will be used to generate patient utilities from the 
5 dimensions.  Analysis details will  be further specified in the SAP.
[IP_ADDRESS]. Duration of Response
Duration of response (DOR) is defined as duration in days from the date of initial documentation 
of a response (PR or better) to the date of firs t documented evidence of progressive disease or 
death for responders (PR or better) as assessed by [CONTACT_26732].  DOR will be analyzed descriptively 
using Kaplan-Meier estimate.
[IP_ADDRESS]. Clinical Response Rate
Clinical Response Rate (CRR) is defined as the proportion of subjects who achieve MR or better 
according to the modified IVthIWWM ( NCCN 2014) criteria as assessed by [CONTACT_26732]. CRR will 
be analyzed in a similar fashion as ORR.
[IP_ADDRESS]. Efficacy Assessments by [CONTACT_393075]-assessed PFS, ORR, CRR and DOR will be analyzed in a similar fashion as 
corresponding endpoints assessed by [CONTACT_26732]. 
10.6.4. Other Exploratory Endpoints
[IP_ADDRESS]. Pharmacokinetic Analyses 
Plasma concentrations of ibrutinib and metabolite PCI-[ZIP_CODE] will be determined using a 
validated analytical method. Other potential metabolites of ibrutinib may be explored.
Bioanalytical data from this study will be used  in noncompartmental PK analysis and also may 
be combined with data from other studies perfor med with ibrutinib in subjects with hematologic 
malignancies as part of a population PK analysis  using nonlinear mixed effects models. For the 
population PK analysis, covariates that could potentially  correlate with plas ma PK parameters 
will be evaluated. The results of the population PK  analyses will be presented in a separate 
report.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493318] transfus ions, and number of use of hematopoietic 
growth factors. Those parameters will be summar ized with descriptive statistics by [CONTACT_54012]. The SAP will provide additional analysis details.
[IP_ADDRESS]. Biomarker Analyses
Prognostic and predictive biomarkers and gene tics relative to treatment outcomes will be 
evaluated, eg, change in peripheral T/B/ NK counts and profiling of immunophenotypes ; Change 
in secreted protein levels (ie, ch emokines, cytokines, growth factors) ; Identification of 
biomarkers that predict sensit ivity or resistance to ibru tinib (ie, GEP, WES, etc.).
A Fisher Exact test or other methods may be used to estimate the association between the clinical 
response rates and each biomarker. The SAP will provide additional analysis details.
10.7. Safety Endpoints and Methods
Safety parameters of ibrutinib when used in combination with rituximab in subjects with WM
will be evaluated. 
Analysis of safety data will be conducted on the safety population, which includes enrolled 
subjects who receive at leas t [ADDRESS_493319] dose of study 
drug(s) unless otherwise specified. The safety  variables to be analyzed between the two 
treatment arms include adverse events, clin ical laboratory test results (hematology and 
chemistry), physical examination findings, and vital signs measurements. Exposure to study 
drug and reasons for discontinuation from study tr eatment will be tabulated by [CONTACT_5268].
In general, continuous variables will be su mmarized by [CONTACT_393076] (n, mean, median, sta ndard deviation, standard error a nd range).  Categorical variables 
will be summarized by [CONTACT_393077].  No formal statistical testing is planned between treatment arms.
For the open-label substudy (Arm C), all re levant safety outcomes will be descriptively 
summarized.
In addition to the study monitors an d investigators, the DMC will assess toxicity and safety at the 
time point of the pre-scheduled safety analyses.
Adverse Events
The verbatim terms used in the eCRF by [CONTACT_393078]-hematological adverse 
events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA).
Adverse events (AEs) will be graded by [CONTACT_941] I nvestigator according the NCI CTCAE v4.03 or 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493320] udy drug; any adverse event that is 
considered study drug- related regardless of the st art date of the event; or  any adverse event that 
is present at baseline but wors ens after the first administration of study drug in severity or is 
subsequently considered drug-related by [CONTACT_18413]. All treatment-emergent adverse events 
will be included in the analysis. Adverse event parameters to be evaluated by [CONTACT_393079], incidence, and intensity of a dverse events; the relationship of adverse events to 
ibrutinib; and the action taken with respect to ibrutinib tr eatment due to adverse events .
Summaries, listings, or subject narratives may be provided, as appropriate, for those subjects 
who die, who discontinue treatment due to an ad verse event, or who experience a severe or a 
serious adverse event.
Clinical Laboratory Tests
All central laboratory values will  be converted to Standard Intern ational units (SI) and classified 
as normal, low, or high based on the SI refe rence ranges supplied by [CONTACT_2237].
Where local labs are used, values will be convert ed to PCYC Standard un its and flagged against 
PCYC Standard Ranges. Gradable  laboratory parameters will be graded using the NCI CTCAE 
Version 4.03 or higher.  Treatment emergent lab abnormalities will be summarized.  
Laboratory tests will be summarized by [CONTACT_393080].  Selected hematologic and chemis try laboratory parameters are detailed in 
Section 7.2.  Descriptive statistics will be provided for the values of  selected clinical laboratory 
tests at each scheduled on-treat ment evaluation including the fina l value.  Change or percent 
change from baseline to each scheduled on-treat ment evaluation and to the final value will also 
be summarized. For selected variables, the mean value and mean percent change over time will 
be presented graphically.
10.8. Interim Analysis
An interim analysis for the randomized treatmen t arms (Arm A and Arm B) will be conducted at
approximately 70% information, ~50 PFS events based on IRC assessment.  The interim analysis 
will be performed by [CONTACT_393081] l supporting group. PCYC will remain blinded to 
the results that are provided to the independent DMC at the interim analysis. In order to preserve 
the study wise two-sided type I error rate of  0.05, the two-sided signifi cance level for PFS will 
be 0.015 at 50 PFS events, based on O’Brien Fl eming boundary. However, the alpha spending 
for PFS will be determined based on the actual  information fraction using O’Brien-Fleming 
boundary at the time of the interim analysis.
If the primary endpoint achieves statistical si gnificance, tests of secondary endpoints will be 
performed at the two-sided significance level of  0.05 in a sequential hierarchical manner based 
on a closed testing procedure. All key secondary  endpoints will be ranked in sequence according 
to a hierarchical order to be specified in the S AP.  Further details regarding interim efficacy 
analysis will be described in  the DMC charter and the SAP.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 77The ibrutinib monotherapy substudy (Arm C) w ill not be included in the interim analysis. 
10.9. Final Analysis
The final analysis will be conducted at approxim ately 71 PFS events, which are confirmed by [CONTACT_393082] (Arm A and Arm B). The two-si ded significance level 
for the primary and all secondary endpoints wi ll be adjusted to account for interim alpha 
spending so the overall two-sided significance le vel for the study will be preserved at 0.05. Tests 
of secondary endpoints will be performed using th e same approach for the interim analysis. The 
ibrutinib monotherapy substudy (Arm C) will be analyzed separately at the final analysis. 
10.10. Independent Review Committee (IRC)
The IRC will be chaired by a physician with  expertise in WM and the IRC will conduct 
progression and response evaluations. The IRC assessment will incorporate nodal and 
extranodal assessments from the central radiolog y review in addition to the laboratory efficacy 
evaluations outlined in Section 7.5. Details regarding IRC and central radiology review 
activities will be outlined in a separate charter. IRC is established to conduct response assessment centrally according to the IRC charter.
10.11. Independent Data Monitoring Committee (DMC)
The safety and the interim analysis of this st udy will be monitored by [CONTACT_3153].  The 
independent DMC includes two medical experts in the relevant therapeutic area and one 
statistician to monitor data on an ong oing basis throughout the conduct of the study.
The independent DMC may recommend stoppi[INVESTIGATOR_393022]-specified 
stoppi[INVESTIGATOR_393023]. In addition to the ongoing safety 
monitoring and planned interim analyses for e fficacy, periodic safety review meetings are 
planned. The first DMC meeting will occur approximately [ADDRESS_493321] 
been randomized. The safety review will focus on deaths, treatment discontinuations, serious 
adverse events, Grade ≥[ADDRESS_493322] safety analysis, all deaths, treatment 
discontinuations and serious adverse events wi ll be reviewed in a blinded fashion by [CONTACT_103]’s responsible physician on an ongoing ba sis to identify safety concerns, and the 
independent DMC will be informed of any new potential signals. The plan for monitoring 
subject safety and evaluating efficacy, and the ro les and responsibilities of the independent 
DMC, will be detailed in the independent DMC Charter.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493323] Oper ating Procedures in 
conformity with regulatory requirements worldw ide to ensure appropriat e reporting of safety 
information; all clinical studies conducted by [CONTACT_3433] e sponsor or its affiliates will be conducted in 
accordance with those procedures.
11.1. Adverse Event Definitions and Classifications
11.1.1. Adverse Events
An AE is any untoward medical occurrence in a subject administered a pharmaceutical product 
and which does not necessarily have a causal re lationship with this treatment.  An AE can 
therefore be any unfavorable and unintended si gn (including a clinical ly significant abnormal 
laboratory finding, for example), symptom, or diseas e temporally associated  with the use of an 
investigational study drug, whether or not considered related to the study drug ( ICH-E2A 1995).
For the purposes of this clinical study, AEs incl ude events which are either new or represent 
detectable exacerbations of  pre-existing conditions.
Disease progression is not an adverse event; rather  it may be the cause of an adverse event.  
The clinical diagnosis that is a ssociated with disease progression must be reported as all other 
adverse events.  “Disease progression” should never be used as an  adverse event term.
Adverse events may include, but are not limited to:
• Subjective or objective symptoms provide d by [CONTACT_3184]/or observed by [CONTACT_393083].
• Any AEs experienced by [CONTACT_393084] e completion of final study procedures.
• AEs not previously observed in the subject that  emerge during the pr otocol-specified AE 
reporting period, including signs or  symptoms associated with  the underlying disease that 
were not present before the AE reporting period 
• Complications that occur as a result of pr otocol-mandated interventions (eg, invasive 
procedures such as biopsies).
The following are NOT considered AEs:
• Pre-existing condition: A pre-existing condition (docum ented on the medical history 
eCRF) is not considered an AE unless the seve rity, frequency, or character of the event 
worsens during the study period.
• Pre-planned or elective hospi[INVESTIGATOR_059]: A hospi[INVESTIGATOR_14147], but rather a ther apeutic intervention.  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 79However, if during the pre-planned hospi[INVESTIGATOR_14148], which prolongs the 
hospi[INVESTIGATOR_14149],  the event will be considered an SAE.  
Surgeries or interventions that were under consideration, but not performed before enrollment in the study, will not be consider ed serious if they are performed after 
enrollment in the study for a condition that has not changed from its  baseline level.  
Elective hospi[INVESTIGATOR_393024] r social reasons, solely for the administration of 
chemotherapy, or due to long travel  distances are also not SAEs.
• Diagnostic Testing and Procedures: Testing and procedures sh ould not to be reported 
as AEs or SAEs, but rather the cause for the test or procedure should be reported.
Serious Adverse Events
A serious adverse event based on ICH and EU Gu idelines on Pharmacovigilance for Medicinal 
Products for Human Use is any untoward medical occurrence that at any dose:
• Results in death (ie, the AE act ually causes or leads to death).
• Is life-threatening.  Life-threate ning is defined as an AE in which the subject was at risk 
of death at the time of the event.  It does not refer to an event which hypothetically might 
have caused death if it were more severe.  If either the Investigator or the Sponsor 
believes that an AE meets the definition of life-threatening, it will be considered 
life-threatening.
• Requires in-subject hospi[INVESTIGATOR_12191] >24 hours or prolongation of existing hospi[INVESTIGATOR_059].
• Results in persistent or significant disability/in capacity (ie, the AE results in substantial 
disruption of the subject’s abilit y to conduct normal life functions).
• Is a congenital anomaly/birth defect.
• Is an important medical event that ma y not result in death, be immediately 
life-threatening or require hospi[INVESTIGATOR_059], but may be considered an SAE when, 
based upon appropriate medical judgment, the event may jeopardize the subject or 
subject may require interventi on to prevent one of the othe r outcomes listed in this 
definition.  Examples of such events are inte nsive treatment in an emergency department 
or at home for allergic bronchospasm, blood dys crasias, or convulsion that does not result 
in hospi[INVESTIGATOR_059]; or development of drug dependency or drug abuse.
Given that the Investigator’s perspective may be informed by [CONTACT_393085], 
and the Sponsor is likely to have broader knowle dge of the drug and its effects to inform its 
evaluation of the significance of the event, if eith er the Sponsor or the Investigator believes that 
the event is serious, the event will be considered serious.
11.1.2. Severity Criteria (Grade 1-5)
Definitions found in the Common Terminology Cr iteria for Adverse Events version 4.03 
(CTCAE v4.03) will be used for grading the se verity (intensity) of AEs. The CTCAE v4.[ADDRESS_493324] experience any AE not liste d in the CTCAE v4.03, the following grading 
system should be used to assess severity:
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 80• Grade 1 (Mild AE) – experiences which are usually transient, requiring no special 
treatment, and not interfering with the subject’s daily activities
• Grade 2 (Moderate AE) – experiences which in troduce some level of inconvenience or 
concern to the subject, and which may inte rfere with daily activ ities, but are usually 
ameliorated by [CONTACT_14212]
• Grade 3 (Severe AE) – experiences which are unacceptable or intolerable, significantly 
interrupt the subject’s usual daily activity, and require sy stemic drug therapy or other 
treatment
• Grade 4 (Life-threatening or disabling AE) – e xperiences which cause the subject to be in 
imminent danger of death
• Grade 5 (Death related to AE) – experi ences which result in subject death
11.1.3. Causality (Attribution)
The Investigator is to assess the causal relation (ie, whether there is a reasonable possibility that 
the study drug caused the event) using the following definitions:
Not Related: Another cause of the AE is more plau sible; a temporal sequence cannot be 
established with the onset of the AE and administration of the 
investigational product; or , a causal relationship is considered biologically 
implausible.
Unlikely: The current knowledge or informati on about the AE indicates that a 
relationship to the investigational product is unlikely.
Possibly Related: There is a clinically plausible time sequence between onset of the AE and 
administration of the investigational product, but the AE could also be 
attributed to concurrent or underlying disease, or the use of other drugs or 
procedures.  Possibly related should  be used when the investigational 
product is one of several biologically plausible AE causes.
Related: The AE is clearly related to us e of the investigational product.
11.2. Unexpected adverse events
An “unexpected” AE is an AE that is not listed in the Investigator 's Brochure/package insert or is 
not listed at the specificity or severity that ha s been observed.  For example, hepatic necrosis 
would be “unexpected” (by [CONTACT_393086]) if the Investigator 's Brochure referred only 
to elevated hepatic enzymes or hepatitis.  Similarly, cerebral thromboembolism and cerebral 
vasculitis would be “unexpected” (by [CONTACT_145178]) if the Investigator's 
Brochure/package insert listed only cerebral vascular accidents.  "Unexpected" also refers to AEs 
that are mentioned in the Investigator's Brochur e as occurring with a class of drugs or as 
anticipated from the pharmacological properties of  the drug, but are not specifically mentioned 
as occurring with the study drug under investigation.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 8111.3. Documenting and Reporting of Adverse Events
11.3.1. Reporting of “IgM flare” (Tumor flare)
Therapy with rituximab in WM is commonly associated with a surge of IgM levels (IgM flare).
This transient increase of IgM levels will mo st likely not indicate disease progression and 
subjects may continue therapy with rituximab.
The Medical Dictionary for Regulatory Activitie s (MedDRA) does not sup port the reporting of 
“IgM flare” and therefore these ev ents should be reported as an a dverse event of 'tumor flare'.
Table 5 provides guidance on grading this particular event.
Table 5: Grading for Adverse Events of IgM Associated Tumor Flare
“IgM flare” (Tumor flare)
Grade 1 <25% IgM increase during rituximab therapy  
Grade 2 ≥25% IgM increase during rituximab therapy  
Grade 3 IgM increase during rit uximab therapy associated with  clinical intervention (e.g. 
plasmapheresis)\
Grade 4 IgM increase during rituximab therap y associated with life-threatening con sequences;
urgent intervention indicated
Grade [ADDRESS_493325] ug that may require expedited reporting and/or 
safety evaluation include, but are not limited to:
• Overdose of a study drug
• Suspected abuse/misuse of a study drug
• Inadvertent or accidenta l exposure to a study drug
• Medication error involving a product (with or without subject/patient exposure to the 
study drug, eg, name [CONTACT_2976], incorrect doses)
Special reporting situatio ns should be recorded in the eCRF . Any special reporting situation that 
meets the criteria of a serious adverse event shou ld be recorded on the serious adverse event page 
of the eCRF and should be reported on the Seriou s Adverse Event Worksheet and sent via email 
or fax to Pharmacyclics Drug Safety, or designee, within 24 hours of awareness.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 8211.3.3. Adverse Event Reporting Procedures
[IP_ADDRESS]. All Adverse Events
All subjects who receive at le ast one dose of study drug(s) will be considered evaluable for 
safety assessments. All adverse events, whether serious or non-serious, will be documented in 
the source documents from the time signed and da ted ICF is obtained unt il [ADDRESS_493326] be reported to 
the Sponsor as a serious adverse event. Progressive disease should NOT be reported as an adverse even t term, but instead symptoms/
clinical signs of disease progr ession may be reported. Otherwise, all events that meet the 
definition of a serious adverse event will be reported as serious adverse events, regardless of 
whether they are protocol-specific assessments.
If study drug is discontinued because of a serious adverse event, this information must be 
included in the seriou s adverse event report.
All adverse events, regardless of seriousness, seve rity, or presumed relationship to study drug, 
must be recorded using medical terminology in the source document. All records will need to 
capture the details of the durati on and the severity of each epi[INVESTIGATOR_1865] , the action taken with respect 
to the study drug, investigator’s evaluation of its relationship to the study drug, and the event 
outcome. Whenever possible, diagnoses should be given when signs and symptoms are due to a 
common etiology (eg, cough, runny nose, sneezing, so re throat, and head congestion should be 
reported as "upper respi[INVESTIGATOR_306712]"). Investigators must r ecord in the eCRF their opi[INVESTIGATOR_393025] t to study therapy. All measures required for 
adverse event management must be recorded in  the source document and reported according to 
sponsor instructions.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 8311.3.3.2. Reporting Criteria for Serious Adverse Events
All serious adverse events (initial and follow- up information) will be reported on the Serious 
Adverse Event Worksheet and sent via email or fa x to Pharmacyclics Drug Safety, or designee, 
within [ADDRESS_493327] follow-
up and other additional information from the Inve stigator (eg, hospi[INVESTIGATOR_393026]/discharge notes 
and laboratory results). The cont act information (phone, email and fax) for Pharmacyclics Drug 
Safety or designee can be found on the Serious A dverse Event Worksheet form and instructions.
All serious adverse events that have not reso lved by [CONTACT_2054], or that have not 
resolved upon discontinuation of the subject's pa rticipation in the study, must be followed until 
any of the following occurs:
• The event resolves
• The event stabilizes
• The event returns to baseline, if a baseline value/status is available
• The event can be attributed to agents other than the study drug  or to factors unrelated to 
study conduct
• It becomes unlikely that any additional info rmation can be obtained  (subject or health 
care practitioner refusal to provide additional information, lost to follow-up after 
demonstration of due dilige nce with follow-up efforts)
11.3.4. Adverse Events of Special Interest (AESI)Specific AEs or groups of AEs will be followed as pa rt of standard safety  monitoring activities 
by [CONTACT_1034]. These events will be reported to  Pharmacyclics within 24 hours of awareness 
irrespective of seriousness (ie, serious and non-serious adverse events) following the procedure 
described above for SAEs and will re quire enhanced data collection.
[IP_ADDRESS]. Major Hemorrhage
Major hemorrhage is defined as any of the following: 
1. Any treatment-emergent hemorrhagic adverse events of Grade 3 or higher*
2. Any treatment-emergent serious adverse events of bleeding of any grade3. Any treatment-emergent centr al nervous system hemorrhage/hematoma of any grade
*All hemorrhagic events requiring transfusion of red blood cells should be reported as grade 3 or higher 
AE per CTCAE.
Events meeting the definition of major hemorrhag e will be captured as an AESI according to 
Section 11.3.4 above.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493328] dose of ibrutinib/placebo or [ADDRESS_493329] dose of 
ibrutinib/placebo or [ADDRESS_493330] dose of rituximab, whichever occurs later. Any 
female subjects receiving study drug(s) who b ecome pregnant must im mediately discontinue 
study drug. The Investigator should  counsel the subject, discussi ng any risks of continuing the 
pregnancy and any possible effects on the fetus.  
Although pregnancy itself is not regarded as an  adverse event, the outcome will need to be 
documented. Any pregnancy occurring in a subject from the time of consent to [ADDRESS_493331] dose of ibrutinib/placebo or  [ADDRESS_493332]’s partner fro m the time of consent 
to [ADDRESS_493333] dose of ibrutinib/placeb o or [ADDRESS_493334] be recorded on the 
Pregnancy Report Form Part I and sent via em ail or fax to Pharmacyclics Drug Safety, or 
designee, within 24 hours of learning of the event. All pregnancies will be followed for 
outcome, which is defined as elective termination of the pregnancy, miscarriage, or delivery of 
the fetus. For pregnancies with an outcome of live birth, the newborn infant will be followed 
until 30 days old by [CONTACT_36094]. Any congenital anomaly/birth defect noted in the infant mu st be reported as a serious adverse event.
11.3.6. Other Malignancies
All new malignant tumors including solid tu mors, skin malignancies and hematologic 
malignancies are to be reported for the durati on of study treatment and during any protocol-
specified follow-up periods including post-progression follow-up for overall survival.
11.3.7. Eye-related Adverse Events
New or worsening eye-related symptoms that ar e Grade [ADDRESS_493335] whose 
findings should be reported on the ophthalmologic eCRF.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 8512. STUDY ADMINISTRATION AND INVESTIGATOR OBLIGATIONS
12.1. Regulatory and Ethical Compliance
This clinical study was designed and will be im plemented in accordance with the protocol, 
the ICH Harmonized Tripartite Guidelines for G ood Clinical Practices, with applicable local 
regulations (including US Code of Federal Regulations [CFR] Title 21 and European Directive 
2001/20/EC), and with the ethical principles laid down in the Decl aration of Helsinki. 
12.2. Institutional Review Board (IRB), Resea rch Ethics Board (REB) and Independent 
Ethics Committee (IEC) Approval
The Investigator will submit this protocol, th e ICF, IB, and any other relevant supporting 
information (eg,IMPD, all advertising materials or materials given to the subject during the 
study) to the appropriate  IRB/REB/IEC for review and appr oval before study initiation.  
Following the respective rules and regulations in different countries, amendments to the protocol 
and informed consent form must also be submitted and if necessary approved by [CONTACT_1201]/REB/IEC before the implementation of changes in this study.
The Investigator is responsible for providing the IRB/REB/IEC with any required information 
before or during the study, such as SAE expedited reports or study progress reports.
The IRB/REB/IEC must comply with current Unit ed States (US) regulations (§21 CFR 56) as 
well as country-specific national regulations and/or local laws.
The following documents must be provided to Ph armacyclics or its auth orized representative 
before entering subjects in this study: (1) a copy of the IRB/REB/IEC letter that grants formal 
approval; and (2) a copy of the IRB/REB/IEC -approved ICF. 
12.3. Informed Consent
The ICF and process must comply with the US re gulations (§ 21 CFR Part 50) as well as country 
specific national regulations and/or local la ws.  The ICF will document the study-specific 
information the Investigator or his/her desi gnee provides to the subj ect and the subject’s 
agreement to participate.  
The Investigator or designee (designee must be listed on the Delegati on of Authority log), must
explain in terms understandable to the subjec t the purpose and nature of the study, study 
procedures, anticipated benefits, potential risks, possible AEs, a nd any discomfort participation 
in the study may entail.  This process must be doc umented in the subject’s source record.  Each 
subject must provide a signed and dated ICF befo re any study-related (nonstandard of care) 
activities are performed.  The or iginal and any amended signed and dated consent forms must 
remain in each subject’s study file at the study site and be av ailable for verification by [CONTACT_33483].  A copy of each signed cons ent form must be given to the subject at the 
time that it is signed by [CONTACT_423].
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 8612.4. Quality Control and Quality Assurance
Sponsor shall implement and maintain quality cont rol and quality assurance procedures to ensure 
that the study is conducted and data are generated, documented and reported in compliance with 
the protocol, GCP, and applicable regulatory re quirements.  This study shall be conducted in 
accordance with the provisions of  the Declaration of Helsinki (October 2008) and all revisions 
thereof, and in accordance with FDA re gulations (21 CFR Parts 11, 50, 54, 56, and 312, 
Subpart D – Responsibilities of Sponsors and In vestigators), ICH guidelines on GCP (ICH E6),
and/or applicable local  country requirements.
12.5. Protected Subject Health Information AuthorizationInformation on maintaining subjec t confidentiality in accordance to individual local and national 
subject privacy regulations must be provided to each subject as part of the informed consent 
process (refer to Section 7.1.1 ), either as part of the ICF or as a separate signed document (for 
example, in the US, a site-specific HIPAA consent may be used).  The Investigator or designee must explain to each subject that for the evalua tion of study results, the subject’s protected 
health information obtained during the study ma y be shared with Pharmacyclics and its 
designees, regulatory agencies, and IRBs/REBs/IE Cs.  As the study Sponsor, Pharmacyclics will 
not use the subject’s protected hea lth information or disclose it to a third party without applicable 
subject authorization.  It  is the Investigator’s or designee’s responsibility to obtain written 
permission to use protected health informati on from each subject.  If a subject withdraws 
permission to use protected health information, it is  the Investigator’s resp onsibility to obtain the 
withdrawal request in writing from the subject andto ensure that no further data will be 
collected from the subject.  Any data collected on the subject before withdrawal will be used in 
the analysis of study results.
During the review of source documents by [CONTACT_36097], the confidentiality of the 
subject will be respected with strict adhere nce to professional standards and regulations.
12.6. Study Files and Record Retention
The Investigator must keep a record that lists allsubjects who signed informed consent for the
study.  For those subjects subsequently excluded from enrollment, the reason(s) for exclusion is 
to be recorded.
The Investigator/study staff must maintain adequate and accurate  records to enable the conduct 
of the study to be fully documented and the study data to be subsequently  verified.  Essential 
documentation includes, but is not limited t o, the IB, signed protocols and amendments, 
IRB/REB/IEC approval letters (dated), signed Form FDA 1572 and Financial Disclosures, 
signed ICFs (including subject confidentiality information), drug dispensing and accountability 
records, shippi[INVESTIGATOR_36075]-related materials, signed 
(electronically), dated and completed eCRFs,  and documentation of eCRF corrections, SAE 
forms transmitted to Pharmacyclics and notific ation of SAEs and related reports, source 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493336] marketing application is approved for the drug for the indicati on for which it is being 
investigated and until there are no pending or contemplated marketing applications; or, if no application is to be filed or if  the application is not approved for such indication, until [ADDRESS_493337] notify Pharmacyclics a nd obtain written approval from Pharmacyclics 
before destroying any clinical study documents or images (eg, scan, radiograph, ECG tracing) at 
any time.  Should an Investigator wish to assign the study records to another party or move them 
to another location, advance writ ten notice must be given to Phar macyclics.  Pharmacyclics will 
inform the Investigator of the date that st udy records may be destroyed or returned to 
Pharmacyclics.
Pharmacyclics must be notified in advance of, and Pharmacyclics must provide express written 
approval of, any change in the maintenance of  the foregoing documents if the Investigator 
wishes to move study records to another location or assign responsibility fo r record retention to 
another party.  If the Investigat or cannot guarantee the archiving requirements set forth herein at 
his or her study site for all su ch documents, special arrangement s must be made between the 
Investigator and Pharmacyclics to store such doc uments in sealed containers away from the 
study site so that they can be  returned sealed to the I nvestigator for audit purposes.
12.7. Case Report Forms and Record Maintenance
CRFs will be used to collect the clinical study data and must be completed for each enrolled 
subject with all required study data  accurately recorded such th at the information matches the 
data contained in medical records (eg, physicians ’ notes, nurses’ notes, cl inic charts and other 
study-specific source documents).  Authorized study site personnel (ie, listed on the Delegation 
of Authority log) will complete CRFs designe d for this study according to the completion 
guidelines that will be provided.  The Investigat or will ensure that the CRFs are accurate, and 
completed within a reasonable pe riod of time.  At all times, the Investigator has final 
responsibility for the accuracy and au thenticity of all clinical data.
The CRFs exists within an electronic data capt ure (EDC) system with controlled access managed 
by [CONTACT_36098].  Study staff will be appropriately 
trained in the use of CRFs and application of el ectronic signatures before the start of the study 
and before being given access to th e EDC system.  Original data a nd any changes of data will be 
recorded using the EDC system, with all changes tracked by [CONTACT_36099].  The Investigator attests th at the information contai ned in the CRFs is true 
by [CONTACT_393087].  After database lock, the Investigator 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493338] data (eg, paper, CD, or other appropriate media) for archiving 
at the study site.
12.8. Investigational Study Drug Accountability
Ibrutinib and any comparator used must be kept  in a locked limited access room.  The study drug 
must not be used outside the context of the protocol.  Under no circumstances should the 
Investigator or other site personnel supply ibru tinib or comparator to other Investigators, 
subjects, or clinics or allow supp lies to be used other than as di rected by [CONTACT_393088].
Accountability records for ibru tinib and any comparator must be maintained and readily 
available for inspection by [CONTACT_393089]. An Investigational Drug Accountability Log must be used for drug accountability.  For accurate 
accountability, the following information must be noted when drug supplies are used during the 
study:
1. Study identification number (PCYC-1127-CA)
2. Subject identif ication number
3. Lot number(s) of ibrutinib or comparator dispensed for that subject4. Date and quantity of drug dispensed
5. Any unused drug returned by [CONTACT_393090], the monitor will evaluate and a pprove the site’s proced ure for investigational 
product disposal/destruction to ensu re that it complies with Pharmacy clics’ requirements.  If the 
site cannot meet Pharmacyclics’ requirements  for disposal/destruction, arrangements will be 
made between the site and Pharmacyclics or  its representative, for return of unused 
investigational product.  Before disposal/destr uction, final drug accountability and reconciliation 
must be performed by [CONTACT_2037].
All study supplies and associated documentation w ill be regularly reviewed and verified by [CONTACT_36102].
12.9. Study Monitoring/Audit Requirements
Representatives of Pharmacyclics or its designee will monitor this study until completion.  
Monitoring will be conducted through personal visits with the Investigator and site staff, remote monitoring, as well as any appropriate communica tions by [CONTACT_2319], fax, email, or telephone.  The 
purpose of monitoring is to ensure that the study  is conducted in compliance with the protocol, 
standard operating procedures (SOPs), and other written instructions and regulatory guidelines, 
and to ensure the quality and integrity of the data.  This study is also subject to reviews or audits.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 89To assure the accuracy of data collected in th e CRFs, it is mandatory th at the monitor/auditor 
have access to all original source documents, in cluding all electronic medical records (EMR) at 
reasonable times and upon reasonable notice.  During the review of source documents, every 
effort will be made to maintain  the anonymity and confidential ity of all subjects during this 
clinical study.  However, because of the experime ntal nature of this treatment, the Investigator 
agrees to allow the IRB/REB/IEC, representative s of Pharmacyclics, its designated agents and 
authorized employees of the appropriate Regulator y Authority to inspect the facilities used in 
this study and, for purposes of veri fication, allow direct access to th e hospi[INVESTIGATOR_393027].  A statement to this effect will be included in the informed 
consent and permission form authorizing th e use of protected health information.
Pharmacyclics or its authorized representative ma y perform an audit at any time during or after 
completion of this study.  All study-related doc umentation must be made available to the 
designated auditor.  In addition, a representative of the FDA or other Regulatory Agencies may 
choose to inspect a study site at  any time before, during, or after completion of the clinical study.  
In the event of such an inspecti on, Pharmacyclics will be available to assist in the preparation.  
All pertinent study data should be made availabl e as requested to the Regulatory Authority for 
verification, audit, or inspection purposes.
12.10. Investigator Responsibilities
A complete list of Investigator responsibilities are outlined in the clinical trial research 
agreement and the Statement of Investigator Form FDA 1572, both of which are signed by [CONTACT_393091].   In summary, the Investigator will conduct the 
study according to the current protocol; will read and understand the IB; will obtain IRB/REB/IEC approval to conduc t the study; will obtain inf ormed consent from each study 
participant; will maintain and supply to the S ponsor or designee, auditors and regulatory 
agencies adequate and accurate records of study activity and drug accountability for study-related monitoring, audits, IRB/REB/IEC revie ws and regulatory inspections; will report SAEs 
to the Sponsor or designee and IRB/ REB/IEC according to the specifics outlined in this 
protocol; will personally conduct or supervise the study; and will ensure that colleagues 
participating in the study are informed about  their obligations in meeting the above 
commitments.
12.11. Sponsor Responsibilities
A complete list of the Sponsor responsibilities is outlined in the clinical trial research agreement 
and in the laws and regulation of  the country in which the resear ch is conducted.  In summary, 
the Sponsor will select qualified Investigators, provide them with the information they need to 
properly conduct the study, ensu re adequate monitoring of th e study, conduct the study in 
accordance with the general investigational plan and protocols and promptly inform 
Investigators, health and regulatory agencies/a uthorities as appropria te of significant new 
adverse effects or risks with respect to the drug.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493339] igator (as designated on the Form FDA1572) will 
provide a personally signed Financial Disclosure Form in accordance with § [ADDRESS_493340] or injury, a ppropriate medical care as determined by [CONTACT_3786]/designee will be provided.
If a bodily injury is sustained, resulting directly  from the use of the study drug, Pharmacyclics 
will reimburse for reasonable physician fees and medical expenses necessary for treatment of 
only the bodily injury which is not covered by [CONTACT_941] s ubject’s medical or hospi[INVESTIGATOR_36076], 
provided that the injury is not due to a negligent or wrongful act or omission by [CONTACT_737]/ 
study staff.  The ICF will include a descripti on of this reimbursement policy, incorporating 
country-specific national regulations  and/or local laws.  Financia l compensation for lost wages, 
disability or discomfort due to the study is not available.
Clinical trial insurance has been undertaken acco rding to the laws of the countries where the 
study will be conducted.  An insurance certificate will be made avai lable to the participating sites 
at the time of study initiation.
12.14. Protocol Amendments
Pharmacyclics will initiate any change to the pr otocol in a protocol amendment document.  The 
amendment will be submitted to the regulatory authorities and IRB/REB/IEC, as appropriate,
together with, if applicable, a revised model IC F.  Written documentation of health authority 
and/or IRB/REB/IEC and required site approval, as applicable, must be received by 
[CONTACT_393092] e ffect at each site.  Additionally under this 
circumstance, information on any change in risk and/or change in scope must be provided to 
subjects already actively participating in the st udy, and they must read, understand and sign each 
revised ICF confirming willingness to remain in the trial.
No other significant or consistent change in  the study procedures, except to eliminate an 
immediate hazard, shall be effected without th e mutual agreement of the Investigator and 
Pharmacyclics.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493341].  The results may also be used for papers, abstracts, posters, or 
other material presented at scient ific meetings or published in prof essional journals or as part of 
an academic thesis by [CONTACT_39595].  In all cases, to avoid disclosures that could jeopardize 
proprietary rights and to ensure a ccuracy of the data, Pharmacyclics reserves the right to preview 
all manuscripts and abstracts related to this  study, allowing Pharmacyclics sufficient time to
make appropriate comments before submission for publication. Pharmacy clics adheres to the 
guidelines on authorship established by [CONTACT_393093] (h ttp://www.icmje.org/ethi cal_1author.html).
In most cases, the Investigators at the sites with th e highest accruals of eligible subjects shall be 
listed as lead authors on manuscripts and repor ts of study results.  The Medical Monitor, study 
director and/or lead statistician ma y also be included in the list of  authors.  This custom can be 
adjusted upon mutual agreement of the authors and Pharmacyclics and in accordance with 
current standards for authorship as recorded in professional c onference and journal submission 
instructions.
12.16. Study Discontinuation
The Sponsor reserves the right to terminate th e study at any time.  Should this be necessary, 
both the Sponsor and the Investigator will arrange discontinuation procedures.  In terminating the 
study, the Sponsor and the Investigator will assure  that adequate consideration is given to the 
protection of the subjects’ interests.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 9213. REFERENCES
1. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyro sine kinase inhibitor ibrutinib (PCI-[ZIP_CODE]) has 
significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 
2013;31:88 -94.
2. Anderson KC, Alsina M, Bensinger W, et al . Waldenström’s Macroglobulinemia/Lymphoplasmacytic 
Lymphoma, Version 2.2013. J Natl Compr Canc Netw. 20 12;10:1211 -1219.
3. Bishop GA, Haxhinasto SA, Stunz LL, et al. Antig en-specific B-lymphocyte activation.  Crit Rev 
Immunol 2003;23:165 –197.  
4. Brown JR, Barrientos JC, Barr PM, et al. Ibru tinib In Combination With Bendamustine and 
Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of 
a Phase 1b Study . Blood 2013; 122: 525. 
5. Burger JA, Keating MJ, Wierda WG, et al. Ibrutinib plus rituximab for patients with high-risk chronic 
lymphocytic leukaemia: a single-arm phase 2 study. Lancet Oncol. 2014 ;15(10):1090-1099.
6. Buske C, Leblond V, Dimopoulos M, et al. Walde nström’s macroglobulinaemia: ESMO Clinical 
Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl 6): 
vi155-vi159.
7. Cella D, Zagari MJ, Vandoros C, et al. Epoetin alfa treatment results in  clinically significant 
improvements in quality of life in anemic cancer pa tients when referenced to the general population.
JClin Oncol. 2003;21:366 -73.
8. Cella D. The Functional Assessment of Cancer Ther apy-Anemia (FACT-An) Scale: a new tool for the 
assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34([ADDRESS_493342] 2):13 -9.
9. Chang BY, [LOCATION_009]sco M, De Rooij MF, et al. Egre ss of CD19(+)CD5(+) cells into peripheral blood 
following treatment with the Bruton tyrosine kinase  inhibitor ibrutinib in mantle cell lymphoma 
patients. Blood. 2013a;122:2412 -24. 
10. Chang BY, [LOCATION_009]sco M, Steggerda S, et al. Ibrutinib Inhibits Mali gnant Cell Adhesion and 
Migration and Reduces Tumor Burden in Lymph Node and Bone Marrow in  a Murine Model of 
Mantle Cell Dissemination and Progression. 2013b AACR: Abstract 923.
11. Cheson BD. Rituximab: clinical development a nd future directions. Expert Opin Biol Ther 
2002;2:97 -110.
12. Cheson BD, Pfistner B, Juweid ME, et al. Revise d response criteria for malignant lymphoma. J Clin 
Oncol . 2007;25:579-586.
13. Child CG, Turcotte JG.  “Surgery and portal hypertension”. In Child CG. The liver and portal 
hypertension. 1964. Philadelphia:Saunders. pp. 50-64.  
14. Dimopoulos MA, Zervas C, Zomas A, et al. Tr eatment of Waldenström’ s macroglobulinemia with 
rituximab. J Clin Oncol 2002a ;20:2327 -33.
15. Dimopoulos MA, Zervas C, Zomas A, et al. Exte nded rituximab therapy for previously untreated 
patients with Waldenström's macr oglobulinemia. Clin Lymphoma. 2002b ;3:163 -6
16. Dimopoulos MA, Kastritis E, R oussou M, et al. Rituximab-base d treatments in Waldenström’s
macroglobulinemia. Clin Lymphoma Myeloma 2009;9:59 -61.
17. EuroQol Group. EuroQol-a New Facility for the M easurement of Health-Related Quality of Life. 
Health Policy. 1990;16:199 -208.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 9318. Ghobrial IM, Uslan DZ, Call TG, et al. Initial in crease in the cryoglobulin level after rituximab 
therapy for type II cryoglobulinemia secondary to  Waldenström macroglobulinemia does not indicate 
failure of response. Am J Hematol. 2004 ;77:329-30.
19. Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenström’s
macroglobulinemia (WM): an Eastern Coopera tive Oncology Group Study (E3A98). Leuk 
Lymphoma 2004;45:2047 -55.
20. Harris NL, Jaffe ES, Diebold J, et al. World Health  Organization classification of neoplastic diseases 
of the hematopoietic and lymphoid tissues: report of  the Clinical Advisory Committee meeting-Airlie 
House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-49.
21. Harris NL, Jaffe ES, Stein H, et al. A revise d European-American classification of lymphoid 
neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361 -92.
22. Herman SE, Gordon AL, Hertlein E, et al. Bruton ty rosine kinase represents a promising therapeutic 
target for treatment of chronic lymphocytic leukemia and is effectively targeted by [CONTACT_9090]-[ZIP_CODE]. Blood. 
2011;117:6287 -96.
23. IMBRUVICA®(ibrutinib) Prescribing Information. Phar macyclics, Inc., Sunnyvale, [LOCATION_004]; 2015.
24. International Conference on Harmonization (ICH) Gu ideline for Industry: Clinical Safety Data 
Management: Definitions and Standards for Expedited Repor ting (ICH-E2A).  March 1995.
25. Jaglowski SM, Jones JA, Flynn JM, et al. A phase Ib/II study evaluating activity and tolerability of 
BTK inhibitor PCI-[ZIP_CODE] and ofatumumab in patie nts with chronic lymphocytic leukemia/small 
lymphocytic lymphoma (CLL/SLL) and related di seases [abstract]. ASCO. 2012. Abstract 6508.
26. Kilidireas C, Anagnostopoulos A, Karandreas N, et al. Rituximab therapy in monoclonal IgM-related 
neuropathies. Leuk Lymphoma. 2006 ;47:859-64.
27. Konoplev S, Medeiros LJ, Bueso-Ramos CE, Jo rgensen JL, Lin P. Imm unophenotypic profile of 
lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia. Am J Clin Pathol 2005;124:414 -
20.
28. Kyle RA, Treon SP, Alexanian R, et al. Prognostic  markers and criteria to initiate therapy in 
Waldenström’s macroglobulinemia : consensus panel recommendations  from the Second International 
Workshop on Waldenström’s Macroglobulinemia. Semin Oncol 2003;30:116 –120.
29. Morel P, Duhamel A, Gobbi P, et al. Interna tional prognostic scoring system for Waldenström’s
macroglobulinemia. Blood. 2009;113:4163 -70. 
30. National Comprehensive Cancer Network. C linical practice guidelines in oncology (NCCN 
guidelines). Waldenström’s Macroglobulinemia / Ly mphoplasmacytic Lymphoma, Version 1, 2014. 
Available at: http://www.nccn.org /professionals/physician_gls/pdf/ Waldenström’ss.pdf. Accessed 
January 08, 2014.
31. Ngo VN, Young RM, Schmitz R, et al. Oncogenica lly active MYD88 mutations in human lymphoma. 
Nature. 2011;470:115 -9.  
32. O’Brien S, Furman RR, Coutre SE, et al.  Indepe ndent evaluation of ibruti nib efficacy [ADDRESS_493343]-
initiation of monotherapy in patie nts with chronic lymphocytic le ukemia/small lymphocytic leukemia 
including deletion 17p disease.  J Clin Oncol. 2014:32(5s):abstract 7014
33. O’Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elde rly patients with chronic 
lymphocytic leukaemia or small lymphocytic lymphoma : an open-label, multicentre, phase 1b/2 trial.  
Lancet Oncol. 2014;15:48 -58.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 9434. Oken MM, Creech RH, Tormey DC, et al. Toxicity And Response Criteria Of The Eastern 
Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982.
35. Owen RG, Treon SP, Al-Katib A, et al. C linicopathological definition of Waldenström’s
macroglobulinemia: consensus panel recommendati ons from the Second Inte rnational Workshop on 
Waldenström’s Macroglobulinemia. Semin Oncol 2003;30:110 -5
36. Pan Z, Scheerens H, Li SJ, et al. Discovery of selective irreversible  inhibitors for Bruton's tyrosine 
kinase. ChemMedChem 2007;2:58 -61.
37. Pugh RN, Murray-Lyon IM, Dawson L, Pi[INVESTIGATOR_9051], Williams R . Transection of the oesophagus for 
bleeding oesophageal varices. The British journal of surgery 1973 ;60: 646-9
38. Rourke M, Anderson KC, Ghobria l IM. Review of clinical tria ls conducted in Waldenström’s
macroglobulinemia and recommendations for reporting c linical trial responses in these patients. Leuk 
Lymphoma. 2010;51:1779 -92. Review.
39. San Miguel JF, Vidriales MB, Ocio E, et al. Immunophenotypic analysis of Waldenström’s
macroglobulinemia. Semin Oncol 2003;30:187 -95.
40. Satterthwaite AB, Witte ON. The role of Bruton's ty rosine kinase in B cell development and function: 
a genetic perspective . Immunol Rev 2000;175:120 -127.
41. Shaffer AL, Rosenwald A, Staudt LM. Lym phoid malignancies: The dark side of B-cell 
differentiation.  Nat Rev Immunol 2002;2:920 –932.  
42. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations  for the use of white 
blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 
2006;24:3187 -205. 
43. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomi b therapy in patients with  relapsed or refractory 
lymphoma: potential correlation of in vitro sensitivit y and tumor necrosis fact or alpha response with 
clinical activity. J Clin Oncol 2006;24:2105 –2112.
44. Treon SP, Tripsas CK, Yang G, et al. A Prosp ective Multicenter Study Of The Bruton’s Tyrosine 
Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenström’sMacroglobulinemia [abstract]. ASH me eting (oral presentation) Blood 20 13;122: 251
45. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's 
macroglobulinemia. N Engl J Med. 2012;367:826-33.
46. Treon SP, Merlini G, Morra E, et al. Report from the Sixth International Wo rkshop on Waldenström's 
Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011;11:68 -73.
47. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory 
Waldenström’s macroglobulinemia: results of  WMCTG Trial 03-248. Clin Cancer Res 
2007;13:3320 –3325.  
48. Treon SP, Gertz MA, Dimopoulos M, et al , Owen R, Stone MJ. Update on treatment 
recommendations from the Third International Workshop on Waldenström’s macroglobulinemia. 
Blood. 2006;107:3442 -6.
49. Treon SP, Emmanouilides C, Kimby E, et al. Extended rituximab therapy in Waldenström's 
macroglobulinemia. Ann Oncol 2005;16:132 -8
50. Varghese AM, Rawstron AC, Ashcroft AJ, et al. Assessment of bone marrow response in 
Waldenström’s ma croglobulinemia. Clin Lymphoma Myeloma 2009;9:53 –55.
51. Xu L, Hunter ZR, Yang G, et al. MYD 88 L265P in Waldenström macroglobulinemia, 
immunoglobulin M monoclonal gammopathy, and ot her B-cell lymphoproliferative disorders using 
conventional and qua ntitative allele- specific polymerase chain re action. Blood. 2013;121:2051 -8.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 9552. Yang G, Zhou Y, Liu X, et al. A mutati on in MYD88 (L265P) supports the survival of 
lymphoplasmacytic cells by [CONTACT_393094]öm macroglobulinemia.
Blood. 2013;122:1222 -32.
53. Yang G, Xu L, Zhou Y, et al. Participation of BTK in MYD88 signaling in malignant cells expressing 
the L265P mutation in Waldenström’s macroglobulin emia, and effect on tumor cells with BTK-
inhibitor ibrutinib in combination with M YD88 pathway inhibitors. J Clin Oncol 2012; 30 (suppl; 
abstr 8106).
54. Yellen SB, Cella DF, Webster K, et al. Measuring fatigue and other anemia-r elated symptoms with 
the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom 
Manage. 1997;1 3:63-74.
55. Younes A, Thieblemont C, Morschhauser F, et al.  Combining Ibrutinib With Rituximab, 
Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): Updated Results From a 
Phase 1b Study in Treatment-Naïve Patients With CD20-Positive B-Cell Non-Hodgkin’s Lymphoma 
(NHL).  Lancet Oncol. 2014;15:1019 -26.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 9614. APPENDICES
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version: Amendment [ADDRESS_493344]-Treatment/
Follow-Up Phase
Study Weeks 12 345-16
q4 weeks17 18 19 20 2125+
q8 weeksSuspected 
PD VisitEnd-of-
Treatment 
VisitsResponse 
Follow-Up
Visits
(Until PD )
q12 weeksSurvival 
Follow-Up
q12 weeks
Study Day 11 1 1 1 1
Study Windows -30 days + 3 days ± 3 days + 3 days ± 3 days ± 3 days anytime ± 7 days ± 7 days ± 7 days
Study Drug Administration
ARM A and ARM B 
Rituximab  375 mg/m2IVaxx xx x xx x
Ibrutinib/Placebo 420mg PO Continuous dosi ng until PD or unacceptable toxicity
ARM C (Substudy)
Open-label ibrutinib 420mg PO Continuous dos ing until PD or unacceptable toxicity
Dispense Study Drug 
(ibrutinib/placebo)xx x x x
Administrative Procedures
Informed consentrXr
Confirm eligibility & randomize X x
Medical history and Demographics X
PRO assessmentsbxx x x x x x x xc
Safety Assessments
Physical exam (height at Screening 
only)xdxdxexexexexdxdxd
Eye-related symptom assessment X x x x x x x x x
ECOG status X x x x x x x x
Vital signs X x x x x x x x
ECG X Additional assessments may be performed if cl inically indicated during the course of the study
Clinical Laboratory Assessments
Hematology X x x x x x x x x
Serum chemistry X x x x x x x
Coagulation (PT, IN R, and aPTT) X x x
Pregnancy testfXx
Hepatitis serologies X
Serum viscositygX
Serum immunofixationhX
β2-microglobulin X
PKi
xWeek 5 
Only
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version: Amendment [ADDRESS_493345]-Treatment/
Follow-Up Phase
Study Weeks 12 345-16
q4 weeks17 18 19 20 2125+
q8 weeksSuspected 
PD VisitEnd-of-
Treatment 
VisitsResponse 
Follow-Up
Visits
(Until PD )
q12 weeksSurvival 
Follow-Up
q12 weeks
Study Day 11 1 1 1 1
Study Windows -30 days + 3 days ± 3 days + 3 days ± 3 days ± 3 days anytime ± 7 days ± 7 days ± 7 days
Efficacy Assessments
Serum protein electrophoresis 
(SPEP)xx x x x x x x x
Quantitative serum immunoglobulins 
(IgA, IgG and IgM)xx xjxjxjxx xx x x x
Serum free light chain assayxWeeks 
[ADDRESS_493346] Scans xkxlxlxm
Bone Marrow Aspi[INVESTIGATOR_393028] 
49 and 97 
(± 2 weeks)xx
Overall Disease Assessment x x x x x x x
Survival Status a nd new anticancer 
therapyxx
Ongoing Subject Assessments
Concomitant medications x Continuous  from Informed Consent to [ADDRESS_493347] dose of study drug
Biomarkers
T/B/NK cell counts
xxWeeks 
33 and 
49 Onlyxx
Predictive biomarkers & 
mechanisms of resistancepxqxWeeks 
33 and 
49 Onlyxx
Abbreviations: aPTT=activated partial t hromboplastin time; ECG=electro cardiogram; ECOG=Eastern Cooperative Oncology Group; EO T=end-of- treatment; INR=inte rnational normalized 
ration; PD=progressive disease; PO=orally; PRO=patient- reported outcome; PT=prothrombin time; q4 weeks=every 4 weeks; q 8 weeks = every 8 weeks; q12 weeks=every 12 weeks
Footnote:
aRituximab doses may be delayed for up to [ADDRESS_493348].  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version: Amendment [ADDRESS_493349].
dPhysical Examination includes: general appear ance of subject, examination of skin, ey es and fundi, ears, no se, throat, lungs, h eart, abdomen, extremities, 
musculoskeletal system, lymphatic system, and nervous system.
eOnly a limited symptom-directed physical examination is required.  Review of symptoms should include inquiry of ocular symptoms; subjects should be 
referred to an ophthalmologist for a formal examination if any Grade ≥[ADDRESS_493350] be ruled out by [CONTACT_375842].
gSubsequent Serum viscosity (after Screening) should be perfor med at the discretion of the treatin g physician in any subject with signs and symptoms 
suggesting a hyperviscosity syndrome.
hRepetitive serum immunofixation on study is only required to confirm CR (conducted on the first observation that the subject has  no detectable monoclonal 
protein) and then repeated every time until disease progression.
iPharmacokinetic samples will be drawn for all subjects according to the schedule in Section 7.4.[ADDRESS_493351], abdomen, and pelvis should be obta ined during Screening (up to [ADDRESS_493352] dose) for each s ubject.
lFollow-Up CT scans will be required at Weeks 17, 33, 49 65, 81, 97 and thereafter every 24 weeks for all su bjects with measureable nodal /extranodal disease 
per central radiology review during Screening.  Additional asse ssments may be performed if clinically indicated during the cour se of the study at any time. 
mCT scan at Suspected PD visit may be performed if  clinically indicated as reason for progression. 
nBone marrow aspi[INVESTIGATOR_393029], Weeks 49 an d 97 (± 2 weeks) to confirm paraprotein changes, and at any ti me as determined 
necessary or to confirm a complete response  if the subject has no detectable monoclonal protein, and if clinically indicated at d isease progression or end-of-
treatment visit. A portion of these samples may be used for biomarker assessments.
oWith Bone Marrow Aspi[INVESTIGATOR_393030] 4 smears, perform required assays at site and submit up to 10 mL aspi[INVESTIGATOR_393031]: One 8.5 mL blood sample in Acid Citrate Dextro se (ACD) and one 10mL blood sample in Sodium Heparin will be co llected for biomarker 
evaluations at the beginning of Week 1, Week 17, Week 33 and Week  49.  Additional samples will also be obtained at the time of c omplete response 
assessment and at disease progression (or at End-of Treatment Visit for subjects who discontinue treatment without disease prog ression). 
qPortion of sample collected at Week [ADDRESS_493353] read, understand, and sign the IRB/REB/IEC-approved ICF before any study-specific screening procedures are performed.  
s30 days from last dose of study drug or prior to the start of a new anticancer treatment. 
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 100Appendix 2. ECOG Status Scores
Status Eastern Cooperative Oncology Group (ECOG) Performance Status**
0 Fully active, able to carry on all pred isease performance without restriction.
1Restricted in physically strenuous activity but am bulatory and able to carry out work of a light 
or sedentary nature, eg, lig ht housework, office work.
2Ambulatory and capable of all self-care, but unab le to carry out any wo rk activities.  Up and 
about more than 50% of waking hours.
3 Capable of only limited self-care, confined to  bed or chair more than 50% of waking hours.
4 Completely disabled.  Cannot carry on any self -care.  Totally confined to bed or chair.
5 Dead.
**Oken, M.M., Creech, R.H., Tormey, D.C., et al.  Toxi city And Response Criteria Of The Eastern Cooperative 
Oncology Group.  Am J Clin Oncol 5:649-655, 1982.
Available at: http://www.ecog.org/general/perf _stat html.  Accessed January 4, 2008.
  
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 101Appendix 3. Inhibitors and Inducers of CYP3A
Inhibitors and inducers of CYP3A are defined as fo llows.  A comprehensive lis t of inhibitors can be 
found at the following website: http://medicine.i upui.edu/clinpharm/ddis/ta ble.aspx. The general 
categorization into strong, moderate , and weak inhibitors according to the website is displayed below.  
Refer to Section [IP_ADDRESS] on instructions for concomitant use of  CYP3A inhibitors or inducers with 
ibrutinib.
Inhibitors of CYP3 A Inducers of CYP3A
Stron g inhibitors: Carbamazepi[INVESTIGATOR_393032]: Rifampin
Aprepi[INVESTIGATOR_393033]. John’s Wort
Erythromycin Troglitazone
diltiazem 
Fluconazole
grapefruit juice
Seville orange juice
Verapamil
Weak inhibitors:
Cimetidine
All other inhibitors:
Amiodarone
NOT azithromycin
Chloramphenicol
Boceprevir
Ciprofloxacin
Delaviridine
diethyl-dithiocarbamate
Fluvoxamine
Gestodene
Imatinib
Mibefradil
Mifepristone
Norfloxacin
Norfluoxetine
star fruit
Telaprevir
Troleandomycin
Voriconazole
Source:http://medicine.iupui.edu/clinpharm/ddis/table.aspx.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 102Appendix 4. Modified 6th WM Response Criteria ( NCCN 2014 ) for Investigator Assessment
Modified WM Response Criteria for Investigat or Assessment of Response and Progression*
Category Response Criteria
Complete Response 
(CR)•Serum IgM values in normal range
•Disappearance of monoclonal protein by [CONTACT_393095]: Reconfirmation of CR status is required with a second immunofixation at 
any time point
•No histological evidence of  bone marrow involvement
•Complete resolution of  lymphadenopathy4/splenomegaly if present at baseline
Very Good Partial 
Response (VGPR)•At least 90% reduction of serum IgM from baseline or serum IgM values in 
normal range 
•Reduction in lymphadenopathy4/splenomegaly if present at baseline
Partial Response (PR)•At least 50% reduction of serum IgM from baseline 
•Reduction in lymphadenopathy4/splenomegaly if present at baseline
Minor Response (MR) •At least 25% but <50% reduction of serum IgM from baseline
Stable Disease (SD) •Not meeting criteria for CR, VGPR, PR , MR, or progressive disease (PD)
Progressive Disease 
(PD) At least one of the following 
•A ≥25% increase in serum IgM with a total increase of at least 500 mg/dL from 
nadir1
oConfirmation of the initial IgM increa se is required when IgM is sole 
criterion for progressive disease.
•Appearance of a new lymph nodes > 1.5 cm in any axis, ≥50% increase from 
nadir in sum of product of diameters (SPD) of more than one node, or ≥ 50% 
increase in longest diameter of a previous ly identified node > 1 cm in short axis2
•Appearance of  new splenomegaly or  ≥50% increase from nadir in enlargement 
of the spleen2
•Appearance of  new extranodal disease 2/3
•New or recurrent involvement in the bone marrow
•New symptomatic disease on the basis of malignant pleural effusion, Bing Neel 
(WM CNS disease) syndrome, amyloidosis or light chain deposition disease, or 
other paraprotein mediated disorder.
1. Nadir for serum IgM is defined as the lowest serum IgM value obtained at any time from baseline onwards 
with the exception that serum IgM levels post-plasmapheresis will not be considered for up to 35 days.
2. For additional clarification to assess the appearance or  progression of existing nod al and extranodal disease 
(Refer to Section 7.5.4 .) 
3. Measurable extranodal disease should be assessed in a manner similar to that for nodal disease. 
4. Sum of the products of multiple lymph nodes (as eval uated by [CONTACT_5291]) or the longest diameter of one 
target lymph node
*   The primary efficacy evaluations are based on IRC evaluation. In additi on, eligibility for potential next-line 
therapy with ibrutinib will be base d on IRC confirmed progression.  The IRC assessment will incorporate 
assessments from the central radiology review and the details regarding the IRC evaluation for response and 
progression will be outlined in a separate charter.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 103Appendix 5 .[LOCATION_001] Heart Association Functional Classification
NYHA Class 
SymptomsNYHA Class Symptoms
INo symptoms and no limitation in ordinary physical activity, eg, shortness of breath 
when walking, climbing stairs etc.
IIMild symptoms (mild shortness of breath and/or angina) and slight limitation during 
ordinary activity.
IIIMarked limitation in activity due to symptoms , even during less-than-ordinary activity, 
eg, walking short distances (20–100 m).
Comfortable only at rest.
IV Severe limitations.  Experiences symptoms ev en while at rest.  Mo stly bedbound patients.
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 104Appendix 6. WM IPSS Calculation
Factors associated with Prognosis Value
Age > 65 years
Hemoglobin ≤ 11.5 g/dL
Platelet count ≤ 100 x 109/L
β2-microglobulin > 3 mg/L
Serum monoclonal IgM > 7.0 g/dL
Risk Category Score
I   (low risk) 0 or 1 factors ( ≤ 65 years)
II  (intermediate risk) 2 factors OR age > 65 years
III (high risk) > 2 factors
An international prognostic scoring system for ne wly diagnosed WM patients was recently developed 
(Morel et al, 2009) based on 5 factors associated with a poor prognosis include advanced age, high beta 
2-microglobulin (ß 2M), low albumin, cytopenias, serum IgM monoclonal protein, and organomegaly
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 105Appendix 7. EQ-5D-5L Health Questionnaire

Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 106

Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 107

Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493354]-An (Version 4)
Below is a list of statements that other peopl e with your illness have said are important. Please 
circle or mark one number per line to indica te your response as it applies to the past 
[ADDRESS_493355] pain............................................................... 0 1 2 3 4
GP5 I am bothered by [CONTACT_123490].............. 0 1 2 3 4
GP6 I feel ill.................................................................... 0 1 2 3 4
GP7 I am forced to spend time in bed............................. 0 1 2 3 4
SOCIAL/FAMILY WELL-BEINGNot at 
allA little 
bitSome
whatQuite
a bitVery 
much
GS1 I feel close to my friends......................................... 0 1 2 3 4
GS2 I get emotional support from my family................. 0 1 2 3 4
GS3 I get support from my friends ................................. 0 1 2 3 4
GS4 My family has accepted my illness......................... 0 1 2 3 4
GS5 I am satisfied with family communication about my illness ................................................................ 0 1 2 3 4
GS6 I feel close to my partner (or the person who is my main support) .................................................... 0 1 2 3 4
Q1 Regardless of your current level of sexual activity, 
please answer the following question. If you prefer 
not to answer it, please mark this box 
and go to the next section.
GS7 I am satisfied with my sex life ................................ 0 1 2 3 4
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493356] my illness..... 0 1 2 3 4
GE4 I feel nervous.......................................................... 0 1 2 3 4
GE5 I worry about dying................................................ 0 1 2 3 4
GE6 I worry that my condition will get worse............... 0 1 2 3 4
FUNCTIONAL WELL-BEING Not at 
allA little 
bitSome
whatQuite
a bitVery 
much
GF1 I am able to work (include work at home).............. 0 1 2 3 4
GF2 My work (include work at home) is fulfilling ........ [ADDRESS_493357] accepted my illness ...................................... 0 1 2 3 4
GF5 I am sleepi[INVESTIGATOR_102641] ................................................... 0 1 2 3 4
GF6 I am enjoying the things I usually do for fun.......... 0 1 2 3 4
GF7 I am content with the qualit y of my life right now . 0 1 2 3 4
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493358]
7 days .
ADDITIONAL CONCERNS Not 
at allA little 
bitSome
whatQuite
a bitVery 
much
HI7 I feel fatigued .......................................................... 0 1 2 3 4
HI12 I feel weak all over.................................................. 0 1 2 3 4
An1 I feel listless (“washed out”)................................... [ADDRESS_493359] trouble walking ............................................ 0 1 2 3 4
An7 I am able to do my usual activities ......................... 0 1 2 3 4
An8 I need to sleep during the day ................................. 0 1 2 3 4
An9 I feel lightheaded (dizzy) ........................................ [ADDRESS_493360] to limit my social activity because I am 
tired .........................................................................01 234
Ibrutinib (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment [ADDRESS_493361] to 
Receive Next-line Ibrutinib Therapy
Study WeeksAssessment for 
Eligibility for 
Next-line 
Ibrutinib 
TherapyTreatment PhaseFollow-up 
Phase
Every 4 weeks 
for 16 weeksEvery 8 weeks 
thereafter
until PD End-of-
Treatment
VisitFollow-up 
(Every 
12 weeks)
Study Windows ±3 d ±3 d 30 (±3 d) ±7 d
Study Drug 
Administration
Ibrutinib 420 mg per day 
PO Continuous Daily Dosing
Procedures
IRC-confirmed PD ax
Sponsor’s Designee
approvalx
Concomitant medications xx x x
Adverse events xx x
Physical examination, 
vital signs, ECOG xbxx x
Hematology cxbxx x
Serum chemistrycxbxx x
Serum immunoglobulinsc
(IgM)xbxx x
Investigator assessment 
of response and for 
progressionxx
Survival status x
Subsequent anticancer 
therapi[INVESTIGATOR_393034]
d=day; ECOG=Eastern Cooperative Oncology Group; IRC=Independent Review Committee; PD=progre ssive disease; PO=oral; 
qd=once daily
aDocumentation from IRC required for Sponsor’s designee approval to receive next-line ibrutinib therapy
bAssessments for next-line ibrutinib should be performed ±10 days from unblinding 
cAssessments performed by [CONTACT_393096] (PCI-[ZIP_CODE]) PCYC-1127-CA 09 October 2015
Version:  Amendment 3
Pharmacyclics LLC Proprietary and Confidential Page 112Appendix 10. Child-Pugh Score
Measure 1 point 2 points 3 points
Total bilirubin, μmol/l 
(mg/dl)<34 (<2) 34-50 (2-3) >50 (>3)
Serum albumin, g/L (g/dl) >35 (>3.5) 28-35 (2.8-3.5) <28 (<2.8)
PT INR <1.7 1.71-2.30 >2.30
Ascites None Mild Moderate to Severe
Hepatic encephalopathy None Grade I-II (or suppressed 
with medication)Grade III-IV 
(or refractory)
Points Class
5-6 A
7-9 B
10-15 C
Source: 
1. Child CG, Turcotte JG (1964) “Surgery and portal hypertension”. In Child CG. The liver and portal
hypertension. Philadelphia:Saunders. pp. 50-64.  
2. Pugh RN, Murray-Lyon IM, Dawson L, Pi[INVESTIGATOR_9051], Williams R (1973). “Transection of the oesophagus  
for bleeding oesophageal varices”. The British journal of surgery , 60 (8): 646-9